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Many questions remain regarding the molecular mechanisms by which proteins 
evolve new properties and functions. How do proteins evolve new functions 
without perturbing existing ones? How do changes in protein biophysics affect 
function? How are protein functions maintained, altered, or improved over time? 
We used the multifunctional innate immune protein S100A9 (A9) as a model to 
dissect mechanisms of protein evolution. A9 performs two primary innate immune 
functions. As a homodimer, it potently stimulates inflammation by interacting with 
Toll-like receptor 4 (TLR4). As part of a heterocomplex with S100A8 (A8/A9), it 
is potently antimicrobial. A9 and the A8/A9 complex are further regulated by 
proteolysis: the A9 homodimer is highly proteolytically susceptible, while the 
A8/A9 heterocomplex is resistant. The evolutionary origins and mechanisms by 
which these functions arose are poorly understood, and the mechanism by which 
A9 activates TLR4 to drive inflammation is unknown. 
We took an evolutionary biochemical approach to determine how A9 evolved 
its innate immune functions. Chapter I comprises an introduction. Chapter II 
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examines the role of pleiotropy in the evolution of A9 multifunctionality. We find 
that A9s gained proinflammatory activity and lost proteolytic resistance from a 
weakly proinflammatory, proteolytically resistant ancestral protein. A single 
ancient substitution had pleiotropic effects on A9 without affecting the A8/A9 
complex, revealing a beneficial role for pleiotropy in the evolution of 
multifunctionality. Chapter III examines the biophysical mechanism by which A9 
activates TLR4 to drive inflammation. We show that reverting the ancient 
substitution identified in chapter II compromises A9 activation of TLR4 by 
restricting access to a functionally necessary conformation of the protein. These 
findings highlight how subtle changes to a protein’s conformational energy 
landscape can have critical impacts on protein evolution. In chapter IV, I outline 
ongoing work examining how later-diverging A9s have evolved more potent and 
promiscuous activation of TLR4 and determining how, mechanistically, A9 
activates TLR4. This work provides novel insight into how a key innate immune 
protein evolved multifunctionality and highlights how basic changes in protein 
biophysics can have profound impacts on biological systems. 





NAME OF AUTHOR: Joseph Leslie Harman Jr. 
 
GRADUATE AND UNDERGRADUATE SCHOOLS ATTENDED: 
 
University of Oregon, Eugene, OR 





Doctor of Philosophy, Chemistry, 2020, University of Oregon 
Bachelor of Arts, Biochemistry, 2014, Willamette University 
 
 










PhD Candidate & Graduate Research Fellow, Harms Lab, University of 
Oregon, Eugene, OR, 2016-2020 
 
PhD Student and Graduate Teaching Fellow, Department of Chemistry 
and Biochemistry, University of Oregon, Eugene, OR, 2014-2015 
 
Undergraduate Researcher, Hoobler Lab, Department of Chemistry, 
Willamette University, Salem, OR, 2013-2014 
 
Chemistry/Chemical Engineering Intern, Lawrence Berkeley National 
Laboratory, Berkeley, CA, Summer 2013. 
 
Biochemistry Intern, Life Technologies, Eugene, OR, Summer 2012. 
 




GRANTS, AWARDS, AND HONORS: 
 
 
National Institutes of Health, Genetics Training Grant, 2014-2017 
 






Harman JL, Anderson JA, Reardon P, Warren GD, Costello SM, Connor 
P, Marqusee S, Harms MJ. “Biophysical studies of a conserved historical 
mutation reveal that S100A9 activates Toll-Like Receptor 4 through a 
non-native conformation.” (in preparation) 
 
Harman JL, Loes AN, Warren GD, Heaphy MC, Lampi KJ, Harms MJ 
(2020). “Evolution of multifunctionality through a pleiotropic substitution 
in the innate immune protein S100A9.” eLife. 2020;9:e54100. DOI: 
10.7554/eLife.54100 
 
Harman JL (2014). “Synthesis of a Novel Pyridine-Substituted 7- 
Nitrobenz-(2,1,3)-Oxadiazol-4-yl (NBD) Fluorescent Compound to 
Monitor the Anti-Cancer Functionality of a NAMI-A Derivative.” 





I am sincerely grateful for the veritable village of mentors, colleagues, 
friends, and family who have helped me complete my PhD. I first thank my advisor, 
Michael Harms, for his constant mentorship and dedication to student success. I 
cannot speak highly enough of his intelligence, effort, and thoughtfulness as a 
scientist and mentor. I thank members of the Harms lab for years of mentorship and 
collaboration, thoughtful discussion and feedback, and friendship. Thank you to 
Andrea Loes, who was my first mentor in the Harms lab, provided a constant source 
of new and thoughtful ideas, and laid an excellent foundation for the work described 
in this dissertation. Thank you to Jeremy Anderson, an excellent mentor and friend 
who taught me protein NMR, spent many days commiserating with me in the cell 
culture room, and reminded me of the value of a good laugh. Thank you to previous 
lab members Luke Wheeler and Zach Sailer for mentorship and feedback early in 
my PhD and for staying in touch from afar through the Beer and Theory Society – 
a group that meets regularly to discuss scientific topics of interest outside of our 
immediate research. Thank you to Harms lab members Anneliese Morrison, Nick 
Frantz, and Michael Shavlik for friendship, feedback, and collegiality – I look 
forward to seeing where your work and interests take you. Thank you to Lauren 
Lehmann, Sophia Phillips, and Jon Muyskens for working with me to develop 
ongoing projects in the Harms lab, some of which are highlighted here. Thank you 
to the many excellent students who have worked in our lab – a special thanks to 
Maureen Heaphy and Gus Warren, who both contributed heavily to this work and 
were a pleasure to mentor. 
Thank you to my committee members – Jim Prell, Brad Nolen, Ken 
Prehoda, and Alice Barkan – for constructive feedback and encouragement during 
my dissertation research. Thank you to the many graduate students, researchers, 
staff, and other members of my department for your kindness, collaboration, 
guidance, and support over the years. 
Thanks are in order for several wonderful collaborators. Thank you to 
Patrick Reardon for enthusiastically contributing to protein NMR studies. Thank 
ix  
you to Shawn Costello and Susan Marqusee for collaborating on mass spectrometry 
studies and for years of excellent discussions at various meetings – the Protein 
Folding Consortium meeting, in particular, shaped who I am as a scientist today. 
Thank you to members of the Bowman lab for help with molecular dynamics 
simulations and friendship. Thank you to the many labs and researchers with whom 
I’ve had wonderful discussions and interacted with over the years. 
Thank you to previous mentors and educators at Willamette University for 
getting me excited about scientific research and encouraging me to pursue graduate 
studies – a special thanks to Sarah Kirk, Alison Fisher, Todd Silverstein, Chuck 
Williamson, and Tony Hoobler. 
Thank you to my friends in Eugene and across the globe for your continued 
support and friendship. I particularly thank Berry Street and our local Eugene 
friends for many fun adventures, trips, constant encouragement, and regular laughs. 
Thank you especially to my family. I thank my parents, Becky and Joe 
Harman, for their support, love, and encouragement over the years. Thank you to 
my siblings, Philip and Anna, and siblings-in-law, Andy, Trey, and Stephanie, for 
continued support and laughs. Thank you to my parents-in-law, Mary and Peter, for 
welcoming me into your family as one of your own. Thank you to my extended 
family for support and encouragement. 
Most importantly, thank you to my wife, Lizzy. Thank you for your daily 
encouragement, kindness, and understanding. I truly couldn’t have done this 














For my grandparents – James and Carol Harman and William and Judy Smith. 
xi  
TABLE OF CONTENTS 
 
Chapter Page 
I. INTRODUCTION .............................................................................................1 
II. EVOLUTION OF MULTIFUNCTIONALITY THROUGH A 
PLEIOTROPIC SUBSTITUTION IN THE INNATE IMMUNE 
PROTEIN S100A9...............................................................................................16 




Materials and Methods ...................................................................................46 
Bridge to Chapter III ......................................................................................56 
III. BIOPHYSICAL STUDIES OF A CONSERVED HISTORICAL 
MUTATION SUGGEST THAT S100A9 ACTIVATES TLR4 THROUGH 
A NON-NATIVE CONFORMATION................................................................58 







Materials and Methods ...................................................................................78 
Bridge to Chapter IV ......................................................................................87 
IV. MOLECULAR MAPPING OF CHANGES IN S100A9 
PROINFLAMMATORY POTENCY, PROMISCUITY, AND THE 
S100A9:TLR4 INTERACTION ..........................................................................88 




Materials and Methods .......................................................................................104 
Bridge to Chapter V .....................................................................................105 
V. SUMMARY AND CONCLUDING REMARKS ........................................111 
APPENDICES ...................................................................................................116 
A. CHAPTER II SUPPLEMENTARY INFORMATION ...........................116 
B. CHAPTER III SUPPLEMENTARY INFORMATION .........................133 
C. CHAPTER IV SUPPLEMENTARY INFORMATION .........................159 
REFERENCES CITED ......................................................................................166 
xiii  






2.1. A9s evolved to form the antimicrobial A8/A9 complex early in 
mammals .......................................................................................................21 
 
2.2. A9s gained proinflammatory activity from a weakly 
proinflammatory ancestor .............................................................................24 
 
2.3. A9s lost proteolytic resistance from a proteolytically resistant 
amniote ancestor ...........................................................................................29 
 
2.4. A single historical substitution alters A9 proinflammatory activity and 
proteolytic resistance without affecting the A8/A9 complex ........................33 
 
2.5. M63F increases human A9 apparent stability by decreasing its 
unfolding rate ................................................................................................38 
 
2.6. Proteolysis is not required for A9 activation of TLR4 ..................................41 
 
3.1. M63F specifically stabilizes the calcium-bound form of A9 ........................62 
 
3.2. M63F does not significantly alter A9 structure ............................................65 
 
3.3. M63F does not alter A9 dynamics on short (ps-us) timescales ....................67 
 
3.4. M63F strongly increases local A9 stability...................................................68 
 
3.5. Disrupting the M63F-37F interaction restores A9 stability & TLR4 
activation .......................................................................................................72 
 
4.1. Later-diverging A9s activate amniote TLR4s more potently 
and promiscuously than earlier-diverging A9s .............................................92 
 
4.2. Elephant A9 and the reconstructed eutherian A9 ancestor activate 
human TLR4 better than earlier-diverging A9s ............................................95 
 
4.3. An MD2 mutant screen identifies candidate mutations that 
selectively decrease A9 activation of TLR4 .................................................99 
 
AA1. Hexahistidine site conservation of modern and ancestrally 
reconstructed A8s and A9s .........................................................................117 
xiv  
Figure Page 
AA2. Oligomeric state analysis of S100 proteins by SECMALS .....................118 
AA3. S. epidermidis growth curves in the presence of S100 proteins ...............119 
AA4. Average posterior probabilities for ancestrally reconstructed proteins ....120 
AA5. Circular dichroism spectroscopy measurements of ancestral proteins .....121 
AA6. Validation of polymyxin B treatment for endotoxin contamination ........122 
AA7. Human TLR4 dose curves ........................................................................123 
AA8. Opossum TLR4 dose curves ....................................................................124 
AA9. Extant S100 protein proteolysis fits .........................................................125 
AA10. Mammalian A8, A9, and A8/A9 complex proteolysis fits .....................126 
AA11. Ancestral S100 proteolysis fits ...............................................................127 
AA12. Mutant S100 proteolysis fits ..................................................................128 
AA13. Sequence alignment highlighting identification of position 63 .............129 
AA14. Human A9 and A9 M63F proteolytic degradation using 
neutrophil proteases ....................................................................................130 
AA15. A9 equilibrium chemical denaturation experiments ..............................131 
AA16. A9 kinetic chemical denaturation experiments ......................................132 
AB1. Oligomeric state analysis of A9 and A9 variants by SECMALS .............134 
AB2. Fits for A9 and A9 M63F NMR HDX experiments .................................135 
AB3. Data table for A9 and A9 M63F NMR HDX experiments ......................138 
AB4. A9 mutant cycle chemical denaturation data............................................139 
AB5. A9 mutant cycle HDXMS data ................................................................140 
AB6. A9 mutant cycle raw calcium binding data by ITC ..................................154 
xv  
Figure Page 
AB7. Models fit to A9 mutant cycle calcium binding data................................155 
AB8. Model fit parameters for A9 mutant cycle calcium binding by ITC ........156 
AB9. A9 mutant cycle TLR4 activation dose curves .........................................158 
AC1. Activation of amniote TLR4s by modern and ancestrally 
reconstructed S100 proteins ........................................................................160 
AC2. Alignment of S100A9s, highlighting highly mutated region ...................162 
AC3. CD spectroscopy of therian ancA9 and 5X mutant therian ancA9...........163 
AC4. Mutation rates for MD2 mutant library treatment conditions ..................164 





Organism-level evolution can be directly mapped to changes in protein 
biochemistry 
Organisms have evolved to perform an incredible array of functions, some 
of which include growth,1–3 movement,4 conversion of nutrients to energy,5,6 and 
defense against disease.7,8 Underlying these macroscale processes are multitudes of 
biomolecules – including proteins, nucleic acids, and small molecules – that act in 
exquisite concert to produce organism-level functions. Proteins, in particular, 
mediate functions by performing essential biochemical processes that include 
catalysis,9,10 molecular transport,11,12 binding interactions,13 and signaling.2,3,14 
Determining the mechanisms by which protein functions change over time is 
central to our understanding of how life as we know it has evolved. 
Remarkably, the properties and functions of a protein are almost entirely 
encoded in its amino acid sequence.15–17 The composition and ordering of amino 
acids within a protein dictates its chemistry, 3-dimensional structure, and 
biophysical properties, impacting protein function and ultimately organism-level 
outcomes.18–20 Indeed, there are many well-established cases in which single amino 
acid changes within a protein can severely impact an organism. In humans, a single 
mutation in beta-hemoglobin – G7V – promotes hemoglobin aggregation and 
causes sickle cell anemia,21 while mutations in the enzyme beta-hexosaminidase A 
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decrease the ability of the enzyme to break down fat in the nervous system, leading 
to Tay-Sachs disease.22 
This physical reality of proteins – that amino acid changes within a protein 
can be directly mapped to functional outcomes in organisms – has profound 
implications for evolutionary biology. Evolutionary biologists have long sought 
mechanistic descriptions of how and why organisms have evolved various 
functions.23,24 While much progress has been achieved in studying evolutionary 
processes at the level of both organismal traits and genetic composition,2,3,25–28 
comparatively less is known about the biochemical mechanisms by which proteins 
evolve new functions.20,29–31 This gap in knowledge resulted in the creation of a 
relatively new field termed evolutionary biochemistry.29,32–35 The primary goal of 
evolutionary biochemical research is to mechanistically describe evolution at the 
molecular level by combining the physical, mechanistic logic of biochemistry with 
the tools and reasoning of evolutionary biology.29,32–34 
 
 
Evolutionary biochemistry has enabled mechanistic studies of protein 
evolution 
Evolutionary biochemical studies over the last two decades have proven 
fruitful in determining the mechanisms by which a variety of protein functions have 
evolved. Early pioneering work combined phylogenetics,36,37 ancestral sequence 
reconstruction,38,39 and biochemical/functional characterization to examine ancient 
protein functions. These approaches – which are now hallmarks of evolutionary 
biochemistry – consist of constructing phylogenetic trees from alignments of 
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modern proteins,37 estimating ancestral protein sequences within a phylogenetic 
tree using statistical methods (including maximum likelihood and Bayesian 
inference),38–40 synthesizing reconstructed ancient proteins alongside their modern 
counterparts, and comparing them in functional experiments. Early studies using 
these techniques provided insight into ancient protein functions such as 
chromophore binding by ancestrally reconstructed archosaur rhodopsins,41 
diversification of hormone binding specificity in an ancestral steroid receptor,42 and 
temperature-dependent GDP binding by an ancient bacterial EF-Tu protein.43 
More recent evolutionary biochemical analyses have delved deeper into the 
biochemical and biophysical mechanisms underlying ancient changes in protein 
function. These studies often expand upon the techniques mentioned above by 
isolating functional transitions between ancestrally reconstructed proteins, 
identifying the key mutations that drove a functional transition, and using 
biophysical and biochemical techniques to determine how, mechanistically, key 
mutations cause changes in protein function. For example, a detailed mechanistic 
study of ancient steroid receptors revealed that key changes in receptor hormone 
specificity were mediated by two large-effect substitutions – out of 171 possible 
amino acid changes - that radically rewired the hydrogen bonding network and 
energetic landscape of the ancient steroid receptor.44 A large-scale study of 
hemoglobins in birds adapted to living at higher altitudes found that while many 
avian hemoglobins convergently evolved tighter oxygen binding affinity, the 
mutations and molecular mechanisms by which this occurred often varied from 
species to species.45 This study and many others highlight how introducing 
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mutations into different genetic backgrounds can have unpredictable outcomes – a 
phenomenon known as epistasis.46 Understanding epistasis is a key area of 
evolutionary biochemical research, with many studies showing that epistasis 
profoundly shapes the evolutionary trajectories taken, or not taken, by proteins as 
they evolve.47–49 
Modern evolutionary biochemical studies have made great progress in 
addressing key mechanistic questions in evolutionary biology. Studies examining 
the reversibility of protein functions have identified restrictive mutations that 
discourage reversion of protein function by physically or functionally restricting 
“backwards compatibility.”50,51 Permissive mutations along evolutionary 
trajectories have been identified that had no effect on protein function when they 
were acquired but were necessary for changes in function induced by later- 
occurring mutations.52 Contingency in protein evolution has been elegantly 
examined using techniques such as deep mutational scanning on ancestrally 
reconstructed proteins, revealing that hundreds of different evolutionary 
trajectories and biochemical solutions are possible for a given protein function.53,54 
These studies and others not only provide unprecedented insight into mechanisms 
of protein evolution, but also facilitate an evolutionarily informed – and thus more 
targeted – analysis of the biophysical mechanisms underlying various protein 
functions. 
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How do proteins evolve multifunctionality? 
 
The majority of studies in evolutionary biochemistry have focused on 
proteins with a single function. In contrast, few studies delve into the mechanisms 
by which proteins evolve multiple functions. Given the large number of 
multifunctional proteins present in biology, understanding how proteins evolve 
multifunctionality is central to our understanding of protein evolution and is a 
primary focus of this dissertation. 
A paradox of multifunctional proteins is that while many exist in biology, 
it is generally believed that evolving multifunctionality is more challenging and 
under more constraint than evolving a single function.55–57 Many studies in the field 
of protein engineering suggest that evolving multifunctionality is a problem of 
optimization. Adaptive constraint – or the complete incompatibility of two different 
functions in a protein simultaneously – has been elegantly demonstrated in studies 
of coenzyme use by β-isopropylmalate dehydrogenase (IMDH).58 Constraints in 
enzyme evolution studies, such as stability-function tradeoffs, show that 
biophysical requirements constrain the evolution of proteins having even a single 
function, let alone multiple functions.59–66 Finally, it is well-established that most 
mutations to a protein tend to be neutral or deleterious.67–69 This suggests that 
multifunctionality is evolutionarily disfavored; the conditional probability that 
multiple mutations accumulate to produce multifunctionality without having a 
detrimental effect on a protein is much less likely than mutations accumulating to 
produce a single function. 
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Why, then, do so many multifunctional proteins exist in biology? While 
many studies suggest that evolving multifunctionality is challenging and subject to 
many constraints, these conclusions largely come from artificial directed evolution 
experiments and thus do not account for how multifunctional proteins evolve in 
nature. This raises a host of unanswered mechanistic questions. How do pre- 
existing functions in natural proteins constrain the acquisition of additional 
functions? How do natural proteins optimize multiple functions at once? What is 
the role of pleiotropy – defined as a single change that affects more than one 
function – in the evolution of protein multifunctionality? Experimental studies into 
how multifunctional proteins evolve, such as those presented in this dissertation, 
are necessary to address these questions. 
 
 
Using evolutionary biochemistry to determine unknown mechanisms of 
protein functions 
A central motivator of biological research is to determine how modern 
proteins perform their functions. We know the functions that many proteins 
perform in biology, but we often lack a mechanistic description of how a protein 
actually performs its function(s). Gaining a mechanistic understanding of how 
proteins function is critical for targeted drug design in human health,70–73 rationally 
engineering proteins for desired functions,74–78 and expanding our fundamental 
knowledge of biological systems. 
Biochemists often determine unknown protein mechanisms by identifying 
the minimal set of residues that are important for function and then by 
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biochemically characterizing the mechanistic contributions of these residues to the 
function. A key challenge to this approach is that it can be difficult to determine 
which of the many protein residues to test. Modern mechanistic studies of proteins 
often require a priori knowledge of function from related proteins and/or large- 
scale mutagenesis screens that can be expensive, time-consuming, and difficult to 
interpret due to challenges such as epistatic interactions between mutations. 
Evolutionary biochemical approaches such as phylogenetics and ancestral 
sequence reconstruction can alleviate some of these challenges because they 
estimate realized amino acid changes in proteins over their evolutionary history.29 
This powerfully constrains the search space of amino acids that are important for 
protein function, thus permitting more targeted studies of functionally relevant 
amino acid changes. By measuring the functions of just a few proteins in a 
phylogenetic tree, researchers can efficiently isolate intervals of functional change 
in a protein’s evolutionary history and then rapidly identify functionally important 
and evolutionarily informed substitutions. This approach not only facilitates rapid 
dissection of mechanisms underlying protein function, but also provides valuable 
insight into mechanisms by which protein functions evolve. 
 
 
S100A9 is a multifunctional protein in mammalian innate immunity 
 
This dissertation seeks to examine outstanding topics in evolutionary 
biochemistry, including how proteins evolve multifunctionality and the use of 
evolutionary biochemical approaches in determining unknown mechanisms of 
protein function. To address these questions, we used the multifunctional innate 
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immune protein S100A9 (A9) as a model system. The following section details 
aspects of A9 biology that are pertinent to this work. 
A9 and closely related protein S100A8 (A8) are two of the most abundant 
proteins in neutrophils79,80 and are primary biomarkers for a variety of 
inflammatory diseases.81–85 A9 and A8 are released by neutrophils at sites of 
infection as part of the innate immune system’s first line of defense against 
pathogens,86–90 where they perform several critical innate immune functions. 
A9 is released into the extracellular space as both a homodimer and as a 
heterodimeric complex with A8 (the A8/A9 complex – often called 
calprotectin).86,87,89,90 These two states of A9 have distinct innate immune 
functions. The A9 homodimer potently drives inflammation by directly interacting 
with proinflammatory cell surface receptor Toll-like receptor 4 (TLR4).91–95 The 
A8/A9 heterocomplex exerts antimicrobial activity by sequestering transition 
metals away from microbes with extremely high affinity.96–104 Finally, an additional 
layer of regulation is that A9 and the A8/A9 complex are differentially degraded 
by proteases; A9 is highly susceptible to proteolytic degradation, while the A8/A9 
complex is resistant.105–108 The differential proteolytic susceptibility of A9 and the 
A8/A9 complex is thought to regulate the relative abundances of these two states 
of A9 at sites of infection and has been proposed to play a functional role in A9 
proinflammatory activity.109 
The mechanism by which the A8/A9 complex exerts antimicrobial activity 
is well-established. Six histidines – four from A9 and two from A8 – form a 
biologically rare hexahistidine metal coordination site at the interface between the 
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two proteins that binds a variety of transition metals with extremely high 
affinity.98,100–102,104,110 This metal binding site is unique to the A8/A9 complex 
within the S100 protein family. Most S100 proteins – including A8 and A9 – bind 
transition metals with varying affinities via a His3Asp site that is largely conserved 
across the S100s.111–113 While a small portion of the antimicrobial activity of the 
A8/A9 complex is attributed to the His3Asp site, the distinct, broad-spectrum 
antimicrobial potency of the A8/A9 complex is largely due to the broad metal 
specificity and extremely high binding affinity of the hexahistidine site.99,102–104 
The mechanism by which A9 activates TLR4 to drive inflammation, in 
contrast, is poorly understood. TLR4 activation by exogenous molecules, such as 
the bacterial cell wall component lipopolysaccharide (LPS), is mechanistically 
well-studied.114,115 LPS is bound by the TLR4 cofactor CD14, which delivers LPS 
to a second cofactor, MD2.116–118 Binding of LPS to a hydrophobic pocket within 
MD2 promotes dimerization of the TLR4/MD2 complex to form 
(TLR4/MD2)2.
114,115,119 LPS-induced formation of the (TLR4/MD2)2 complex 
leads to activation of the highly conserved Myd88 and TRIF/TRAM pathways, 
ultimately resulting in activation of the transcription factor NF-κB.120–122 NF-κB 
activation drives cytokine production that produces an inflammatory cascade and 
recruits additional neutrophils to the site of infection.123–125 LPS-induced activation 




Few studies, in contrast, have examined the mechanism by which A9 
activates TLR4 to drive inflammation. It was previously suggested that A9 binding 
10  
to zinc is required for TLR4 activation based on in vitro binding studies.129 This 
theory was later disproven in a study where ablating zinc binding in A9 did not alter 
A9 activation of TLR4.111 The disordered C-terminal extension of A9 (residues 
~95-114) has also been shown to be dispensable for A9 activation of TLR4.111 It is 
established that TLR4 cofactors MD2 and CD14 are both required for A9 activation 
of TLR4 across mammals,130 suggesting a possible shared mechanism of activation 
with LPS. However, A9 is much larger than LPS and is simply too big to fit within 
the MD2 hydrophobic binding pocket in its native homodimeric state. It has been 
suggested that proteolytic fragments of A9 might activate TLR4,109 as A9 is highly 
susceptible to proteolytic degradation and the extracellular space is rich in 
proteases. Indeed, proteolytic fragments of A9 have been described to modestly 
activate TLR4, although it is unclear whether this is the primary mode by which 
A9 activates TLR4. Previous work has identified pairs of point mutations to 
charged residues within A9 that disrupt A9 binding to TLR4 in vitro, leading to a 
proposed in silico docking model of A9 to TLR4.109 However, the effect of these 
mutations on A9 activation of TLR4 were not characterized. Similar to LPS, A9 is 
a desirable therapeutic target due to its potent proinflammatory activity. Selectively 
inhibiting A9 activation of TLR4 could be an effective therapeutic strategy for 
reducing host-induced inflammation while retaining TLR4 sensing of exogenous 
danger signals like LPS. Designing such a strategy, however, is hampered by not 
knowing the molecular mechanism by which A9 activates TLR4. A key focus of 
this dissertation is using evolutionary biochemical approaches to expand our 
mechanistic understanding of how A9 activates TLR4 to drive inflammation. 
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Lastly, the role of proteolytic regulation in A9 biology is poorly understood. 
Various roles, both functional and regulatory, have been proposed for the 
differential proteolytic susceptibility of A9 and the A8/A9 complex. Proteolysis 
could selectively remove proinflammatory A9 from sites of inflammation, thus 
enriching for the antimicrobial A8/A9 complex.105,107 It has also been suggested 
that proteolytic degradation of A9 could be required for proinflammatory activity, 
as proteolytic fragments of A9 are capable of activating TLR4.109 Determining the 
mechanistic connection between A9 proteolytic regulation and the other innate 
immune functions of A9 is necessary for understanding how A9 balances multiple 
functional roles in mammalian innate immunity. 
 
 
Evolutionary studies of S100A9 proinflammatory activity 
 
Previous studies of A9 evolution have laid the groundwork for determining 
how A9 evolved multifunctionality and for examining the mechanism by which A9 
activates TLR4. Phylogenetic analyses of A9 and closely related proteins revealed 
that A9s share a common amniote ancestral protein with three other S100 proteins 
– A8s, S100A12s (A12s), and MRP126s.112,130 These four protein clades – which 
together form a group of S100 proteins called the calgranulins – form a polytomy, 
meaning that it is unclear exactly when each of these four clades diverged. 
However, MRP126s are only present in sauropsids (birds and reptiles), while A8s, 
A9s, and A12s are only present in mammals, indicating that the sauropsid MRP126 
proteins are likely co-orthologous to the mammalian A8, A9, and A12 proteins.130 
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Previous work determined that A9s from multiple mammals (human, 
mouse, and opossum), as well as the chicken MRP126 protein, are each able to 
activate their respective species-matched TLR4s.130 CD14 and MD2 were shown 
to be required for A9 and chicken MRP126 activation of TLR4.130 
Complementation experiments – in which TLR4 components from different species 
were swapped out and tested for activity – revealed that while CD14s from most 
species could complement TLR4 activation by most A9s, MD2s tended to only 
complement more closely related TLR4s and thus exhibited stronger species- 
specific co-evolution. Further, while A9s and LPS exhibited largely similar 
TLR4/MD2/CD14 requirements in complementation experiments, some 
differences were observed that suggest potential mechanistic differences in TLR4 
activation between A9 and LPS.130 These findings formed the foundation for much 
of the work that is presented in this dissertation. 
 
 
Chapter-by-chapter breakdown of dissertation 
 
Chapter II describes how A9 evolved multifunctionality, examines the 
evolutionary and functional interplay between A9 functions, and highlights a 
pleiotropic substitution that played a key role in A9 evolution.131 We used 
phylogenetics, ancestral sequence reconstruction, and functional characterization 
to show that A9s and A8s evolved to form antimicrobial, proteolytically resistant 
heterocomplexes early in mammals. We found that A9 homodimers evolved potent 
proinflammatory activity and lost proteolytic resistance from a proteolytically 
resistant, weakly proinflammatory amniote ancestor. We identified a single key 
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substitution that occurred in the mammalian A9 ancestor and played key roles in 
the evolution of A9 multifunctionality. Reverting this substitution to its amniote 
ancestral state in human A9 rendered the protein proteolytically resistant and 
strongly decreased its proinflammatory activity, while introducing the modern 
substitution into the A9 amniote ancestor increased its proinflammatory activity. 
The substitution had no effect on the antimicrobial activity of the A8/A9 complex. 
Lastly, we showed that proteolytic degradation is not required for A9 activation of 
TLR4. These findings together show that A9 evolved multifunctionality by 
partitioning innate immune functions between the A9 homodimer and the A8/A9 
complex. A key substitution had pleiotropic effects on the A9 homodimer – 
increasing its proinflammatory activity and driving a loss of proteolytic resistance 
– without affecting the antimicrobial activity or proteolytic resistance of the A8/A9 
complex. This reveals that pleiotropy can play a beneficial role in the evolution of 
multifunctionality by selectively altering one protein functional state without 
affecting another. We propose that given the large number of proteins that have 
interaction partners and/or occupy multiple functional states, this is likely a 
common route by which multifunctional proteins arise in biology. 
Chapter III consists of an in-depth biophysical analysis of the mechanism 
by which the historical mutation found in Chapter II decreases A9 proinflammatory 
activity. The goal of this study was to gain insight into the mechanism by which A9 
activates TLR4 to drive inflammation. Thermodynamic studies of A9 and the A9 
mutant – A9 M63F – revealed that the M63F mutation specifically stabilizes the 
calcium-bound form of A9, but not the calcium-free state. Structural 
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characterization of A9 M63F suggests that it does not significantly alter A9 
structure. Given the lack of obvious structural changes, we hypothesized that the 
M63F mutation might alter some functionally important dynamic process of the 
protein. We observed no changes in dynamics on short timescales by NMR, but in 
long timescale hydrogen-deuterium exchange studies we observed significant local 
stabilization of A9 M63F compared to wildtype A9. This analysis enabled 
identification of a second critical amino acid position – F37 – that is well-positioned 
to form a pi-stacking interaction with the M63F mutation. Reverting F37 to its 
mammalian ancestral state in the A9 M63F background (A9 M63F F37L) negates 
the stabilizing effect of M63F and fully restores A9 proinflammatory activity. 
These findings show that M63F decreases A9 activation of TLR4 by locally 
stabilizing the protein via a direct interaction with a nearby residue. Given M63F 
does not appear to alter the native A9 protein structure, we propose that M63F 
inhibits access to an excited state conformation of A9 that is necessary for 
proinflammatory activation of TLR4. These findings provide unprecedented insight 
into the mechanism by which a key innate immune protein drives inflammation in 
mammals and highlight the utility of evolutionary biochemical analyses in 
dissecting poorly understood protein functions. 
Chapter IV highlights ongoing studies examining how later-diverging A9 
proteins have evolved proinflammatory activity and determining the mechanism by 
which A9 activates TLR4 to drive inflammation. We previously found that A9s 
evolved enhanced proinflammatory activity early in mammals. However, these 
studies revealed distinct differences in both A9 proinflammatory potency and cross- 
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reactivity with TLR4s from different species. In particular, human A9 potently 
activates TLR4s from various species better than species-matched A9s activate 
their respective TLR4s, and human TLR4 is much more potently activated by 
human A9 than by any other A9 protein. Further, the magnitude of A9 
proinflammatory activity is often higher in later-diverging A9s. These findings 
suggest that A9 activation of TLR4 has been enhanced in later-diverging species. 
We also hypothesize that certain A9-TLR4 pairs, such as human A9 and human 
TLR4, have evolved increased specificity. This chapter highlights ongoing 
evolutionary biochemical analyses to examine these possibilities, including testing 
the proinflammatory activities of uncharacterized A9s from later diverging 
mammals such as elephants and identifying key amino acid substitutions that 
mediated changes in proinflammatory potency and TLR4 specificity. 
Finally, I conclude chapter IV by describing ongoing orthogonal approaches 
for determining the mechanism by which A9 activates TLR4 to drive inflammation. 
We have implemented a high-throughput cell sorting and sequencing method for 
screening mutations in TLR4, MD2, and CD14 that alter LPS and/or A9 activation 
of TLR4. This unbiased approach complements previous evolutionary and 
mechanistic studies of A9 proinflammatory activity. We highlight how this 
approach is currently being employed to determine the A9:TLR4/MD2/CD14 
interaction interface. We conclude by describing future characterizations of modern 
and ancestrally reconstructed A9s, TLR4s, MD2s, and CD14s from various species 
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The innate immune system uses a small number of multifunctional proteins 
to respond to diverse immune challenges. Multifunctional immune proteins are 
critical for pathogen defense,132–134 shaping host-associated microbial 
communities,135 and well-regulated tissue growth.136–138 They also drive 
pathological inflammation in disease, including autoimmune disorders, cancer, and 
cardiovascular disease.96,139–142 These multifunctional proteins raise both 
mechanistic and evolutionary questions. How can one protein sequence satisfy the 
multiple constraints imposed by having multiple functions? How can multiple 
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functions evolve in one protein when, as a result of multifunctionality, each 
mutation likely has pleiotropic effects?143–146 
One such multifunctional protein is S100A9 (A9), a small, soluble protein 
found at high concentrations in the extracellular space during an inflammatory 
response.147 It has at least two key immune functions. As a homodimer, A9 potently 
activates inflammation via Toll-like receptor 4 (TLR4).86,91–95,129,148–153 As a 
heterocomplex with S100A8 (A8/A9, also known as calprotectin), it is 
antimicrobial (Figure 2.1a).97–104,110,154–158 A9 exacerbates endotoxin-induced shock 
in mice.159 Both A9 and A8/A9 are primary biomarkers for many human 
inflammatory diseases.81–85 Further, dysregulation of A9 is associated with various 
cancers, pulmonary disorders, and Alzheimer’s disease.81–85,93,160,161 Understanding 
the mechanisms by which A9 performs its innate immune functions is critical for 
developing treatments for A9-mediated diseases. 
The mechanism of A8/A9 antimicrobial activity is well established: it 
sequesters a variety of transition metals through both a hexahistidine site and a 
His3Asp site formed at the A8/A9 heterodimer interface, thereby limiting the 
concentrations of essential microbial nutrients in the extracellular space.97– 
104,110,154–158 Other S100 proteins exert weaker antimicrobial activity via the 
His3Asp site, which has lower metal binding affinity and binds fewer types of 
transition metals than the A8/A9 hexahistidine site.101–103,110,156,162,163 In contrast, 
the proinflammatory mechanism of A9 is not well understood. A9 acts as a 
Damage-Associated Molecular Pattern (DAMP), activating NF-B and other 
cytokines through Toll-like receptor 4 (TLR4).86,91–95,129,148–153 The interaction 
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interface(s), affinity, and stoichiometry for the A9/TLR4 interaction are not known. 
A small region of A9 has been suggested to form part of the A9/TLR4 binding 
surface,109 but no mutant of A9 has been identified that substantially compromises 
its activation of TLR4. 
An additional layer of A9 immune function is that A9 and A8/A9 are 
thought to be regulated in the extracellular milieu by proteases. Neutrophils release 
multiple proteases along with A9 at sites of inflammation that regulate the 
inflammatory response.164–169 A9 is very susceptible to proteolytic degradation, 
while A8/A9 is highly resistant (Figure 2.1a).105,107 Proteolysis may serve to purge 
proinflammatory A9 from sites of inflammation and thus selectively enrich for 
antimicrobial A8/A9. There may even be a direct, functional link between A9 
proteolytic degradation and inflammation. Proteolytic fragments of A9 are 
sufficient to activate TLR4,109 and proinflammatory stimuli are thought to stabilize 
A9 homodimers against proteolytic degradation.105 Directly testing the relationship 
between A9 proteolytic susceptibility and proinflammatory activity, however, has 
been challenging. There is no obvious way to selectively increase the proteolytic 
resistance of A9 and test its effect on A9 activation of TLR4, making it difficult to 
understand the relationship, if any, between these two functions. 
We took an evolutionary biochemical approach to mechanistically dissect 
the evolution of A9 innate immune functions. Using phylogenetics, ancestral 
sequence reconstruction (ASR), and biochemical studies, we show that A9s evolved 
to form proteolytically resistant, antimicrobial A8/A9 complexes in early 
mammals. We find that A9 homodimers gained proinflammatory activity and lost 
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proteolytic resistance in the ancestor of therian mammals from a weakly 
proinflammatory, proteolytically resistant amniote ancestor. We identify a 
pleiotropic substitution that is necessary for A9 activation of TLR4, sufficient to 
increase TLR4 activation by the A9 amniote ancestor and played a role in loss of 
A9 proteolytic resistance. Mutating this site has minimal effect on A8/A9 
antimicrobial activity or proteolytic resistance. Lastly, we show that proteolysis is 
not required for A9 activation of TLR4. Taken together, this work reveals that 
mammals concomitantly evolved A8/A9 antimicrobial activity, A9 
proinflammatory activity, and a way to selectively regulate A9 inflammation via 
loss of A9 proteolytic resistance. These findings provide unprecedented 
mechanistic and evolutionary insight into A9 function and show how a single 
mutation can have pleiotropic effects in one functional state of a protein while not 





We first set out to establish when A9 evolved three innate immune 
properties: antimicrobial activity via formation of the A8/A9 complex, 
proinflammatory activation of TLR4 by A9 alone, and the differential proteolytic 
susceptibility of A9 and A8/A9. 
 
 
A9s evolved to form antimicrobial A8/A9 complexes early in mammals 
 
We sought to determine when A9 evolved to form the antimicrobial A8/A9 
complex. We hypothesized that A8/A9 antimicrobial activity evolved in the 
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ancestor of therian mammals (the shared ancestor of marsupials and placental 
mammals) for several reasons. First, the broad-spectrum antimicrobial activity of 
human and mouse A8/A9 is well established.97–104,110,155–158 Second, A9 and A8 
genes are only found together in therian mammals (Figure 2.1b);130 therefore the 
A8/A9 complex could not have arisen earlier than in the ancestor of therian 
mammals. Lastly, the residues composing the antimicrobial hexahistidine metal 
binding site are fully conserved across therian mammals (Figure AA1). 
To determine whether the antimicrobial A8/A9 complex arose in the 
ancestor of therian mammals, we compared human A8/A9 to two previously 
uncharacterized A8/A9 complexes. We first tested the antimicrobial activity of 
A8/A9 from opossum, which is one of the earliest-diverging mammals relative to 
humans that possesses both of the S100A8 and S100A9 genes. Opossum and human 
A8 and opossum and human A9 have sequence identities of approximately 50%, 
respectively (Figure AA1). Following previous work,104 we produced a cysteine- 
free variant of the complex to avoid the use of reducing agents in the antimicrobial 
assay. We confirmed that cysteine-free opossum A8/A9 formed a heterotetramer 
(46.8  0.7 kDa) in the presence of calcium – like the human and mouse proteins170 
– using size exclusion chromatography coupled with multi-angle laser light 







Figure 2.1. A9s evolved to form the antimicrobial A8/A9 complex early in 
mammals. (a) Table of A9 and A8/A9 properties. “~” represents weak or 
ambiguously characterized function, check marks and red “X” represent confirmed 
property (check) or lack thereof (“x”). (b) Schematic of previously published S100 
protein tree. Colored nodes represent single protein sequences. Species cartoons 
shown are human, opossum, and chicken. Ancestrally reconstructed protein nodes 
are labeled. Branch lengths not to scale. (c) Representative growth curves for 
Staphylococcus epidermidis in the presence or absence of 10 M S100 proteins. 
Each point represents optical density at 600 nm. S. epidermidis growth alone and 
in the presence of modern proteins are shown as circles, growth in the presence of 
ancestrally reconstructed proteins shown as triangles. Error bars are standard 
deviation of three technical replicates. (d) Percent of untreated S. epidermidis 
growth at 12 hours with S100 protein treatments. Data are average of three 
biological replicates. Error bars are standard error of the mean. Species cartoon 
labels are the same as in (b). 
 
 
We measured cysteine-free opossum A8/A9 antimicrobial activity against a 
representative gram-negative bacterium, Staphylococcus epidermidis. In studies of 
A8/A9 from other species, activity against S. epidermidis tracked with the broad- 
22  
spectrum antimicrobial activity of the complex.97 We assayed activity using a 
previously established in vitro antimicrobial assay that monitors bacterial growth 
in the absence or presence of S100 proteins (Figures 2.1c, AA3).104 compare the 
activity of different proteins, we quantified inhibition at seven hours (Figure 2.1d). 
We observed a dose-dependent decrease in S. epidermidis growth in the presence 
of low micromolar concentrations of cysteine-free opossum A8/A9 (Figures 2.1c- 
d, AA3). The antimicrobial activity of opossum A8/A9 was weaker than that of 
human A8/A9: opossum A8/A9 delayed bacterial growth, while human A8/A9 both 
delayed growth and decreased bacterial carrying capacity (Figure 2.1c). It was 
previously found that cysteine-free human A8/A9 was potently antimicrobial,104 
while cysteine-free mouse A8/A9 exhibits weaker antimicrobial activity than 
wildtype mouse A8/A997 To determine whether the weaker activity of opossum 
A8/A9 was due to the removal of cysteines, we also measured the activity of 
wildtype opossum A8/A9 against S. epidermidis. We found that wildtype opossum 
A8/A9 had higher activity than cysteine-free opossum A8/A9 over the 
concentration range tested (Figure AA3). This suggests that the cysteines present in 
mouse and opossum A8/A9 play a role in their antimicrobial activity, unlike in 
human A8/A9. The antimicrobial activity of the opossum A8/A9 complex thus 
appears to be more similar to that of mouse A8/A9 than human A8/A9. 
The shared antimicrobial activity of human, mouse, and opossum A8/A9 
 
strongly suggests that the antimicrobial A8/A9 complex evolved in the ancestor of 
therian mammals. To test this further, we measured the ntimicrobial activity of 
ancestrally reconstructed therian mammalian A8/A9 (ancA8/A9 – Figure 2.1b). We 
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used our previously published phylogenetic tree130 consisting of 172 S100 
sequences to reconstruct therian mammalian ancestral A8 and A9 (ancA9 and 
ancA8 – Figure 2.1), which were used to form the ancA8/A9 complex. AncA8 and 
ancA9 had average posterior probabilities of 0.88 and 0.83, with sequence 
similarities to human A8 and A9 of 66% and 64%, respectively (Figure AA4). 
Average posterior probabilities in this range have been previously described as 
medium confidence reconstructions, with reconstructions characterized by others 
having average posterior probabilities as low as 0.7.171 We confirmed that each 
protein was folded and had secondary structure content similar to that of human 
A8/A9 using far-UV circular dichroism (CD) spectroscopy (Figure AA5). 
We then measured the antimicrobial activity of ancA8/A9 against S. 
epidermidis. We observed a potent reduction in S. epidermidis growth comparable 
to that of human A8/A9 (Figures 2.1c-d, AA3). To test for the robustness of this 
finding to phylogenetic uncertainty, we also tested the antimicrobial activity of an 
AltAll171 reconstruction of ancA8/A9 against S. epidermidis (altancA8/A9, Figures 
2.1c-d, AA4). In this reconstruction, we swapped all ambiguously reconstructed 
amino acid positions for their second-most likely state (see methods). AncA8/A9 
and altancA8/A9 differ by 27 amino acids total (10 between ancA8 and altancA8 
and 17 between ancA9 and altancA9 - Figure AA4). AltancA8/A9 exhibited 
antimicrobial activity against S. epidermidis similar to opossum A8/A9: it delayed 
growth but did not ultimately limit bacterial carrying capacity. While the 
hexahistidine site residues are conserved in ancA8/A9 and altancA8/A9 (Figure 
AA1), it appears that a subset of the ambiguously reconstructed 27 residues are 
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important for A8/A9 antimicrobial activity, perhaps affecting the orientation and/or 
affinity of the hexahistidine metal binding site. 
Taken together, the antimicrobial activity of modern mammalian A8/A9 
complexes (human, mouse, and opossum) and the antimicrobial activity of the 
reconstructed ancA8/A9 complex suggest that A9s evolved to form the 
antimicrobial A8/A9 complex in the ancestor of mammals. 
 
 
Figure 2.2. A9s gained proinflammatory activity from a weakly 
proinflammatory ancestor. (a) Schematic of previously measured 
proinflammatory activity of S100s against various TLR4s. Species labels on x and 
y-axes of heatmap are the same as Figure 2.1. Heatmap coloring is scaled to match 
2 M S100 activity levels measured in supplementary figure S2 of Loes et al. 
2018.130 (b) and (c) NF-B production of human and opossum TLR4 in response 
to treatment with modern and ancestral S100 proteins. Bars represent average of >3 
biological replicates, error bars are standard error of the mean. All values are 
background-subtracted and normalized to LPS positive control (see methods). 
 
 
A9s evolved potent proinflammatory activity from a weakly active amniote 
ancestor 
We next sought to determine when A9s evolved potent proinflammatory 
activity via activation of TLR4. Our previous work revealed that human A9 potently 
activates not only human TLR4 in functional assays, but also opossum and chicken 
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TLR4 (Figure 2.2a).130 In contrast, chicken MRP126, the sauropsid ortholog of A9s, 
was found to be a weak activator of all TLR4s, including chicken TLR4. Both 
human and opossum A9 activate chicken TLR4 better than chicken MRP126 does. 
Two possibilities are consistent with these observations. Either mammalian A9s 
evolved enhanced proinflammatory activity from a less active amniote ancestral 
state, or A9s maintained a potent ancestral activity that was lost by chicken 
MRP126. 
To differentiate between these two possibilities, we determined the ancestral 
proinflammatory activity of these proteins. We used ASR to reconstruct the shared 
amniote ancestor of A9s, A8s, A12s, and MRP126s. This group of proteins is 
known collectively as the “calgranulins”, so we will refer to this ancestral protein 
as ancCG (ancestor of calgranulins). We also constructed an alternate, “alt All” 
version of this ancestor (altancCG, S4), which differed from ancCG by 8 amino 
acids. The average posterior probability of ancCG was 0.86 (table S4). We also 
expressed and purified ancA9 and altancA9 – the A9 subunits from the ancestral 
A8/A9 complexes described above. We confirmed that each protein was folded and 
had secondary structure content similar to that of modern S100s using far-UV CD 
spectroscopy (Figure AA5). 
We then tested modern and ancestral S100s for activity against human 
TLR4. Following previous work,130,159,172,173 we transiently transfected HEK293T 
cells with plasmids encoding TLR4 and its species-matched cofactors MD-2 and 
CD14, added purified S100 proteins to the growth media, and then measured output 
of luciferase under control of an NF-B promoter. Consistent with previous 
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results,130 we found that human A9 potently activated human TLR4, resulting in 
high levels of NF-B production (Figures 2.2b, AA6). Human A8/A9 and opossum 
A9 exhibited much weaker activity against human TLR4. Lastly, we tested ancA9, 
altancA9, ancCG, and altancCG for activity against human TLR4 and observed 
weak or no activation for each ancestral protein. This result is unsurprising, as we 
previously found that human TLR4 is more specific than other amniote TLR4s: 
human TLR4 is activated much more potently by human A9 than by any other S100 
protein (Figure 2.2a-b).130 In contrast, TLR4s from other species (mouse, opossum, 
and chicken) appear to be more promiscuous and can be activated similarly by 
S100s from various species (Figure 2.2a).130 This is consistent with lineage-specific 
coevolution between human TLR4 and human A9 – a confounding variable that 
makes assessment of ancestral S100 protein proinflammatory activity difficult 
using human TLR4. 
We predicted that opossum TLR4 would be a better protein to probe 
ancestral S100 proinflammatory function because opossum TLR4 is broadly 
activated by A9s across mammals and gives little indication of lineage-specific 
coevolution.130 We therefore tested the proinflammatory activity of ancA9, ancCG, 
and their corresponding alternate reconstructions against opossum TLR4. 
Corroborating previous results, human A9 strongly activated opossum TLR4, while 
opossum A9 activity was approximately half that of human A9 (Figures 2.2c, AA6- 
8). AncA9 and altancA9 activated opossum TLR4 to the same extent as opossum 
A9. AncCG and altancCG were the weakest activators of opossum TLR4, with 
activity approximately 25% or less than that of human A9. These findings suggest 
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that A9s evolved enhanced proinflammatory activity early in mammals from a 
weakly proinflammatory amniote ancestor, while A8/A9s and chicken MRP126 
maintained weak, ancestral proinflammatory activity. 
 
 
A9s evolved proteolytic susceptibility from a proteolytically resistant amniote 
ancestor 
We next sought to determine when the differential proteolytic susceptibility 
of A9 and A8/A9 evolved. We used a simple in vitro assay to monitor S100 protein 
degradation over time in the presence of proteinase K, a potent non-specific serine 
protease (Figure 2.3a). Proteinase K was chosen both because of its low specificity 
and to mimic other serine proteases that A9 and A8/A9 encounter when released 
from neutrophils during an inflammatory response.164–167,174 Proteolytic decay rates 
were estimated by fitting a single exponential decay function to the data (Figures 
2.3b, AA9-12). 
Human A8/A9 has been described as extremely resistant to proteases;107 
however, it has not been compared to S100 proteins besides human A8 and A9. To 
establish a baseline expectation for S100 protein proteolytic resistance, we 
characterized the proteolytic resistance of a broad set of human S100s against 
proteinase K. As previously shown,107 human A9 and A8 alone were rapidly 
proteolytically degraded, while the human A8/A9 complex exhibited strong 
resistance (Figures 2.3c, AA9-10). Under our conditions, the degradation rates for 
human A8 and A9 were approximately three orders of magnitude faster than that of 
the human A8/A9 heterocomplex. We then characterized closely related protein 
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human S100A12 (A12), the chicken ortholog MRP126, and six distantly related 
human S100s.112 Human A12, chicken MRP126, and five out of six more distantly 
related human S100s exhibited intermediate to strong proteolytic resistance, each 
degrading 1-2 orders of magnitude slower than human A8 or A9 but, on average, 
one order of magnitude faster than human A8/A9 (Figures 2.3c, AA9-10). Notably, 
human A12 and chicken MRP126 formed predominantly homodimers by SEC 
MALS under these conditions (Figure AA2), indicating that higher-order 
oligomerization (> 2 subunits) isn’t required for S100 proteolytic resistance. Lastly, 
human A14 degraded faster than A9 or A8. This protein is evolutionarily distant112 
and therefore likely reflects independent evolution of this property. Taken together, 
these data show that the A8/A9 complex, A9, and A8 indeed fall at the extremes of 
human S100 proteolytic resistance; human A9 and A8 are among the fastest- 
degrading S100s tested, while human A8/A9 is one of the slowest. 
To test whether A9 and A8 proteolytic susceptibility and A8/A9 resistance 
are conserved across mammals, we characterized mouse and opossum A9, A8, and 
A8/A9 for proteolytic resistance. Mouse A9 and A8 were found to be highly 
proteolytically susceptible and mouse A8/A9 strongly proteolytically resistant, 
matching the pattern observed for their human counterparts (Figures 2.3c, AA10). 
Opossum A9 and A8 were also highly proteolytically susceptible, while opossum 
A8/A9 was resistant (Figures 2.3c, AA10). This indicates that the susceptibility of 




Figure 2.3. A9s lost proteolytic resistance from a proteolytically resistant 
amniote ancestor. (a) In vitro proteolytic resistance assay showing SDS-PAGE gel 
of S100 protein degradation via proteinase K over time. Gels were quantified using 
densitometry and normalized to the undigested protein band intensity. (b) A single 
exponential decay model was globally fit to the data to quantify decay rates. Points 
are biological replicates, lines are model fit to data. (c) S100 protein proteolysis 
rates mapped onto schematized S100 phylogeny. X-axis cartoon labels same as in 
Figure 2.1. Circles indicate proteolytic susceptibility (faded/dashed) and resistance 
(solid), with predicted resistance shown for ancA8, ancA9, and ancCG nodes. (d) 
Decay rates for ancestrally reconstructed proteins, with gels shown on the right. For 
panels (c) and (d), error bars are the square root of the diagonalized covariance 
matrix from the fit and the y-axis is in log scale. (e) Summary model for proposed 
evolution of A9 and A8/A9 innate immune properties. Box around A8/A9 and A9 




When mapped onto the S100 phylogeny, the most parsimonious explanation 
for these data is that the shared amniote ancestor—ancCG—was proteolytically 
resistant (Figure 2.3c). In this scenario, A12s, MRP126s, and A8/A9s conserved 
ancestral resistance, while A9s and A8s independently lost resistance early in 
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mammals. Alternatively, ancCG could have been proteolytically susceptible. This 
would mean that A9s and A8s maintained an ancestral susceptibility, while 
MRP126s, A12s, and A8/A9s each evolved novel proteolytic resistance. 
To distinguish between these possibilities, we characterized ancestrally 
reconstructed S100s for proteolytic resistance. AncCG and altancCG exhibited 
extremely high proteolytic resistance (Figures 2.3d, AA11), with degradation rates 
3-4 orders of magnitude slower than modern A8s or A9s and approximately one 
order of magnitude slower than modern A8/A9s. AncA8/A9 and altancA8/A9 also 
demonstrated high proteolytic resistance, with degradation rates approximately 2- 
3 orders of magnitude slower than A8s and A9s and comparable to modern A8/A9 
complexes (Figures 2.3d, f). Together, these data paint a consistent picture: the 
amniote ancestor of A9s, ancCG, was strongly resistant to proteolytic degradation. 
Modern A9s and A8s lost proteolytic resistance from an ancestrally resistant state, 
while modern A12s, A8/A9 complexes, and MRP126s maintained the ancestral 
proteolytic resistance (Figure 2.3e). 
Finally, we sought to better resolve when A9s acquired proteolytic 
susceptibility. We hypothesized that this occurred in the ancestor of mammalian 
A9s before the divergence of therian mammals and marsupials. To test this 
hypothesis, we measured the proteolytic susceptibility of therian mammalian 
ancA9 and found that it degraded rapidly. However, its alternative reconstruction 
(altancA9), was slow to degrade, with a rate two orders of magnitude slower than 
ancA9 and comparable to other highly resistant S100s. Because the descendants of 
ancA9 all exhibit proteolytic susceptibility, the simplest explanation is that 
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altancA9 is a low-quality reconstruction that does not capture the properties of the 
historical protein. Alternatively, proteolytic susceptibility could have been 
independently acquired along marsupial and placental mammal lineages. 
 
 
A single substitution had pleiotropic effects on A9 proinflammatory activity 
and proteolytic resistance 
We found above that A9 evolved to form the antimicrobial A8/A9 complex, 
gained potent proinflammatory activity, and lost proteolytic resistance over the 
narrow evolutionary interval after the divergence of mammals and sauropsids but 
before the divergence of placental mammals and marsupials. We next sought to 
determine how A9 evolved its antimicrobial and proinflammatory activities and lost 
proteolytic resistance. 
The mechanism by which A9 evolved to form the antimicrobial A8/A9 
complex is straightforward. After ancCG duplicated, additional histidines 
accumulated in the mammalian A8 and A9 ancestors that created the antimicrobil 
hexahistidine metal binding site in the A8/A9 complex (Figures 2.3e AA1). A8s 
acquired one additional histidine while retaining the three histidines present in 
ancCG, while A9s acquired two additional histidines via acquisition of a C-terminal 
extension (Figure AA1). While A9s evolved five of the six histidines composing 
the hexahistidine metal binding site, this was not sufficient to convey potent 
antimicrobial activity (Figure 2.1c). Instead, preservation of A8/A9 heterocomplex 
formation resulted in proper assembly of the complete antimicrobial hexahistidine 
site early in mammals. The quantitative difference between ancA8/A9 and 
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altancA8/A9 antimicrobial activity suggests that other amino acid changes tuned 
the antimicrobial activity of the molecule, but the core functionality is determined 
by whether the six histidine residues were present. This is independently supported 
by Brunjes Brophy et al., who showed that mutating the two C-terminal histidines 
in A9 is sufficient to strongly decrease the A8/A9 complex’s antimicrobial 
activity.110 
The mechanisms by which A9s gained proinflammatory activity and lost 
proteolytic resistance are less obvious, particularly because the mechanism by 
which A9 activates TLR4 is not well understood. We reasoned that we could 
identify functionally important amino acid substitutions by focusing on the 
evolutionary interval over which these properties evolved. We therefore compared 
the sequences of ancCG (weakly proinflammatory and resistant to proteolytic 
degradation) and ancA9 (potently proinflammatory and susceptible to proteolytic 
degradation). We further narrowed down sequence changes of interest by looking 
for residues conserved in modern A9s (Figure AA13). Finally, we focused on amino 
acid changes in helix III of A9, as this region is thought to be important for A9 
activation of TLR4 based on in vitro binding studies and in silico docking studies.109 
Only one historical amino acid substitution met all three criteria: position 63 
(human A9 numbering). This residue is a phenylalanine in both ancCG and 
altancCG, is conserved as a phenylalanine in 95% of modern A8s and A12s and has 
been substituted for a methionine or leucine (M/L) in 97% of A9s (Figure 2.4a). 
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Figure 2.4. A single historical substitution alters A9 proinflammatory activity 
and proteolytic resistance without affecting properties of the A8/A9 complex. 
(a) Schematic S100 phylogenetic tree with the amino acid state of position 63 
shown at key nodes. Wedges represent clades, colored as in Figure 2.1. Lines 
indicate proteolytic susceptibility (faded/dashed) and resistance (solid). Circles 
indicate characterized ancestors. Amino acid labels represent maximum likelihood 
state/alternate amino acid state for position 63 at ancestral nodes, while labels at 
clade tips represent percent conservation across modern S100 protein sequences. 
(b-c) NF-B production of S100 point mutants at position 63 against human (b) and 
opossum (c) TLR4. (d) Proteolysis rates for S100 point mutants at position 63 
(human A9 numbering). Error bars and y-axis are the same as in Figure 2.1. (e) 
Antimicrobial activity of hA9 and hA8/A9 with and without M63F mutation 
against S. epidermidis. Axes and error bars same as in Figure 2.1d. 
 
 
We hypothesized that reverting this site to its amniote ancestral state— 
M63F—might affect A9 proinflammatory activity. We mutated this position to a 
phenylalanine in human A9 and opossum A9 and tested each protein for TLR4 
activation. Strikingly, we found that introducing M63F into human A9 severely 
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compromised its ability to activate human TLR4 (Figures 2.4b, AA7). This was also 
true for opossum A9: introduction of M63F (human numbering) strongly decreased 
opossum A9 activation of opossum TLR4 (Figures 2.4c, AA8). We next introduced 
the forward substitution, F63M, into ancCG and tested its proinflammatory activity 
against opossum TLR4. We observed a modest increase in ancCG activity with the 
F63M substitution, with activity comparable to that of opossum A9 (Figures 2.4c, 
AA8). 
For most proteins we studied, the amino acid at position 63 did indeed play 
an important role in determining the pro-inflammatory activity of A9. The effects 
of toggling position 63 between Met and Phe were not, however, universal. We 
introduced M63F into ancA9 and observed no change in proinflammatory activity 
(Figures 2.4c, AA8). Further, altancA9 has a Phe at position 63 but activates TLR4 
in the assay (Figures 2.2c, AA8). Thus, while position 63 is an important contributor 
to activity in modern A9s, other substitutions were also important for the transition 
from a weakly pro-inflammatory ancestor to the modern set of potently pro- 
inflammatory A9s. 
Because A9s lost proteolytic resistance and gained proinflammatory 
activity over the same evolutionary time interval, we reasoned that the F63M 
substitution might have also played a role in A9 loss of proteolytic resistance. To 
test this, we characterized the proteolytic resistance of human A9 M63F and ancA9 
M63F. Strikingly, reversion of this single mutation rendered both ancA9 and human 
A9 strongly resistant to proteolytic degradation, decreasing their respective 
degradation rates by 1-2 orders of magnitude and approaching the degradation rates 
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of ancCG and various A8/A9 complexes (Figures 2.4d, AA12). To relate these 
findings to proteases that A9 might encounter at sites of inflammation, we also 
measured the proteolytic resistance of human A9 and human A9 M63F against two 
neutrophil-specific proteases – cathepsin G and neutrophil elastase (Figure AA14). 
Neutrophils release these proteases along with A9 at sites of inflammation, often 
through Neutrophil Extracellular Traps (NETs).88,164–169 We found that M63F 
decreased the rate of human A9 degradation in the presence of cathepsin G and 
neutrophil elastase in vitro by approximately one order of magnitude, matching our 
results using proteinase K (Figure AA14). Lastly, we tested the effect of the forward 
mutation – F63M – on ancCG proteolytic resistance. We observed no change in 
resistance for ancCG F63M, indicating that additional substitutions were required 
to render ancA9 proteolytically susceptible. Together these data show that a single 
historical reversion is sufficient to render A9s proteolytically resistant, indicating 




The pleiotropic substitution minimally affects the A8/A9 complex 
 
A primary goal of this study was to understand the role of pleiotropy in the 
evolution of multifunctionality. M63F clearly has pleiotropic effects on A9, altering 
both its proinflammatory activity and proteolytic resistance (Figure 2.4b-d). We 
next asked whether introducing M63F would pleiotropically affect the 
antimicrobial A8/A9 complex. Position 63 is somewhat distant from the A8/A9 
interface and the antimicrobial hexahistidine site (~10 Å in the manganese-bound 
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A8/A9 crystal structure);33 we therefore hypothesized that M63F should not affect 
A8/A9 complex formation or function. To test this hypothesis, we introduced M63F 
into human A8/A9 and tested it for oligomeric state, proteolytic resistance, and 
antimicrobial activity against S. epidermidis. As predicted, human A8/A9 M63F 
predominantly formed a heterotetramer in the presence of calcium by SECMALS 
with a molecular weight similar to that of wildtype human A8/A9 (48.7  4.2 kDa 
– Figure AA2). We found that human A8/A9 M63F was also strongly resistant to 
proteolytic degradation, similar to human A8/A9 (Figure 2.4d). Lastly, M63F had 
minimal impact on human A8/A9 antimicrobial activity against S. epidermidis, 
retaining potent antimicrobial activity (Figure 2.4e). In contrast, neither human A9 
nor human A9 M63F were antimicrobial against S. epidermidis (Figure 2.4e). These 
findings suggest that this single amino acid position had important effects on the 
evolution of A9 activation of TLR4 and loss of proteolytic resistance without 




M63F increases protein thermodynamic stability and decreases unfolding rate 
of human A9 
We next asked what effect M63F has on the biophysical properties of human 
A9. Residue 63 sits in the middle of helix III of A9, pointing inward toward helix 
II, and is neither a core residue nor fully surface-exposed (Figure 2.5a).175 Based 
on the published structure of human A9,175 a Phe at position 63 could be plausibly 
tolerated without a steric clash. Using circular dichroism (CD) spectroscopy, we 
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found that the bulk secondary structure content of human A9 M63F was similar to 
that of hA9 (Figure 2.5b). We measured the oligomeric state of human A9 M63F 
by SEC MALS and found that it predominantly forms a homodimer in solution 
similarly to human A9, with no detectable monomers or larger oligomers (Figure 
2.5c, 2.5f). These data together indicate that M63F does not significantly alter 
human A9’s secondary structure or oligomeric state. 
We then examined whether M63F alters the stability of human A9. We 
measured equilibrium unfolding curves for human A9 and human A9 M63F using 
CD spectroscopy and chemical denaturation via urea. We found that M63F appears 
to stabilize human A9, increasing the apparent free energy of unfolding by more 
than 4 kcal/mol and shifting the Cm by ~ 2M urea (Figures 2.5d, 2.5f, AA15). We 
also measured the unfolding kinetics of human A9 and human A9 M63F in the 
presence of calcium by spiking protein directly into 6M guanidinium hydrochloride 
(gdn-HCl) denaturant and monitoring its unfolding rate by CD spectroscopy. 
Strikingly, human A9 M63F takes several minutes to unfold under these conditions, 
while human A9 unfolds immediately within the dead time of the experiment 
(Figures 2.5e-f, AA16). We note that the folding pathway for A9 is complex and 
almost certainly not two-state—calcium binding, monomer folding, and 
dimerization all contribute—and thus we cannot reliably determine how M63F 
affects the stability of each of these potential folding intermediates. The large 
increase in apparent stability and unfolding rate suggests, however, that the 





Figure 2.5. M63F increases human A9 apparent stability by decreasing its 
unfolding rate. (a) Crystal structure of hA9 (PDB entry 1irj).175 Cartoon depiction 
left, surface view right. Calcium ions are blue spheres. M63 is highlighted in red – 
two total for homodimeric A9. (b) Far-UV circular dichroism (CD) spectroscopy 
scans of hA9 and hA9 M63F. Data represent average of 3 scans. (c) SEC MALS 
analysis of hA9 and hA9 M63F oligomeric state. Solid lines are refractive index 
(left y-axis), points and molecular weights in table below represent molar mass 
calculated from light scattering detectors using ASTRA software (right y-axis - see 
methods). (d) Equilibrium chemical denaturation (urea) of 5 uM hA9 and hA9 
M63F monitored by CD at 222 nm. Solid lines represent two-state unfolding model 
fit to data. (e) Kinetics of hA9 and hA9 M63F unfolding via chemical denaturation 
(guanidinium hydrochloride). Graph depicts one representative unfolding 
experiment (figure AA16). (f) Thermodynamic parameters estimated from (d) and 
molecular weights estimated from (c). Errors are standard deviations calculated 
from fit (see methods). 
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Proteolysis is not required for A9 activation of TLR4 
 
The work above identified a mutation that, when introduced into human A9, 
increases the stability of the protein while also potently compromising its ability to 
activate TLR4. The mutation is not at a surface position and is therefore not likely 
a direct participant in the A9/TLR4 protein/protein interface. Further, the same 
mutation dramatically decreases the proteolytic susceptibility of the protein. One 
simple way to explain these observations would be if the proteolytic susceptibility 
itself was the feature that evolved to allow activation of TLR4. This would be 
consistent with a previous observation that proteolytic products of A9 activate 
TLR4.109 
To test whether proteolysis itself was sufficient for activity, we engineered 
an alternate variant of A9 that was proteolytically susceptible. We introduced the 
M63A mutation into human A9, anticipating that the short alanine sidechain would 
not have the stabilizing effect of M63F. As expected, human A9 M63A was highly 
susceptible to proteolytic degradation, similar to wildtype human A9 (Figures 2.6a, 
AA12). We reasoned that if proteolysis is the primary determinant of A9 activation 
of TLR4, then proteolytically susceptible human A9 M63A should potently activate 
TLR4. Human A9 M63A, however, exhibited diminished proinflammatory activity, 
similar to human A9 M63F (Figures 2.6b, AA7). This indicates that the methionine 
at position 63 is important for A9 activation of TLR4. Further, we quantified the 
amount of human A9, human A9 M63F, and human A9 M63A before and after 
measuring TLR4 activity and observed no decrease in the amount of full-length 
protein remaining for wildtype human A9 or either mutant by western blot (Figure 
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2.6c). This indicates that A9 is not digested by extracellular proteases over the 
course of the ex vivo assay and that proteolysis is not necessary for A9 activation 
of TLR4. 
Although proteolysis does not appear to be a requirement for TLR4 
activation, this does not rule out that proteolysis could increase A9 
proinflammatory activity by releasing proinflammatory fragments of A9. To test 
for this possibility, we treated human A9 with agarose-immobilized proteinase K 
for increasing amounts of time, removed the protease, and then measured the 
proinflammatory activity of A9 degradation products (Figure 2.6d). If proteolytic 
products of A9 are the most proinflammatory form of the protein, we might expect 
to observe a spike in TLR4 activation upon A9 digestion. Instead, we observed a 
steady decrease in human A9 activity with increasing digestion time. This suggests 
that full-length human A9 is the most potent activator of TLR4. 
We did observe moderate activity for proteolytic products of human A9, as 
previously shown.109 After 30 minutes of digestion, no detectable full-length A9 
remains by western blot (< 30 ng, Figure 2.6d), but NF-B production is still quite 
high, revealing that smaller fragments of A9 are sufficient to provide some degree 
of activation of TLR4. This raised the possibility that part of M63F’s deleterious 
effect on proinflammatory activity could be to limit the release of active proteolytic 
fragments of A9. To test this, we also measured human A9 M63F activation of 
TLR4 after digestion for multiple hours (Figure 2.6d). Unlike wildtype, however, 
fragments of human A9 M63F did not activate TLR4—even after being liberated 
by the protease. This strongly suggests that the historical mutation induced a change 
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in the native structure or dynamics of the molecule to bring about increased activity, 
independent of its effect on proteolytic susceptibility. 
 
 
Figure 2.6. Proteolysis is not required for A9 activation of TLR4. (a) Proteolytic 
decay rates for human point mutants at position 63. Error bars and axes are the same 
as in Figure 2.3. (b) NF-B production of human TLR4 in response to treatment 
with hA9, hA9 M63F, and hA9 M63A. Error bars the same as in Figure 2.2. (c) 
Western blot of hA9 and position 63 point mutants before and after 
proinflammatory activity assay. Left bands represent 10 and 15 kDa ladder. (d) NF- 
B production of human TLR4 in response to hA9 and hA9 M63F pre-proteolyzed 
with proteinase K for increasing amounts of time. Points are biological replicates 
and are the average of three technical replicates. Western blots below depict the 
amount of full-length A9 remaining over time. Left blot shows antibody sensitivity 






The work presented here provides insight into how the multifunctional 
protein A9 evolved critical innate immune functions. We find that mammalian A9s 
gained enhanced proinflammatory activity and lost proteolytic resistance from a 
weakly proinflammatory, proteolytically resistant amniote ancestor. A single 
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substitution played a key role in the evolution of these properties without 
significantly affecting the antimicrobial activity of the A8/A9 heterocomplex. This 
work contributes to our mechanistic understanding of how A9 activates TLR4 to 
drive inflammation and clarifies the role of proteolysis in A9 innate immune 
function. 
Innate immune functions of A9 continued to evolve within the mammals 
 
Our data suggest that the proinflammatory and antimicrobial activities of 
A9 and the A8/A9 complex have undergone further optimization in placental 
mammals since these functions evolved. While the histidines composing the high- 
affinity metal binding site of A8/A9 complexes are conserved, we observed 
differences in antimicrobial potency for different A8/A9 complexes. In particular, 
human A8/A9 is one of the most potently antimicrobial A8/A9 complexes 
characterized. This suggests that further optimization of the metal binding site has 
occurred in along the human lineage within mammals. We also observed 
differences in activation of TLR4 by different A9s—human A9 is a potent, 
promiscuous activator of TLR4s from multiple species, while earlier-diverging A9s 
and other S100s exhibit weaker proinflammatory activity.130 Future studies are 
necessary to understand how, mechanistically, later-diverging A9s and A8/A9 
complexes have optimized these critical innate immune functions. 
 
 
Why did A9s lose proteolytic resistance? 
 
While proteolysis is not required for A9 activation of TLR4, it remains 
unclear why A9s lost proteolytic resistance. We suggest three possibilities. The first 
43  
is that loss of proteolytic resistance in A9s was simply a byproduct of evolving 
proinflammatory activity. No A9 characterized in this study, with the exception of 
the alternate reconstruction of ancA9, is both proteolytically resistant and potently 
proinflammatory. This indicates that the molecular requirements for A9 proteolytic 
resistance may be incompatible with those required for A9 activation of TLR4: A9s 
may have gained proinflammatory activity at the expense of proteolytic resistance. 
A second possibility is that A9 proteolytic susceptibility is being maintained to 
actively remove proinflammatory A9 from the cell and retain the antimicrobial 
A8/A9 complex. The last possibility for A9 loss of proteolytic resistance is adaptive 
constraint. There could be selection for some property of A9 or A8/A9 that we did 
not measure that is incompatible with A9 proteolytic resistance. 
While we cannot explicitly distinguish between each of these possibilities, 
the end result is that A9s lost proteolytic resistance from a resistant ancestor. As 
A9s activate TLR4 in the protease-rich extracellular space, the functional result of 
A9 loss of proteolytic resistance is that A9s evolved a proteolytic “timer” 




Novel mechanistic insight into A9 activation of TLR4 
 
Our findings suggest new directions for understanding how A9 potently 
activates TLR4. TLR4-driven inflammation has been the focus of intense study for 
over 20 years,86,91,93–95,117,172,176–178 and the structural basis of TLR4 activation by 
exogenous agonists, such as the bacterial cell wall component lipopolysaccharide 
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(LPS), is well understood.114 In contrast, little is known about how A9 activates 
TLR4. We have shown here that proteolytic degradation appears dispensable for 
activation; however, smaller fragments of the protein are sufficient activate TLR4 
(Figure 2.6). Given the effect of mutating position 63 on A9 proinflammatory 
activity, we propose that the region surrounding it—helix III—is important for 
activity. This is independently supported by Vogl et al., who identified four pairs of 
double mutants within helix III (amino acids 64, 65, 73, and 77) that, when mutated 
to alanines in pairs, decrease A9 binding to TLR4 in vitro.109 Biophysical 
characterization of hA9 M63F (Figure 2.5) indicates that it is more stable and 
unfolds more slowly, yet it maintains its bulk secondary structure and oligomeric 
state. The simplest explanation for these data is that M63F is affecting some 
functionally important dynamic process of the protein, possibly mediated by helix 
III, that is critical for A9 activation of TLR4. The proteolytic susceptibility of A9s 
also supports this hypothesis, as proteolysis is a dynamic process that often relies 
on substrate flexibility and local unfolding events to proceed.179–183 Damage- 
Associated Molecular Patterns (DAMPs) often interact with their targets via 
hydrophobic surfaces;184–186 one possibility is that A9 undergoes a local unfolding 
event that exposes a hydrophobic surface to interact with TLR4. This would mean 
that studies of the native structure of A9 might not be sufficient to gain mechanistic 
understanding of how it activates TLR4. Further work is required to understand the 
nature of the active functional state of A9. 
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Pleiotropic mutations can facilitate the evolution of multifunctionality 
 
Finally, our results suggest a positive role for pleiotropy in the evolution of 
protein function. Pleiotropy is often viewed as a constraint on evolution: as 
functional complexity is added to a polypeptide sequence, it becomes increasingly 
challenging to introduce substitutions—and new functions—without perturbing 
existing ones.57,143,145,146,187,188 Here, however, we find a single mutation that had 
beneficial pleiotropic effects on two important properties of A9: proinflammatory 
activity and proteolytic susceptibility. If A9 evolved potent proinflammatory 
activity without gaining susceptibility, it could potentially overstimulate 
inflammation simply by lingering in the extracellular milieu. Since both properties 
evolved at once, however, mammals evolved a proinflammatory molecule with a 
built-in “timer”: they gained a new inflammatory signal while avoiding potentially 
deleterious effects. This shows how pleiotropy can positively contribute to the 
evolution of new functions. 
This same mutation, in contrast, had little pleiotropic effect on another 
functional state of A9: the A8/A9 complex. The antimicrobial activity of the A8/A9 
complex was insulated from any pleiotropic effects from the mutation because 
proinflammatory and antimicrobial activities were partitioned between A9 and the 
A8/A9 complex, respectively. A mutation arose in the A9 amino acid sequence and 
is thus present in both A9 and A8/A9 states, but we only observe effects on the A9 
state. This shows that pleiotropic constraint can be reduced when protein functions 
are partitioned amongst different protein states. 
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These findings reveal the diversity of pleiotropic roles that a single mutation 
can play. It further shows how the deleterious pleiotropic effects of mutations can 
be reduced by partitioning protein functions and properties into different functional 
states, thus enabling the acquisition, optimization, and expansion of new protein 
functions. Given the vast diversity of protein functional domains and protein- 
protein interactions in biology, we suspect that this is a common occurrence in the 
evolution of protein multifunctionality. 
 
 
MATERIALS AND METHODS 
 
Phylogenetics and ancestral sequence reconstruction 
 
We reconstructed ancestral sequences using a previously published a 
phylogenetic tree of S100 proteins containing 172 sequences from 30 amniote taxa 
(supplemental files 1-2).130 We used PAML4 to generate maximum likelihood 
ancestors (marginal probability method)36,38 using the previously-identified 
maximum likelihood (ML) substitution model (LG+8)
189 on the ML tree. To 
account for reconstruction uncertainty, we also generated “altAll” versions of each 
ancestor.171 We took every site in which the alternate reconstruction had a posterior 
probability > 0.20 and substituted that amino acid into the maximum-likelihood 
ancestor. These alternate reconstructions had an average of 12 sequence differences 
relative to the maximum-likelihood ancestors (Figure AA4). They represent a 
“worst case” reconstruction relative to our best, maximum likelihood 
reconstruction. 
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We also investigated the effect of topological uncertainty on our 
reconstructed ancestors. In the published phylogenetic analysis, A8s, A9s, A12s, 
and MRP126s all formed distinct and well-supported clades; however, the 
branching pattern between these four clades could not be resolved with high 
confidence.130 To explore how this uncertainty altered our reconstructed ancestral 
proteins, we constructed all 15 possible topologies for the A8, A9, A12, and 
MRP126 clades—i.e ((A8,A9),(A12,MRP126)), ((A8,A12),(MRP126,A9)), etc.— 
while maintaining species-corrected, within-clade topologies. We then optimized 
the tree branch lengths and substitution rates for each tree using PhyML.190 Finally, 
we used PAML to reconstruct ancA9, ancCG, and ancA8 for all 15 possible 
arrangements of the MRP126, A12, A8, and A9 clades. The average number of 
sequence differences for ancestors reconstructed using different topologies was less 
than or equal to the number of sequence differences between the ML and altAll 
reconstructions (Table S1). Further, the sites that differed were a subset of those 
that differed between the ML and altAll reconstructions. Thus, the altAll 
reconstructions account for sequence changes due to both uncertainty given the ML 
tree and uncertainty due to topological uncertainty. 
 
 
Cloning and mutagenesis 
 
All S100 genes in this study were purchased as synthetic constructs in 
pUC57 vectors from Genscript. S100 genes (A8s, A9s, A12s, MRP126s, and 
ancestrally reconstructed genes) were sub-cloned into a pETDuet-1 (pD) vector 
(Millipore). A8s, A12s, MRP126s, and ancCGs were cloned into multiple cloning 
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site #1 (MCS1) of the pD vector, while A9s were cloned into MCS2. For expression 
and purification of A8/A9 heterocomplexes (A8/A9s), pD plasmids containing an 
A8 gene in MCS1 and an A9 gene in MCS2 were used as previously described.191 
Opossum A8 was sub-cloned into an MBP-LIC vector to yield a His-MBP-TEV- 
opA8 construct. For opossum A8/A9, the entire His-MBP-TEV-A8 construct was 
then sub-cloned into MCS1 of a pD vector containing a marsupial A9 in MCS2. 
Other S100s (A1, A5, A7, A11, A14, and P) were previously cloned into a 
pET28/30 vector to yield a TEV-cleavable N-terminal His tag.112 Cysteine-free 
versions of all S100 genes, as well as point mutants, were prepared using site- 
directed mutagenesis (Agilent). 
 
 
Protein expression and purification 
 
Recombinant protein overexpression was conducted in E. coli BL21 (DE3) 
pLysS Rosetta cells. Cultures were innoculated in luria broth overnight at 37°C, 
shaking at 250 rpm, in the presence of ampicillin and chloramphenicol. The 
following day, 10 ml of saturated culture was diluted into 1.5 L of media with 
antibiotics, grown to OD600 = 0.6 – 1, and then induced overnight at 16°C using 1 
mM IPTG. Cells were pelleted at 3,000 rpm for 20 min and stored at -20°C for no 
more than three months. 
Lysates were prepared by vortexing pellets (3-5 g) in tris buffer (25 mM 
tris, 100 mM NaCl, pH 7.4) and incubating for 20 min at RT with DNAse I and 
lysozyme (ThermoFisher Scientific). Lysates were sonicated and cell debris was 
pelleted by centrifugation at 15,000 rpm at 4°C for > 20 min. All proteins were 
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purified on an Äkta PrimePlus FPLC using various 5 ml HiTrap columns (HisTrap 
FF (Ni-affinity), Q HP (anion exchange), SP FF (cation exchange), and MBPTrap 
HP (MBP) - GE Health Science). A1, A5, A7, A11, A14, and S100P were purified 
using a a TEV-cleavable His tag strategy used by our lab previously1,3,4. All other 
S100s, except for opossum A8 and opossum A8/A9, were purified in three steps 
using Ni-affinity chromatography in the presence of calcium followed by two 
rounds of anion exchange chromatography at different pHs. For Ni-affinity 
chromatography, proteins were eluted over a 50 ml gradient from 25-1000 mM 
imidazole in tris buffer. Peak elution fractions were pooled and placed in dialysis 
overnight at 4°C in 4 L of tris buffer (calcium-free) adjusted to pH 8. Anion 
exchange chromatography was then performed the following day over a 50 ml 
gradient from 100-1000 mM NaCl in pH 8 tris buffer. Fractions containing majority 
S100 were pooled and analyzed for purity on an SDS-PAGE gel. If trace 
contaminants remained, an additional anion exchange step was performed at pH 6 
using the same elution strategy as for the previous anion exchange step. 
Opossum A8 and A8/A9 lysates were prepared as above and then flowed 
over a nickel column, eluting over a 50 ml gradient from 25-1000 mM imidazole 
in tris buffer. Peak elution was pooled and the MBP tag was cleaved by incubation 
with ~1:5 TEV protease at 4°C overnight in 4 L of tris buffer. The MBP tag was 
then removed by flowing the sample over an MBPTrap column, step-eluting with 
10 mM maltose. Additional MBP columns were run until all MBP was removed 
from the purified protein, assessed by SDS-PAGE. If necessary, an additional anion 
exchange step at pH 8 was performed to complete purification. All purified proteins 
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were dialyzed overnight at 4°C in tris buffer + 2 g/L Chelex-100 resin (Biorad), 
flash-frozen the following day in liquid nitrogen, and stored at -80°C. 
 
 
Biophysical and biochemical characterization 
 
For all experiments, protein aliquots were thawed fresh from freezer stocks 
and were either dialyzed in the appropriate experimental buffer overnight at 4°C or 
exchanged 3X into experimental buffer using 3K microsep spin concentrator 
columns (Pall Corporation). All samples were filter-sterilized using 0.1 um spin 
filters (EMD Millipore) prior to measuring concentration and using in experiments. 
Thawed aliquots were used for no more than one week before discarding. All 
concentrations were measured by Bradford assay and correspond to micromolar 
dimeric protein. 
For in vitro proteolytic susceptibility experiments, proteins were dialyzed 
or exchanged into tris buffer + 1 mM CaCl2. 12.5 uM S100 protein was treated with 
5 uM monomeric Proteinase K from Tritirachium album (Sigma Aldrich), 
cathepsin G from human neutrophils (Athens Research), or neutrophil elastase from 
human neutrophils (Millipore Sigma) in thin-walled PCR tubes, which were held 
at a constant temperature of 25°C over the course of the experiment using a thermal 
cycler. Proteinase K activity was quenched at different time points by directly 
pipetting an aliquot of the reaction into an equal volume of 95% Laemmli SDS- 
PAGE loading buffer + 5% BME at 95°C in a separate thermal cycler. Time points 
were analyzed via SDS-PAGE, and gels were quantified by densitometry using in- 
house  gel  analysis  software  (https://github.com/harmslab/gelquant,  v1.0).  An 
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exponential decay function ( ) was fit to the data to extract the decay rate, 
floating     and    Standard deviations were calculated from fits by taking the 
square root of the diagonalized covariance matrix and by error propagation. 
Oligomeric states were measured using a superose 12 10/300 GL size 
exclusion column (Amersham Biosciences) with in-line concentration detection 
using refractive index (RI) and particle mass measured using a multiangle laser 
light scattering (MALS) instrument (Dawn Heleos, Wyatt Technology). Samples 
were concentrated to 0.5-2 mg/ml in tris buffer + 0.5 mM CaCl2, 0.1 um sterile- 
filtered, and analyzed at a flow rate of 0.2 ml/min. Data were processed using 
manufacturer’s software (Astra). 
Circular dichroism (CD) and chemical denaturation experiments were 
performed using a Jasco J-815 CD spectrometer and spectroscopy-grade guanidine 
hydrochloride (gdn-HCl) or urea. Chemical denaturation was performed using 25 
uM dimeric protein in tris buffer with CaCl2, with tris substituted for spectroscopy- 
grade trizma. Reversible unfolding and refolding curves were constructed by 
making concentrated 100 uM protein stocks in either buffer or 6M gdm or 10M 
urea and then preparing protein dilutions in various concentrations of gdn-HCl or 
urea in buffer. Samples were left to equilibrate in denaturant between three hours 
and overnight to allow for equilibration and were then analyzed by CD. 
Unfolding/refolding equilibration was confirmed by comparing unfolded vs. 
refolded protein at the same concentration. CD signal was quantified at 222 nm in 
a 1 mm cuvette using a 1 nm bandwidth, standard sensitivity, and 2 second D.I.T. 




to the data to extract thermodynamic parameters, where are the 
folded and unfolded baseline y-intercepts and slopes,    is the unfolding free 
energy,  is the m-value, R = 0.001987 JK-1mol-1 and T = 298.15 K. Standard 
deviations were calculated from fits by taking the square root of the diagonalized 
covariance matrix and by error propagation. Apparent unfolding kinetics studies 
were performed using the above conditions by spiking concentrated protein stock 





We purchased commercially distributed HEK293T cells from ATCC (CRL- 
11268). Because we are using this cell line as a host for heterologous transient 
transfections, the appropriate control for consistency between assays is the 
measurement of reporter output for a set of control plasmids and a panel of known 
treatments. Upon thawing each batch of cells, we run a positive control for ligand- 
induced response. We transfect the cells with plasmids encoding human CD14, 
human MD-2, human TLR4, renilla luciferase behind a constitutive promoter, and 
firefly luciferase behind an NF-KB promoter. We then characterize the raw 
luciferase output for five treatments: 1) mock, 2) LPS, 3) LPS + polymyxin B, 4) 
S100A9 + polymyxin B, and 5) S100A9 + 1.25x polymyxin B. This has a 
stereotypical pattern of responses in renilla luciferase (high for all) and firefly 
luciferase (low, high, low, high, high). To validate that this response is dependent 
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on the transfected TLR4 complex as opposed to the cells themselves, we repeat the 
experiment but exclude the TLR4 plasmid. This should give identical renilla 
luciferase values but no firefly luciferase output in response to any treatment. To 
ensure that the cells maintain their properties between passages, we repeat the 
mock, LPS, and LPS + polymyxin B control on every single experimental plate. 
This assay has a built-in control for mycoplasma contamination: high firefly 
luciferase signal in the absence of added agonist. This indicates that there is another 
source of TLR4-induced NF-kappa B output in the cells—most plausibly, 
contamination. This mycoplasma sensing approach is used in the commercially 
available HEK-BLUE mycoplasma detection kit (Invivogen). We discard any cells 





The antimicrobial activity of S100s was measured against S. epidermidis 
using a well-established assay.97,102,104,110,192 The day before, a 5 ml starter culture 
of S. epidermidis in tryptic soy broth (TSB) was grown overnight. The next day, the 
culture was diluted ~1:100 in TSB and grown for approximately 2 hours to an 
OD600 of ~0.8. Immediately prior to experiment, the S. epidermidis culture was 
again diluted 1:100 at a ratio of 62:38 experimental buffer (25 mM tris, 100 mM 
NaCl, 3 mM CaCl2, pH 7.4):TSB. S100 proteins were exchanged into experimental 
buffer. Each well of a sterile 96-well plate was prepared with 40 ul of S. epidermidis 
diluted in experimental buffer + TSB, S100 protein at the desired concentration in 
experimental buffer, and then filled to 200 ul, maintaining a ratio of 62:38 
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experimental buffer:TB. S. epidermidis growth was monitored on a plate reader, 
measuring OD600 every 15 minutes for 13 hours. Each measurement was collected 
in technical triplicate and background-subtracted using a blank containing 
experimental buffer and TSB alone. Protein samples were confirmed to lack 
bacterial contamination by measuring S100 protein growth in experimental buffer 
and TSB lacking S. epidermidis. 
 
All plasmids, cell culture conditions, and transfections for measuring the 
activity of S100s against TLR4s were identical to those previously 
described.38,39130,172 Briefly, human embryonic kidney cells (HEK293T/17, ATCC 
CRL-11268) were maintained up to 30 passages in Dulbecco’s Modified Eagle 
Media (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C with 
5% CO2. Lipopolysaccharide E. coli K-12 LPS (LPS - tlrl-eklps, Invivogen) 
aliquots were prepared at 5 mg/ml in endotoxin-free water and stored at -20oC. 
Working solutions were prepared at 10 ug/ml and stored at 4oC to avoid freeze- 
thaw cycles. S100 proteins were prepared by exchanging into endotoxin-free PBS 
and incubating with an endotoxin removal column (Thermo Fisher Scientific) for 2 
hours. S100 LPS contamination was assessed by measuring activity with and 
without Polymyxin B, an LPS chelating agent (Figure AA6). LPS (200 ng per 100 
ul well) or S100 (0.8, 0.4, 2, 4, or 5 uM dimer) treatments were prepared by diluting 
in 25:75 endotoxin-free PBS:serum-free Dulbecco’s Modified Eagle Media 
(DMEM – Thermo Fisher Scientific). Polymyxin B (PB, 200 ug per 100 ul well) 
was added to all S100 experimental samples to limit background endotoxin 
contamination activity from recombinant protein preps. Cells were incubated with 
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treatments for 3 hours prior to assaying activity. The Dual-Glo Luciferase Assay 
System (Promega) was used to assay Firefly and Renilla luciferase activity of 
individual wells. Each NF-κB induction value shown represents the Firefly 
luciferase activity divided by the Renilla luciferase activity, background-subtracted 
using the LPS + PB activity for each TLR4 species and normalized to the activity 
of LPS alone for each TLR4 species to normalize between plates. All measurements 
were performed using three technical replicates per plate, a minimum of three 
biological replicates total, and a minimum of two separate protein preps. 
 
For TLR4 activation measurements by A9 proteolytic products, 12.5 uM 
hA9 or hA9 M63F were incubated with 2.5 mg/ml Proteinase K immobilized to 
agarose at 37oC for increasing amounts of time. The reaction was quenched by spin- 
filtering the sample to remove Proteinase K. 2 uM A9 proteolysis treatments were 
then added to cells as outlined above. Western blots were performed by running an 
SDS-PAGE gel and transferring to a nitrocellulose membrane. Membranes were 
blocked using Odyssey Blocking Buffer for 1 hour, incubated with 1:1000 mouse 
anti-S100A9 primary antibody (M13 clone 1CD22, Abnova) for 1 hour, and 
incubated with 1:10,000 IRDye Goat anti-mouse 800CW IgG (H+L, Licor) for 1 
hour, with 3x5 min TBST washes in between each step. Blots were imaged using 
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BRIDGE TO CHAPTER III 
 
 
In this chapter, we determined that A9 gained potent proinflammatory 
activity and lost proteolytic resistance from a weakly proinflammatory, 
proteolytically resistant amniote ancestor.131 We showed that A9 maintained the 
ability to form a complex with A8 post-gene duplication, resulting in the evolution 
of the antimicrobial, proteolytically resistant A8/A9 heterocomplex in mammals. 
We identified a single historical substitution – M63F - that occurred in the 
mammalian A9 ancestor and played a key role in A9 loss of proteolytic resistance 
and gain of proinflammatory activity. The historical substitution altered multiple 
A9 functions without significantly changing the A8/A9 complex, showing that 
pleiotropy can play a beneficial role in the evolution of protein multifunctionality. 
Lastly, we showed that proteolytic degradation of A9 is not necessary for A9 
activation of TLR4. This chapter provides novel insight into how A9 evolved 
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multifunctionality and lays a foundation for determining the mechanism by which 
A9 activates TLR4 to drive inflammation. Chapter III builds upon these findings 
by dissecting the biophysical mechanism through which the M63F mutation alters 
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S100A9 (A9) is one of the most abundant proteins in neutrophils79,80 and 
potently activates inflammation via Toll-like Receptor 4 (TLR4).86,91–95 It is a 
biomarker for various inflammatory diseases,81–85 a damage-associated molecular 
pattern (DAMP) that signals tissue damage to the immune system,92,151,153,186 and a 
drug target for chronic inflammatory disorders.129,193 However, the mechanism by 
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which A9 activates TLR4 to drive inflammation is unknown. Determining how A9 
induces inflammation via TLR4 is critical for understanding mechanisms by which 
DAMPs participate in mammalian innate immunity and for designing drugs to 
reduce aberrant A9-mediated inflammation. 
Previous studies have yielded limited insight into how A9 interacts with 
TLR4. Lipopolysaccharide (LPS) – a small bacterial cell wall component – 
activates TLR4 by binding to a small hydrophobic pocket of MD2, a TLR4 cofactor 
required for activity.117,121 It was previously proposed that smaller proteolytic 
fragments of A9 might activate TLR4 similarly to LPS, as A9 is readily 
proteolytically degraded and the extracellular space is rich in proteases.109 We 
recently showed, however, that A9 proteolytic degradation is not required for TLR4 
activation.131 Additional studies have identified pairs of charged mutations that 
disrupt A9 binding to TLR4 in vitro, leading to a proposed in silico A9:TLR4 
docking model.109 However, the functional effects of these mutations on A9 
activation of TLR4 were not characterized. 
We recently identified a historical mutation in A9 that, when reverted to its 
amniote ancestral state in human A9 (A9 M63F), strongly compromised A9 
activation of TLR4 in an ex vivo cell culture assay.131 This was, to our knowledge, 
the first mutation that has been shown to alter A9 proinflammatory activity. 
Surprisingly, the M63F mutation is at an internal position of the protein, making it 
difficult to identify an A9:TLR4 interaction interface. We further found that M63F 
stabilizes A9 in the presence of calcium by decreasing its unfolding rate. This is 
puzzling because A9 activates TLR4 in the calcium-rich extracellular space, and 
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thus the calcium-bound form of A9 is thought to be the “active” state of the protein. 
How does M63F stabilize the “active” state of the protein, yet also reduce A9 
activation of TLR4? 
We set out to determine how, mechanistically, M63F alters A9 
proinflammatory activity. We find that M63F stabilizes only the calcium-bound 
state – but not the calcium-free state – of A9. Biophysical characterization of the 
A9 M63F structure indicates that M63F does not appreciably alter the native 
structure of the protein. We find that A9 and A9 M63F exhibit similar dynamics 
over short timescales (ps - µs) in NMR NOE and CPMG experiments. However, 
we show that M63F strongly quenches long timescale dynamics in A9 using 
hydrogen-deuterium exchange (HDX) experiments. Mapping differences in 
exchange onto the A9 protein structure175 reveals that M63F locally stabilizes A9 
in regions previously proposed to interact with TLR4.109 We identify a second 
phenylalanine (F37) within the stabilized region that is in close proximity to M63F. 
Mutating F37 to a leucine in the A9 M63F background (A9 M63F F37L) negates 
the stabilizing effect of M63F and fully restores A9 proinflammatory function. 
These findings show that M63F decreases A9 proinflammatory activity by locally 
stabilizing the protein via an interaction with a nearby residue – all without 
significantly altering the protein’s native structure. We propose that A9 adopts a 
non-native conformation – distinct from the native calcium-bound structure – to 
activate TLR4. These findings propose a novel mechanism by which a key innate 
immune protein drives inflammation, enabling the development of treatment 




The M63F substitution stabilizes the calcium-bound state of A9 
 
We first sought to determine which state(s) of A9 are stabilized by M63F 
along the A9 folding pathway. We previously showed that M63F stabilizes A9 in 
the presence of calcium.131 However, A9 folding is a multi-step process that 
includes monomer folding, homodimerization, a conformational change, and then 
calcium binding (Figure 3.1A, i-iv). As the state of A9 that activates TLR4 is 
unknown, an additional state of A9 might also be required for A9 proinflammatory 
activity (figure 3.1A, v). The M63F mutation could hinder A9 activation of TLR4 
by altering any of these folding or conformational intermediates or by stabilizing 
an off-pathway state. 
To determine which state(s) of A9 are altered by M63F, we first measured 
the stability of A9 and A9 M63F in the absence of calcium. We performed 
equilibrium chemical denaturation experiments using urea and monitored protein 
folding using circular dichroism (CD) spectroscopy, as reported previously (see 
methods).131 We fit an apparent two-state unfolding model to the data to extract the 
apparent folding free energy, m-value, and Cm (Figure 3.1b-e). In the absence of 
calcium, we observed little difference in apparent stability between A9 and A9 
M63F at 5 uM protein concentration (2.91 ± 0.63 vs. 3.72 ± 0.12 kcal/mol – Figure 
3.1b, 1e). We also measured the oligomeric states of calcium-free A9 and A9 M63F 
using size exclusion chromatography coupled with multi-angle laser light scattering 
(SECMALS). We found that both proteins form predominantly homodimers at low 
micromolar concentrations (Figure AB1), as previously observed in the presence 
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of calcium,131 indicating that the M63F mutation does not significantly impact A9 
homodimerization. This is unsurprising, as M63F is distant from the A9 
dimerization interface175 and the Kd of A9 homodimerization is sub-micromolar.
170 
These findings indicate that the M63F mutation does not significantly alter the 
intrinsic stability of A9 monomers or the calcium-free A9 homodimer (Figure 1a, 




Figure 3.1. M63F specifically stabilizes the calcium-bound form of A9. a) 
Folding pathway for A9. Unfolded monomers (i) fold (ii) and dimerize (iii), 
followed by calcium binding (iv). Calcium-bound A9 is then thought to activate the 
TLR4/MD2 complex (v). b-d) Equilibrium urea denaturation of A9 (purple) and 
A9 M63F (red) with b) 0.5 mM EDTA, c) 0.5 mM CaCl2, or d) 5 mM CaCl2 present. 
Points are biological replicates and solid lines are a two-state unfolding model fit 
to the data (see methods). e) Thermodynamic parameters calculated from fits in b- 
d). Errors are from fits (see methods). 
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To test whether M63F specifically alters the calcium-bound state of A9, we 
measured the stability of A9 and A9 M63F in the presence of calcium. We 
previously measured A9 and A9 M63F stability in the presence of 0.5 mM CaCl2 
(reproduced in figure 3.1c, 1e).131 We expanded upon these findings by measuring 
A9 and A9 M63F stability with 5 mM CaCl2 present (Figure 3.1d-e). We found that 
M63F stabilizes A9 in a calcium-dependent manner, affording 4.7 ± 0.2 kcal/mol 
and 6.4 ± 3.1 kcal/mol of additional stability at 0.5 mM and 5 mM CaCl2, 
respectively. These findings show that M63F stabilizes the calcium-bound state(s) 
of A9 (Figure 3.1a, i-iii) without significantly affecting the stability of any calcium- 
free states (Figure 3.1a, iv-v). 
 
 
M63F does not appear to significantly alter A9 structure 
 
We next asked whether the structure of A9 is altered by the M63F mutation. 
We previously showed that the bulk secondary structure and oligomeric state of A9 
are unchanged by M63F in the presence of calcium, indicating that M63F doesn’t 
cause a large, global change in A9 structure.131 However, this does not rule out the 
possibility that M63F causes a local structural change and/or stabilizes a misfolded, 
functionally inactive state of the protein. To test whether M63F alters the structure 
of A9, we characterized the A9 M63F mutant by NMR. We transferred and 
confirmed peak assignments for A9 M63F from the calcium-loaded wildtype A9 
NMR structure193 using TROSY-HSQC experiments. We successfully assigned 91 
out of 114 A9 M63F peaks. The majority of unassigned peaks are within the A9 
disordered C-terminal tail, many of which are also unassigned in the wildtype A9 
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structure.193 We then compared changes in chemical shift for each assigned residue 
in A9 and A9 M63F (Figure 3.2a-b). We mapped the combined chemical shift 
differences between A9 and A9 M63F onto the A9 structure and found that the 
largest changes in chemical shift occur locally around the M63F mutation. Minimal 
changes in chemical shift are observed for regions of the protein that are distant 
from M63F. These findings suggest that M63F alters the local chemical 
environment of nearby residues but does not significantly affect the overall 
structure of A9. 
 
 
M63F does not alter A9 dynamics on short timescales 
 
We wondered whether M63F might inhibit A9 proinflammatory activity by 
altering a functionally important dynamic process of the protein. To test for A9 
dynamics that are affected by M63F, we again turned to NMR. We probed protein 
dynamics on three timescales: ps-ns, ns-μs, and ms+. We examined A9 dynamics 
on the ps-ns timescale using a two-point Car-Purcell-Meiboom-Gill (CPMG)194 
experiment. We first measured wildtype A9 (Figure 3.3a). As expected from the 
A9 structure and previous work, the C-terminal tail of A9 exhibited rapid 
movement, as did loop regions. We then repeated the measurement for M63F 
(Figure 3.3a). There was no appreciable difference in CPMG ps-ns dynamics 
between WT and M63F (Figure 3.3a-b). 
We then probed the ns-μs timescale using NOE relaxation-dispersion 
experiments.195 We found that the bulk of A9 operated as a folded unit, with the 
tails moving independently on this timescale (Figure 3.3c). Similar to CPMG 
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experiments, we obtained comparable results for M63F (Figure 3.3c-d). These data 
together indicate that M63F does not alter A9 short timescale dynamics. 
 
Figure 3.2. M63F locally perturbs nearby residues without affecting bulk A9 
structure. a) Overlaid HSQC NMR spectra for A9 (purple) and A9 M63F (red). b) 
Combined chemical shift (CCS) differences between A9 and A9 M63F for 91 
assigned residues (see methods). c) Data from b) mapped onto A9 crystal structure 
(PDB 1irj). Larger tubes and brighter red color indicate larger CCS difference. 
Calcium ions are blue spheres, residue 63 shown as grey spheres. 
 
 
A9 long timescale dynamics are quenched by the M63F mutation 
 
We next asked if M63F alters long timescale dynamics in A9. Supporting 
this possibility, we previously showed that M63F significantly decreases the 
unfolding rate of A9 such that A9 M63F unfolding can be observed over the course 
of several minutes.131 To probe for changes in long timescale dynamics, we 
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measured hydrogen-deuterium exchange (HDX) by NMR for A9 and A9 M63F. 
We collected HSQC spectra for both proteins over the course of 24 hours (Figure 
3.4a-d) and quantified peak intensities for each timepoint. As many peaks 
disappeared more rapidly than the first measured timepoint (~10 minutes), we used 
the Akaike Information Criterion (AIC) to determine whether a single exponential 
decay model or a linear model was more appropriate for extracting an exchange 
rate from the data for each residue (see methods). This is a conservative approach 
that places a lower limit on the exchange rate for each residue – if a linear model 
better describes the exchange process than a single exponential decay model (due 
to a lower AIC), then the exchange rate is simply assigned as faster than the fastest- 
exchanging residue for which a single exponential decay model was employed due 
to a lower AIC (see methods). 
Using this approach, we calculated the log difference in exchange rate for 
each residue between A9 and A9 M63F (Figure 3.4e, AB3). Of the 93 residues 
assigned in A9 and A9 M63F, 49 residues exchanged too rapidly to quantify in both 
A9 and A9 M63F (Figure 3.4e, grey). Two residues exchanged too rapidly in A9 
M63F to quantify but were measurable in wildtype A9 (Figure 3.4e – blue). We 
successfully quantified exchange rates for 26 residues in A9 M63F, 16 of which 
exchanged too rapidly in wildtype A9 to be measured (Figure 3.4e – pink and red, 
respectively). Calculated exchange rates for the remaining 18 assigned residues are 
not shown due to high error (> 3 log units). However, each of these 18 residues 




Figure 3.3. M63F does not alter A9 dynamics on short (ps-us) timescales. a) 
and c) 2-point CPMG and NOE NMR dynamics measurements, respectively. 
Differences in CPMG and NOE between A9 and M63F shown in b) and d). Points 
are average relaxation times, error bars are standard deviation. 
 
 
Mapping differences in log exchange rate for each residue between A9 and 
A9 M63F onto the A9 crystal structure revealed that M63F strongly decreases 
exchange for multiple nearby residues, both in helix III where M63F resides and in 
helix II directly across from M63F. These data parallel the changes in combined 
chemical shift observed Figure 3.2. M63F thus hinders long timescale A9 






Figure 3.4. M63F strongly increases local A9 stability. a) NMR HSQC HDX 
spectra for wildtype A9 (a-b) and A9 M63F (c-d). a) and c) show peaks present 
after 10 minutes of exchange, while b) and d) show peaks present after 24 hours of 
exchange. X and y-axes are 1H and 15N chemical shifts (ppm). e) Log change in 
exchange rate for residues in A9 and A9 M63F. Points are exchange rate extracted 
from fit to HSQC data, error bars propagated from fits (see methods). red and light 
blue = residues that exchanged too fast to be measured only in A9 or M63F, 
respectively; pink = residues for which exponential decay was observed for both 
A9 and A9 M63F; grey = residues that exchanged too quickly to be observed for 
both A9 and M63F. A9 helices shown above (purple). Changes in exchange in e) 
mapped onto A9 crystal structure (PDB 1irj). Colors are the same as in e). Higher 
red intensity and larger tubes indicate residues that are more protected in A9 M63F. 
Positions 63 and 37 are indicated in black text. Calcium ions colored in dark blue. 
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M63F stabilizes A9 through a direct interaction with a nearby residue 
 
We next asked how M63F locally stabilizes A9. We examined residues in 
the region of A9 that is stabilized by M63F and identified a phenylalanine at 
position 37 that is stabilized by M63F in NMR HDX experiments (Figure 3.4f). In 
both the A9 structure and in molecular dynamics simulations (unpublished data), 
F37 is well-positioned to interact with M63F. We reasoned that the increase in 
stability induced by M63F could be due to a pi-stacking interaction between M63F 
and F37. We therefore mutated F37 to a leucine, which is the ancestral state for this 
amino acid in the last common ancestor of amniotes and the most common amino 
acid at this position within calgranulin S100s.130,131 We introduced F37L into both 
A9 and A9 M63F to produce A9 F37L and A9 M63F/F37L. 
We tested the stability of the A9 F37L and A9 M63F/F37L variants using 
chemical denaturation and CD spectroscopy. In the absence of calcium, we 
observed no change in stability between wildtype A9 or any of the A9 variants 
(Figure 3.5a). We verified that the A9 variants were homodimers under these 
conditions using SECMALS (Figure AB1). This indicates that the F37L mutation 
does not appreciably affect the intrinsic stability of each monomer or the A9 
dimerization constant, similarly to M63F. 
In the presence of calcium, we found that both A9 F37L and A9 M63F/F37L 
exhibited wildtype A9 levels of stability (Figure 3.5b-c). This shows that mutating 
F37 in the A9 M63F background (A9 M63F/F37L) completely negates the 
stabilizing effect of M63F. We used the unfolding free energies for A9 and the three 
A9 variants to calculate the interaction energy between F63 and F37 (Figure 3.5d). 
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In the absence of calcium, ∆∆GF-F = 0.43 ± 0.66 kcal/mol, affording no appreciable 
increase in stability. However, upon addition of 0.5 mM or 5 mM calcium, ∆∆GF-F 
= 5.16 ± 1.01 and 6.13 ± 3.11 kcal/mol, respectively (Figure 3.5d, AB4). This 
shows that M63F stabilizes A9 by forming a strong interaction with F37. Mutating 
either residue in the F-F interaction is sufficient to restore wildtype stability. 
We confirmed that mutating either phenylalanine in the F-F interaction 
negates the local stabilizing effect of M63F using HDX measurements by mass 
spectrometry. We monitored HDX for wildtype A9 and the three variants over the 
course of 24 hours, quenching the reaction at each timepoint using chemical 
denaturation at low pH. We then digested each exchanged protein sample using 
trypsin and quantified the number of deuterium ions present per peptide by mass 
spectrometry (Figure AB5). We calculated the percent deuterium uptake for each 
peptide and determined the change in percent uptake between A9 and the three 
variants (Figure 3.5e, AB5). Mimicking our findings by NMR, we found that M63F 
strongly decreased A9 hydrogen-deuterium exchange. In contrast, both A9 F37L 
and A9 M63F/F37L exhibited hydrogen-deuterium exchange that was comparable 
to or higher than A9 (Figure 3.4e), indicating that the F37L mutation locally 
destabilizes both wildtype A9 and A9 M63F. These findings further show that 
M63F primarily stabilizes A9 through a strong interaction with F37. 
 
 
A9 variants bind calcium with high affinity 
 
One explanation for why the M63F-F37 interaction stabilizes A9 is that it 
might alter A9 calcium binding, as M63F causes significant changes in chemical 
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environment (Figure 3.2) and stability (Figure 3.4, 3.5a-e) near A9 calcium binding 
sites. To test this possibility, we measured calcium binding by isothermal titration 
calorimetry (ITC) for A9 and the three A9 variants (Figure AB6-8). A9 monomers 
have two calcium binding sites – one with lower affinity between residues 23-36, 
and one with high affinity between residues 67-78.170,196 We therefore fit a two-site 
binding model to the data (Figure AB6-8). We estimated Kd1 < 100 nM for A9 and 
each A9 variant. However, due to the complexity of fitting a two-site binding model 
in which the sites have different binding affinities, we were unable to reliably 
quantify Kd2 (Table AB7). Fitting a single-site model to each dataset yielded an 
identical Kd to the Kd1 calculated in two-site models (Table AB7). We also found 
that the fraction competent (Ffx) parameter, which is used in ITC fitting to estimate 
the fraction of protein sample that is binding-competent, decreased for each A9 
variant compared to wildtype A9. Ffx for wildtype A9 was estimated to be 0.98, 
while Ffx decreased to 0.21, 0.42, and 0.58 for A9 M63F, A9 M63F/F37L, and A9 
F37L, respectively. Lastly, we were able to resolve a small, second binding 
transition only for A9 M63F. We separately fit this transition using a single-site 
binding model and estimated the Kd = 741 ± 134 nM (Figure AB7-8). These 
findings suggest that calcium binding is modestly perturbed in each of the A9 
variants. However, this perturbation does not correlate with changes in A9 stability, 




Figure 3.5. Disrupting the M63F-37F interaction restores A9 stability and 
TLR4 activation. a-c) Equilibrium urea denaturation of A9 (dark purple), A9 
M63F (red), A9 M63F F37L (pink), and A9 F37L (light purple) with a) 0.5 mM 
EDTA, b) 0.5 mM CaCl2, or c) 5 mM CaCl2 present. Points are biological replicates 
and solid lines are a two-state unfolding model fit to the data (see methods). Free 
energy values are in kcal/mol. d) Mutant cycle thermodynamic values for A9 and 
three mutants at 500 uM CaCl2. e) Differences in deuterium uptake from wildtype 
A9 after 1 hour for three A9 mutants measured by HDX-MS (see methods). Points 
represent one biological replicate, errors bars are standard error. f) Differences in 
TLR4 activation for A9 and three mutants. Colors same as in a-d). Data represent 
> 3 biological replicates, error bars are standard error of the mean. 
 
 
Removing the F-F interaction fully restores A9 proinflammatory activity 
 
Finally, we asked whether the M63F-F37 interaction is the mechanism by 
which M63F decreases A9 proinflammatory activity. If the F-F interaction is the 
primary inhibitor of A9 M63F proinflammatory activity, then removing this 
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interaction – via A9 M63F/F37L – should restore it. Alternatively, the M63F 
mutation could decrease A9 proinflammatory activity through another mechanism. 
To test this, we measured TLR4 activation by the A9 variants using a previously 
described a cell culture assay (Figure 3.5f, AB9). Strikingly, we found that both A9 
F37L and A9 M63F/F37L activated TLR4 similarly to wildtype A9. This shows 
that M63F inhibits A9 proinflammatory activation of TLR4 by forming a strong pi- 





M63F decreases A9 proinflammatory activity through a stabilizing molecular 
“staple” 
This work reveals the mechanism by which a single mutation decreases A9 
proinflammatory activation of TLR4. Lacking a mechanistic understanding of how 
A9 activates TLR4 has hampered the design of strategies for treating A9-induced 
chronic inflammation. The A9:TLR4 binding interface is unknown, and until 
recently, no mutation had been identified that alters A9 proinflammatory activity. 
Here we show that the previously identified M63F mutation decreases A9 
activation of TLR4 by directly interacting with nearby F37, resulting in a strong 
local increase in stability. Disrupting this interaction by mutating either 
phenylalanine restores wildtype A9 stability and fully rescues A9 activation of 
TLR4, revealing that the F-F interaction is the primary determinant by which the 
M63F mutation inhibits A9 function. This finding provides valuable mechanistic 
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A9 might activate TLR4 through a non-native conformation 
 
We propose two possible explanations for how the F-F interaction inhibits 
A9 proinflammatory activity. The first is that the F-F interaction disrupts the native 
structure of A9. This could occur by stabilizing a misfolded intermediate, unfolding 
portions of the protein, or disrupting calcium binding. Alternatively, rather than 
disrupting the native structure of A9, the F-F interaction could restrict A9 from 
accessing a functionally important non-native conformation. 
Supporting the possibility of a structural change, we do observe differences 
in chemical environment for several A9 residues near M63F by NMR. This 
suggests that M63F causes a local structural change. Multiple lines of evidence, 
however, suggest that the F-F interaction does not significantly alter A9 structure. 
We observe no differences in oligomeric state or bulk secondary structure between 
A9 and the three A9 variants, indicating no gross changes in protein folding or 
secondary structure content. By NMR, the majority of residues in A9 maintain their 
chemical environment upon introduction of M63F. The residues that do undergo a 
change in chemical environment are those near the M63F mutation, so it is 
unsurprising that these residues show larger chemical shift differences. This finding 
does not rule out a small, local structural change induced by M63F; however, it 
does further suggest that M63F does not induce a large structural change in the 
protein. Lastly, The A9 M63F/F37L and A9 F37L variants have the same stability 
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and activity as wildtype A9, showing that single substitutions at positions 63 and/or 
37 alone do not functionally disrupt the protein. While we cannot explicitly rule out 
that the F-F interaction does not alter A9 structure, the majority of evidence 
suggests that it is not appreciably affected. To fully address this possibility, we are 
currently working to determine the structure of A9 M63F. 
The F-F interaction could perturb calcium binding, as the largest chemical 
shift changes observed in A9 M63F by NMR occur near calcium binding sites. We 
do observe modest differences in calcium binding for each of the A9 variants by 
ITC. In particular, we resolved a second binding transition in A9 M63F with an 
estimated Kd of ~740 nM, whereas all other estimated Kds for each variant are < 
100 nM. This suggests that the the F-F interaction might decrease calcium binding 
affinity at one of the two calcium binding sites in A9. However, all experiments 
were performed at millimolar calcium concentrations to mimic the high 
concentrations of calcium present in the extracellular space. Under these 
conditions, even if the F-F interaction decreases calcium binding affinity from low 
to high nanomolar, A9 M63F will remain saturated with calcium. Further, the F-F 
interaction stabilizes A9 in a calcium-dependent manner, suggesting that calcium 
binding is not significantly altered. Previous work revealed that the A9 M63F 
mutant robustly forms a functional heterotetramer with S100A8, which is a known 
calcium-dependent process.131 A9 proinflammatory function is also robust to other 
mutations, as A9 retained activity when mutating all zinc-binding residues 
simultaneously (residues 20, 30, 91, 95, 103-105) or when truncating the disordered 
C-terminal tail (residues 100-114).111 These data together suggest that the F-F 
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interaction does not decrease A9 proinflammatory activity by disrupting calcium 
binding. 
We propose, instead, that the F-F interaction prevents A9 from accessing a 
non-native conformation that is necessary to activate TLR4. Our data show that the 
F-F interaction strongly stabilizes nearby residues; the F-F interaction could 
prevent A9 binding to TLR4 by restricting access to these residues. In support of 
this, mutating charged amino acids between residues 64 -77 – near M63F – has 
been shown to decrease A9 binding to TLR4 in vitro.109 This suggests that the F-F 
interaction decreases A9 activation of TLR4 by inhibiting A9 from accessing a 
binding-competent conformation or rearrangement. 
A non-native mode of activation could explain why determining how A9 
activates TLR4 has been challenging. A9 could adopt a non-native structure 
ranging from a simple conformational change – as is common amongst S100 
proteins upon calcium binding170,197 – to an exotic unfolding event or 
rearrangement, which would likely be necessary for A9 to mimic LPS and bind 
within the hydrophobic pocket of MD2. Our findings, which are consonant with 
other groups,109 suggest that the local region of A9 surrounding the F-F interaction 
contains residues that are important for A9 activation of TLR4. We propose that 
this region of A9 should be a primary focus in ongoing studies to determine the 
exact nature of the state through which A9 activates TLR4 to drive inflammation. 
 
Stability/function tradeoffs could be common in DAMPs 
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This work highlights how destabilizing protein structure can be important for 
conferring new protein functions. Stability/function tradeoffs are well-described in 
enzymes – for example, enzyme stability can decrease to increase flexibility, ease 
product release, and increase catalytic efficiency.60,62,65,66,198 However, 
stability/function tradeoffs have not been broadly described for damage-associated 
molecular patterns (DAMPs) such as A9, which activate the innate immune system 
in response to tissue damage.92,151,153,185,186 This is because the mechanisms by 
which many DAMPs elicit an immune response and drive inflammation are 
unknown. DAMPs often live double lives; many perform normal intracellular 
functions until tissue damage occurs, leading to DAMP release and induction of an 
immune response.185,186 Hydrophobic surface exposure has been proposed as a 
mechanism by which DAMPs bind to immune receptors to trigger the immune 
system.199 In the case of A9, we previously showed that A9s gained 
proinflammatory activity while simultaneously losing proteolytic resistance.131 
This suggests that DAMPs might have lost stability over time, allowing for 
exposure of core hydrophobic residues or other conformational rearrangements – 
such as those proposed here for A9 – to signal tissue damage to receptors like TLR4. 
Determining the role of stability and structural rearrangements in DAMP function 
will be critical for understanding how DAMPs mediate the innate immune response 
and for targeting pathological DAMPs to treat inflammatory disease. 
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MATERIALS AND METHODS 
 
 
Cloning and mutagenesis 
 
All S100 genes in this study were purchased as synthetic constructs in 
pUC57 vectors from Genscript. S100 genes were sub-cloned into a pETDuet-1 (pD) 
vector (Millipore) as described previously.131 Cysteine-free versions of all S100 




Protein expression and purification 
 
Recombinant protein overexpression was conducted in E. coli BL21 (DE3) 
pLysS Rosetta cells. Cultures were inoculated in luria broth overnight at 37°C, 
shaking at 250 rpm, in the presence of ampicillin and chloramphenicol. The 
following day, 10 ml of saturated culture was diluted into 1.5 L of media with 
antibiotics, grown to OD600 = 0.6 – 1, and then induced overnight at 16°C using 1 
mM IPTG. Cells were pelleted at 3,000 rpm for 20 min and stored at -20°C for no 
more than three months. 
Lysates were prepared by vortexing pellets (3-5 g) in tris buffer (25 mM 
tris, 100 mM NaCl, pH 7.4) and incubating for 20 min at RT with DNAse I and 
lysozyme (ThermoFisher Scientific). Lysates were sonicated and cell debris was 
pelleted by centrifugation at 15,000 rpm at 4°C for > 20 min. All proteins were 
purified on an Äkta PrimePlus FPLC using various 5 ml HiTrap columns (HisTrap 
FF (Ni-affinity), Q HP (anion exchange)). All S100s were purified in three steps 
using Ni-affinity chromatography in the presence of calcium followed by two 
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rounds of anion exchange chromatography at different pHs. For Ni-affinity 
chromatography, proteins were eluted over a 50 ml gradient from 25-1000 mM 
imidazole in tris buffer. Peak elution fractions were pooled and placed in dialysis 
overnight at 4°C in 4 L of tris buffer (calcium-free) adjusted to pH 8. Anion 
exchange chromatography was then performed the following day over a 50 ml 
gradient from 100-1000 mM NaCl in pH 8 tris buffer. Fractions containing majority 
S100 were pooled and analyzed for purity on an SDS-PAGE gel. If trace 
contaminants remained, an additional anion exchange step was performed at pH 6 
using the same elution strategy as for the previous anion exchange step. All purified 
proteins were dialyzed overnight at 4°C in tris buffer + 2 g/L Chelex-100 resin 
(Biorad), flash-frozen the following day in liquid nitrogen, and stored at -80°C. 
 
 
Biophysical and biochemical characterization 
 
For all experiments, protein aliquots were thawed fresh from freezer stocks 
and were either dialyzed in the appropriate experimental buffer overnight at 4°C or 
exchanged 3X into experimental buffer using 3K microsep spin concentrator 
columns (Pall Corporation). All samples were filter-sterilized using 0.1 um spin 
filters (EMD Millipore) prior to measuring concentration and using in experiments. 
Thawed aliquots were used for no more than one week before discarding. All 
concentrations were measured by absorbance of protein in > 6M urea at 280 nm 
and correspond to micromolar dimeric protein. 
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Oligomeric state characterization by SECMALS 
 
Oligomeric states were measured using a superose 12 10/300 GL size 
exclusion column (Amersham Biosciences) with in-line concentration detection 
using refractive index (RI) and particle mass measured using a multiangle laser 
light scattering (MALS) instrument (Dawn Heleos, Wyatt Technology). Samples 
were concentrated to 0.5-2 mg/ml in tris buffer + 0.5 mM CaCl2, 0.1 um sterile- 
filtered, and analyzed at a flow rate of 0.2 ml/min. Data were processed using 
manufacturer’s software (Astra). 
 
 
CD Spectroscopy and chemical denaturation studies 
 
Circular dichroism (CD) and chemical denaturation experiments were 
performed using a Jasco J-815 CD spectrometer and spectroscopy-grade guanidine 
hydrochloride (gdn-HCl) or urea. Chemical denaturation was performed in tris 
buffer with CaCl2 or EDTA, with tris substituted for spectroscopy-grade trizma. 
Reversible unfolding and refolding curves were constructed by making 
concentrated 100 uM protein stocks in either buffer or 6M gdm or 10M urea and 
then preparing protein dilutions in various concentrations of gdn-HCl or urea in 
buffer. Samples were left to equilibrate in denaturant overnight and were then 
analyzed by CD. Unfolding/refolding equilibration was confirmed by comparing 
unfolded vs. refolded protein at the same concentration. CD signal was quantified 
at 222 nm in a 1 mm cuvette using a 1 nm bandwidth, standard sensitivity, and 2 




to the data to extract thermodynamic parameters, where are the 
folded and unfolded baseline y-intercepts and slopes,    is the unfolding free 
energy,  is the m-value, R = 0.001987 JK-1mol-1 and T = 298.15 K. Standard 
deviations were calculated from fits by taking the square root of the diagonalized 
covariance matrix and by error propagation. 
 
 
Calcium binding measurements by ITC 
 
ITC experiments were performed in 25 mM tris, 100 mM NaCl, pH 7.4 at 
25°C. To ensure removal of calcium, protein samples were treated with 5 mM 
EDTA at room temperature for 1 hour and then exchanged 10X into experimental 
buffer to remove EDTA. Calcium concentration was confirmed to be < 10 uM per 
sample for 50 uM experimental protein samples by ICP-MS. Samples were 
equilibrated and degassed by centrifugation at 18, 000 × g at the experimental 
temperature for 30 minutes. All experiments were performed at on a MicroCal ITC- 
200 or a MicroCal VP-ITC (Malvern). Gain settings were determined on a case-by- 
case basis. A 750 rpm syringe stir speed was used for all ITC-200 experiments 
while 400 rpm speed was used for experiments on the VP-ITC. Spacing between 
injections ranged from 300s-900s depending on gain settings and relaxation time 
of the binding process and were optimized for each measured binding interaction. 
Titration data were globally fit to one- and two-site binding models using the 




Samples were prepared in 25 mM tris, 100 mM NaCl, 10 mM CaCl2, pH 
7.4, 10% D2O. All protein concentrations ranged from 0.5 – 1 mM dimer. We 
collected 2D 1H− 15N TROSY-HSQC NMR spectra and transferred published 
assignments to the hA9 spectrum (BMRB: 30017, PDB 5I8N), and then used 3D 
NOESY-TROSY spectra to verify the assignments. We unambiguously assigned 
91 peaks of the 113 non-proline amino acids. All NMR experiments were 
performed at 25°C or 37°C on an 800 MHz (18.8T) Bruker spectrometer at Oregon 
State University. TROSY spectra were collected with 32 transients, 1024 direct 
points with a signal width of 12820, and 256 indirect points with a signal width of 
2837 Hz in 15N. NOESY-TROSYs were run with 8 transients, non-uniform 
sampling with 15% of data points used, and a 150 ms mixing time. All spectra were 
processed using NMRPipe;200 data were visualized and assignments transferred 
using the CCPNMR analysis program.201 
Relaxation Dispersion (RD) experiments were carried out using the pulse 
sequence developed by Kay and coworkers using a constant time (CT) of 50 ms at 
a field strength of 800 MHz with data collected at relaxation delays of 9.55, 0.25, 
and 0.0 (I0) ms.
202 TROSY HSQC spectra were collected in an interleaved manner 
with 16 transients, a 90 ms T1 period, and a 2.5 second delay between transients 
for each relaxation delay at 19°C. Steady state hNOE values are a measurement of 
backbone flexibility on the ps-ns time scale. NOEs were calculated as the ratio   
of 1H-15N correlation peak volume in the spectra acquired with and without the 
proton saturation. {1H}-15N steady-state NOEs were obtained by recording 
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spectra with and without 1H presaturation, a duration of 3 s and a relaxation delay 
of 6 s.203 
For hydrogen-deuterium exchange (HDX) experiments by NMR, protein 
samples were lyophilized and resuspended in 100% D2O immediately prior to 
beginning to measure 2D 1H− 15N TROSY-HSQC spectra. Spectra were collected 
over 24 hours – every ~11 minutes for the first hour, then every hour up to ~8 hours, 
and then final spectra were measured the following day at 24 hours. Peak intensities 
(after NMRPipe processing) were quantified using Sparky.204 We fit either a single 
exponential model or a linear model to each dataset, using the Akaike Information 
Criterion (AIC) to determine whether a single exponential decay model or a linear 
model was more appropriate (Figure AB2-3). All residues that exchanged too 
rapidly to be measured are reported as having an exchange rate faster than the 
fastest-exchanging residue that could be reliably quantified using an exponential 
model that passed the AIC filter. 
 
 
Hydrogen-deuterium exchange mass spectrometry studies 
 
Hydrogen exchange mass spectrometry (HX-MS) experiments were carried 
out using a LEAP PAL autosampler (LEAP Technologies, Carrboro, NC, USA).10 
uM protein stocks were maintained at 4˚C. 3 uL of 10 uM protein sample was 
diluted into 27 uL of deuterated buffer at 20˚C. After a varying labeling time, 27 
uL of labeled sample was quenched with 27 uL of 3.5M GdmCl , 1.5M Glycine pH 
2.4 at 1˚C. 45 uL of quenched sample was then immediately injected into an 
Thermo UltiMate 3000 UHPLC system (Buffer A, Buffer B). For inline digestion, 
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samples were flowed over two immobilized protease columns (Upchurch C130B), 
one with fungal protease and one with pepsin (conjugated to POROS 20 AL 
Aldehyde Activated Resin, Thermo Scientific), at a flow rate of 100 uL/min of 
buffer A. Digested protein was then desalted on a trap column (Upchurch C-128 
with POROS R2 beads) for 2 minutes at a flow rate of 300 uL/min. An acetonitrile 
gradient (10% buffer B to 60% buffer B over 9 minutes) eluted peptides from this 
trap column onto an analytical C-8 column (Thermo 72205–050565) for separation 
before injection into an ESI source for mass spectrometry analysis on a Thermo Q 
Exactive mass spectrometer operating in positive ion mode. 
For every protein variant, a non-deuterated control was subjected to the 
same LC/MS protocol as the deuterated samples and the resulting peptides were 
identified using tandem MS (MS/MS). Peptide precursor spectra were acquired in 
data-dependent mode with the top 10 most abundant ions (charge state >= 2, <= 6) 
selected for fragmentation and product ion analysis. Following MS/MS acquisition 
precursor ions were excluded from further fragmentation for 4 seconds. The peptide 
identification software Byonic (Protein Metrics Inc.) was used to identify peptides 
from the tandem MS data. Following peptide identification deuterium incorporation 
for each peptide at each labeling time was determined by centroid analysis with the 
software HDExaminer (Sierra Analytics). 
 
 
TLR4 activity assay and cell culture conditions 
 
We purchased commercially distributed HEK293T cells from ATCC (CRL- 
11268). Because we are using this cell line as a host for heterologous transient 
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transfections, the appropriate control for consistency between assays is the 
measurement of reporter output for a set of control plasmids and a panel of known 
treatments. Upon thawing each batch of cells, we run a positive control for ligand- 
induced response. We transfect the cells with plasmids encoding human CD14, 
human MD-2, human TLR4, renilla luciferase behind a constitutive promoter, and 
firefly luciferase behind an NF-KB promoter. We then characterize the raw 
luciferase output for five treatments: 1) mock, 2) LPS, 3) LPS + polymyxin B, 4) 
S100A9 + polymyxin B, and 5) S100A9 + 1.25x polymyxin B. This has a 
stereotypical pattern of responses in renilla luciferase (high for all) and firefly 
luciferase (low, high, low, high, high). To validate that this response is dependent 
on the transfected TLR4 complex as opposed to the cells themselves, we repeat the 
experiment but exclude the TLR4 plasmid. This should give identical renilla 
luciferase values but no firefly luciferase output in response to any treatment. To 
ensure that the cells maintain their properties between passages, we repeat the 
mock, LPS, and LPS + polymyxin B control on every single experimental plate. 
This assay has a built-in control for mycoplasma contamination: high firefly 
luciferase signal in the absence of added agonist. This indicates that there is another 
source of TLR4-induced NF-kappa B output in the cells—most plausibly, 
contamination. This mycoplasma sensing approach is used in the commercially 
available HEK-BLUE mycoplasma detection kit (Invivogen). We discard any cells 
that exhibit high background values or reach 30 passages. 
All plasmids, cell culture conditions, and transfections for measuring the activity 
of S100s against TLR4s were identical to those previously described.111,130,131,172 
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Briefly, human embryonic kidney cells (HEK293T/17, ATCC CRL-11268) were 
maintained up to 30 passages in Dulbecco’s Modified Eagle Media (DMEM) 
supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO2. 
Lipopolysaccharide E. coli K-12 LPS (LPS - tlrl-eklps, Invivogen) aliquots were 
prepared at 5 mg/ml in endotoxin-free water and stored at -20oC. Working solutions 
were prepared at 10 ug/ml and stored at 4oC to avoid freeze-thaw cycles. S100 
proteins were prepared by exchanging into endotoxin-free PBS and incubating with 
an endotoxin removal column (Thermo Fisher Scientific) for 2 hours. S100 LPS 
contamination was assessed by measuring activity with and without Polymyxin B, 
an LPS chelating agent (Figure AA6). LPS (200 ng per 100 ul well) or S100 (0.8, 
0.4, 2, 4, or 5 uM dimer) treatments were prepared by diluting in 25:75 endotoxin- 
free PBS:serum-free Dulbecco’s Modified Eagle Media (DMEM – Thermo Fisher 
Scientific). Polymyxin B (PB, 200 ug per 100 ul well) was added to all S100 
experimental samples to limit background endotoxin contamination activity from 
recombinant protein preps. Cells were incubated with treatments for 3 hours prior 
to assaying activity. The Dual-Glo Luciferase Assay System (Promega) was used 
to assay Firefly and Renilla luciferase activity of individual wells. Each NF-κB 
induction value shown represents the Firefly luciferase activity divided by the 
Renilla luciferase activity, background-subtracted using the LPS + PB activity for 
each TLR4 species and normalized to the activity of LPS alone for each TLR4 
species to normalize between plates. All measurements were performed using three 
technical replicates per plate, a minimum of three biological replicates total, and a 
minimum of two separate protein preps. 
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BRIDGE TO CHAPTER IV 
 
 
In Chapter III, we determine the mechanism by which a previously 
identified point mutation (M63F) decreases A9 activation of TLR4. We find that 
M63F interacts with a nearby residue to locally stabilize A9 using a variety of 
biophysical approaches. We show that disrupting either half of the interaction 
restores wildtype A9 stability and proinflammatory activation of TLR4. We suggest 
that this “molecular staple” does not disrupt A9 proinflammatory activity by 
altering its structure. Instead, we hypothesize that the interaction prevents A9 from 
accessing a non-native excited state conformation that is necessary for A9 
activation of TLR4. We discuss the implications of this hypothesized novel 
mechanism for understanding A9 proinflammatory activity, treating chronic 
inflammation driven by A9, and expanding our understanding of the mechanisms 
by which damage-associated molecular patterns (DAMPs) trigger the innate 
immune system. In chapter IV, we highlight ongoing and future studies focused on 
determining how A9 proteins evolved to potently and promiscuously activate TLR4 
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A primary job of the innate immune system is to respond to damage and 
infection.205,206 Pattern recognition receptors (PRRs) initiate a potent immune 
response by recognizing both exogenous pathogen molecules and endogenous signs 
of tissue damage and subsequently activating inflammation.207–209 The mechanisms 
by which PRRs recognize exogenous pathogen-associated molecular patterns 
(PAMPs) and activate downstream inflammatory pathways are reasonably well 
understood. Comparatively less is known about how endogenous damage- 
associated molecular patterns (DAMPs)185,186 activate PRRs to amplify 
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inflammation. Prolonged activation of inflammation via DAMPs contributes to 
many human inflammatory diseases.184–186,210 Determining the mechanisms by 
which DAMPs drive inflammation through PRRs is critical to our understanding of 
innate immunity and for developing treatments for chronic inflammation. 
TLR4 is a well-studied PRR that recognizes multiple PAMPs and DAMPs to 
activate inflammation.117,121,122,176 The mechanism by which TLR4 is activated by 
PAMPs, such as the bacterial cell wall component lipopolysaccharide (LPS), is well 
understood.115,117,121,122,125 LPS is delivered to a hydrophobic pocket of the TLR4 
cofactor MD2 by a second cofactor, CD14.115–117 LPS delivery promotes formation 
of the (TLR4/MD2)2 heterotetramer and results in activation of downstream 
proinflammatory signaling pathways.120,121 CD14 and MD2 are required for TLR4 
activation by LPS across amniotes.130 
In contrast, TLR4 activation by endogenous DAMPs is poorly understood. 
S100A9 (A9) is a highly abundant neutrophil DAMP that, upon release during an 
immune response, potently activates inflammation through TLR4.86,91–95 Little is 
known about the mechanism by which A9 activates TLR4 to drive inflammation. 
Similarly to LPS, CD14 and MD2 are required for A9 activation of TLR4.130 This 
suggests that LPS and A9 activate TLR4 through a similar mechanism. However, 
unlike LPS, the native state structure of A9 is too large to fit into the MD2 
hydrophobic pocket. Smaller proteolytic fragments of A9 have thus been proposed 
to activate TLR4, as A9 is readily degraded by proteases and smaller A9 fragments 
could mimic LPS.109 We previously showed, however, that proteolytic degradation 
is not a requirement for A9-induced TLR4 activation.131 Ongoing work in our group 
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suggests that A9 might activate TLR4 through a non-native excited state 
conformation, but the exact nature of this proposed A9 excited state – and its 
binding interface to TLR4 – are unknown. 
Evolutionary analyses of A9 proinflammatory activity have provided new 
insight into the mechanism by which A9s evolved to activate TLR4. We recently 
showed that mammalian A9s evolved potent proinflammatory activity from a 
weakly active amniote ancestor.131 We identified a single substitution that played a 
key role in the evolution of A9 proinflammatory activity. Earlier work revealed that 
later-diverging (eutherian) A9s activate TLR4s from multiple species more 
potently and promiscuously than earlier-diverging (therian) A9s.130 
Complementation experiments – in which TLR4 components from different species 
were systematically swapped and tested for activity – have revealed subtle 
differences in TLR4/MD2/CD14 requirements across mammalian A9s compared 
to LPS, suggesting overlapping but different molecular mechanisms for TLR4 
activation by A9 and LPS. These findings together present new avenues for 
determining how the abundant neutrophil DAMP A9 evolved to drive 
inflammation. 
This study outlines ongoing and prospective work to dissect the mechanism by 
which A9s evolved to activate TLR4s in mammals. We highlight two 
complementary approaches – one using evolutionary biochemical analyses and the 
other using a high-throughput mutational screen – to determine how A9s evolved 
to activate TLR4 and identify the A9:TLR4/MD2/CD14 interaction interface. 
Preliminary data suggests that important changes in A9 proinflammatory activity 
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occurred over the narrow evolutionary interval between the therian and eutherian 
A9 ancestors. Of the amino acid differences between these two ancestral states of 
A9, we find that nearly half cluster within a small region of A9 that was previously 
proposed to bind to TLR4 in vitro.109 We show preliminary efforts to determine 
which of these substitutions are important for the evolution of A9 proinflammatory 
activity. Finally, we reveal the results of a pilot cell sorting and sequencing 
experiment to identify mutants of MD2 that alter LPS and/or A9 proinflammatory 
activity. This complementary high-throughput approach shows promise for 
determining the A9:TLR4 binding interface and can be readily employed on A9s, 
TLR4s, MD2s, and CD14s from different species. Combining these orthogonal 
strategies will enable determination of the mechanisms by which A9s activate 
TLR4s to drive inflammation in mammals. These studies will increase our 
understanding of how DAMPs evolved key roles in mammalian innate immunity 






A9s evolved enhanced proinflammatory activity in eutherian mammals 
 
We began by asking why later-diverging A9 proteins activate TLR4s from 
various amniotes more strongly and promiscuously than earlier-diverging A9 
proteins. Previous work showed that therian mammalian A9s evolved enhanced 
proinflammatory activity from a weakly active amniote ancestor (Figure 4.1, 
AC1).130,131 While these findings revealed that the proinflammatory activity of A9s 
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improved in early mammals, they do not explain how later-diverging A9 proteins, 
such as human and mouse A9, evolved such potent activity (Figure 4.1, AC1). 
Further, there are many amino acid changes between human and mouse A9 and the 
therian mammalian A9 ancestor (33/99 and 42/99, respectively, excluding the 
disordered C-terminal tail – Figure AC2), making it difficult to determine which 




Figure 4.1. Later-diverging A9s activate amniote TLR4s more potently and 
promiscuously than earlier-diverging A9s. Data are synthesized from two 
previous studies;130,131 * = preliminary data in this study. Species cartoons are 
human, mouse, elephant, opossum, and chicken. Chicken MRP126 is indicated in 
yellow and the amniote calgranulin ancestor is indicated in orange. A9 nodes are 
purple. Red intensities are scaled from 0-1 for each TLR4 species (table AC1). In 
cases where multiple values are reported, red intensity is the average value of 
reported measurements. N.D. = no data. Numbers in tree are the number of amino 
acid substitutions between nodes, excluding the poorly conserved C-terminal tail 
(residues 100-114). 
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To narrow the interval over which human and mouse A9 evolved potent 
proinflammatory activity, we measured the activities of two additional eutherian 
A9 proteins to compare to human and mouse A9. We selected elephant A9 because 
elephants are among the earliest-diverging eutherian species. We also used 
ancestral sequence reconstruction to infer the eutherian mammalian A9 ancestor 
(eutherian ancA9). Eutherian ancA9 was reconstructed with very high confidence 
(average posterior probability = 0.96), so an AltAll171 control reconstruction was 
not necessary. 
We first compared elephant A9 and eutherian ancA9 against human A9 and 
previously characterized therian ancA9131 for human TLR4 activation. We found 
that elephant A9 and eutherian A9 had approximately 40% and 60% of the activity 
of human A9 against human TLR4, respectively (Figure 4.2a, AC1). Both proteins 
activated human TLR4 more strongly than the earlier therian A9 ancestor, 
reflecting the higher activity previously observed for other eutherian A9 proteins. 
We also tested eutherian ancA9 for activity against opossum TLR4 and found that 
it had activity comparable to therian ancA9 and lower than human A9 (Figure 4.2b). 
These findings indicate that some, but not all, of the increase in later-diverging A9 
proinflammatory potency is accounted for in the amino acid changes in eutherian 
ancA9. This also suggests that the potent activity of human and mouse A9 might 
have evolved even later than the eutherian ancA9 ancestor. 
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Preliminary studies testing how eutherian A9s evolved increased 
proinflammatory activity 
We next sought to identify the amino acid changes between therian ancA9 
and eutherian ancA9 that led to increased proinflammatory activity in eutherian 
A9s. There are 23 amino acid differences between therian ancA9 and eutherian 
ancA9, 10 of which occur within a contiguous stretch of 14 amino acids in helix III 
of the protein (Figure 4.2c, AC2). We previously found that a substitution in helix 
III at position 63 played a key role in A9s evolving increased proinflammatory 
activity.131 Ongoing work by our group, outlined in chapter III of this dissertation, 
suggests that instability in helix III of A9 might be important for A9 activation of 
TLR4. Lastly, work by others has shown that mutating pairs of charged amino acids 
within residues 64-77 altered human A9 binding to TLR4 in vitro.109 
We hypothesized that charge-altering substitutions that occurred between 
the therian and eutherian A9 ancestors in helix III could be important for increasing 
eutherian A9 proinflammatory activity. We selected 5 charge-altering substitutions 
in this region and introduced them together into therian A9 to produce 5X therian 
A9 (N51K, D55N, P56E, A57K, Q64E; human A9 numbering – Figure 2c, AC2). 
We confirmed that 5X therian A9 was folded and had similar helical content to 
therian ancA9 using circular dichroism spectroscopy (Figure AC3). However, we 
observed no difference in activation of human TLR4 between 5X therian A9 and 
therian A9 (Figure 2d). This indicates one of two possibilities. The 5 selected 
substitutions could simply not be important for increasing eutherian A9 
proinflammatory activity. Alternatively, we could have introduced a negative 
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epistatic interaction by introducing some, but not all, of the substitutions required 
to increase therian A9 proinflammatory activity. Determining which substitutions 
drove an increase in A9 proinflammatory activity between the therian and eutherian 
A9 ancestors is an area of ongoing study in our group. 
 
 
Figure 4.2. Elephant A9 and the reconstructed eutherian A9 ancestor activate 
human TLR4 better than earlier-diverging A9s. (a), (b), and (d) NF-B 
production of human and opossum TLR4 in response to treatment with modern and 
ancestral S100 proteins. Bars represent average of >3 biological replicates, error 
bars are standard error of the mean. All values are background-subtracted and 
normalized to LPS positive control (see methods). (c) Sequence alignment of 
residues 51-64 of various A9 proteins. Colored residues are non-consensus sites. 
Boxes show the five mutations introduced into therian (“5X therian A9” – N51K, 
D55N, P56E, A57K, Q64E; human A9 numbering). 
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Mapping the A9:TLR4 interaction interface using a high-throughput mutant 
screen 
The ongoing evolutionary studies of A9 described above focus on the A9 
side of the A9:TLR4 interaction. Here we describe an orthogonal approach to 
examine the other half of the A9:TLR4 interaction by focusing on TLR4, MD2, and 
CD14. Understanding where A9 interacts with TLR4, MD2, and CD14 is necessary 
for determining how A9 activates TLR4 to drive inflammation. 
To address this, we are developing a high-throughput mutant screen to 
determine where A9 interacts with TLR4, MD2, and CD14. The primary goal of 
the screen is to identify mutations in these TLR4 components that decrease A9 
activation of TLR4 without altering LPS activity. Finding mutations that only 
decrease A9 activation, but not LPS activation, will allow us to filter out mutations 
that simply “break” the TLR4 complex. 
The mutant screen is modified from a previously used cell-culture based 
TLR4 activation assay.130,131,172 First, a mutant library of TLR4, MD2, or CD14 is 
produced using random mutagenesis, aiming for an average mutation rate of ~1. 
The mutant library is then transfected into HEK293T cells along with other 
necessary TLR4 components. This includes a GFP plasmid that reports on 
downstream NF-kB production, similarly to the luciferase reporter plasmid used in 
this study and in previous work (Figure 4.2). Transfected cells are treated with 
buffer, LPS, or A9 and sorted based on GFP fluorescence using fluorescence- 
activated cell sorting (FACS). Lastly, Illumina sequencing is used to determine 
which mutants are enriched in each treatment group. This approach is amenable to 
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testing mutant libraries of TLR4, MD2, and CD14, and can be applied to TLR4 
components and A9s from a variety of species. 
As a pilot study, we performed a screen of LPS vs. human A9 activating 
human TLR4 using a mutant human MD2 library. We chose to mutate human MD2 
because it is small (~160 amino acids), amenable to short sequencing reads with 
high coverage, and has a structurally well-defined interaction with LPS.114 We 
confirmed that an increase in GFP signal could be observed over background for 
cells transfected with the MD2 library and treated with LPS or A9 (Figure 4.3a-c). 
We then used FACS to sort cells treated with either buffer, LPS, or human A9 as 
GFP+ or GFP- (Figure 4.3d-e). Six uniquely barcoded Illumina libraries were 
prepared from each sorted condition using PCR and subjected to high-throughput 
sequencing using a MiSeq nano run. We measured a combined ~380,000 reads for 
the six libraries and the input MD2 mutant library. The MD2 library had an average 
of ~2.5 mutations per sequence, which matched the average number of mutations 
observed for each treatment group (Figure AC4). We filtered results to exclude 
sequences with an early stop codon, more than 10 mutations, or less than 6 total 
reads. After filtering, a total of 510 unique mutant sequences were found to be 
shared between all treatment conditions. 
We then quantified enrichment for the 510 unique mutant sequences in the 
LPS vs. human A9 treatment conditions. We calculated the frequency of each clone 
in each library, and then compared enrichment in GFP+ compared to GFP- pools for 
LPS versus human A9 (Figure 4.3f). We focused on the top single mutants that 
were most significantly de-enriched for human A9 activity but remained the same 
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or were enriched for LPS activity (Figure 4.3, red). These are the top candidate 
mutations for decreasing A9 activation of TLR4 without altering LPS activation. 
For comparison, we also identified the top single mutants that were most 
significantly de-enriched for LPS activity but remained the same or were enriched 
for A9 activity (Figure 4.3, purple). We identified top single mutants with a de- 
enrichment score > log2(1), an enrichment score < log2(0.6), and a log2(de- 
enriched/enriched) score < -1 (Figure AC5). Mutant sequences with more than one 
mutation were discarded from this analysis to avoid having to account for epistatic 
interactions. Using these filters, we identified a total of 10 and 12 candidate 
mutations that showed A9 or LPS-specific de-enrichment, respectively. Three of 
these sites were the same position in both categories, although they were different 
amino acid mutations. These residues are therefore not shown in Figure 4.3 but are 
listed in supplemental figure AC5. 
Mapping the remaining top A9-specific and LPS-specific mutations onto 
the TLR4/MD2 structure114 reveals that they are scattered throughout MD2 (Figure 
4.3g). As expected, LPS-specific mutations largely occurred near LPS and tended 
to cluster near the bottom of the MD2 hydrophobic pocket. No A9-specific 
mutations were inside the MD2 hydrophobic pocket, suggesting that A9 interacts 
with the exterior of MD2. Several A9-specific mutations were distant from LPS 
near the bottom of MD2, suggesting that A9 might interact with the bottom of MD2. 
Follow-up studies are required to validate the role of these residues in A9 activation 
of TLR4. This pilot study highlights the potential of an unbiased high-throughput 
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mutant screen for identifying where A9 interacts with TLR4 en route to determining 
the mechanism by which A9 activates TLR4 to drive inflammation. 
 
 
Figure 4.3. An MD2 mutant screen identifies candidate mutations that 
selectively decrease A9 activation of TLR4 without altering LPS activation. (a- 
c) Microscopy images of GFP signal in cells expressing mutant MD2 library and 
treated with (a) buffer, (b) LPS, or (c) human A9. (d-e) FACS of cells from (a) and 
(b), respectively. GFP+ = green, GFP- = blue. (f) Enrichment of MD2 mutants for 
A9 and LPS activity. Each point is a unique MD2 mutant containing at least one 
mutation. The most enriched mutants that decrease A9 GFP signal without 
decreasing LPS GFP signal are shown in red, opposite highlighted in purple 
(decrease LPS GFP signal without decreasing A9 GFP signal). Black point is 
wildtype MD2. (g) Mutants in (f) mapped onto TLR4 structure (PDB 3FXI) as red 
and purple spheres. TLR4 chains shown in white, MD2 chains shown in blue. LPS 




Later-diverging A9s have evolved to more potently and promiscuously 
activate TLR4s 
The data presented here suggests that A9s have continued to evolve improved 
proinflammatory activity over time. Previous work showed that human and mouse 
A9 evolved to be highly potent activators of TLR4 from a modestly active therian 
mammalian ancestor.130,131 Preliminary findings in this study suggest that some of 
these improvements, but not all, occurred between the therian and eutherian A9 
ancestors. The eutherian A9 ancestor and elephant A9 each had higher activities 
than the earlier therian A9 ancestor against human TLR4 (Figure 4.1 & 4.2) but did 
not exhibit the same potency as human A9. This suggests that later-diverging A9s 
may have evolved increased proinflammatory activity in a stepwise fashion. 
A9s do, however, exhibit complex patterns of both proinflammatory 
potency and promiscuity. For example, previous work showed that opossum A9 
activates both human and opossum TLR4 better than the therian A9 ancestor.131 In 
this study, eutherian A9 activates human TLR4 better than therian A9, but both 
proteins have equivalent activity against opossum TLR4 (Figure 4.1 & 4.2). This 
suggests that modern A9s in different species could have independently evolved 
enhanced proinflammatory activity from less active ancestors. This could be a 
product of A9s co-evolving with their species-matched TLR4s, resulting in 
increased proinflammatory activity evolving independently in human, mouse, and 
opossum A9. Further studies, including testing elephant A9 and eutherian ancA9 
against additional TLR4s, are necessary for dissecting when and how A9s evolved 
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potent and promiscuous proinflammatory activity. Testing the supraprimate A9 
ancestor (the shared ancestor of humans and mice) for TLR4 activation will also 
help explain the potency and promiscuity of human and mouse A9 and help 
determine whether patterns of potency and promiscuity are lineage-specific or have 
a common evolutionary origin. 
 
 
A multi-pronged approach for determining the mechanism by which A9 
activates TLR4 
This study highlights the utility of combining evolutionary and biochemical 
approaches to determine mechanisms of protein functions. Determining the amino 
acid changes underlying how proteins change functions provides mechanistic 
insight into how protein functions work.29 This strategy is unveiling a 
comprehensive picture of how A9s have evolved to drive inflammation in 
mammals. By mapping the proinflammatory activities of different A9s against 
different TLR4s onto their evolutionary history and comparing them at the amino 
acid level, we have isolated a region of A9 – helix III – that has acquired many 
substitutions over time and appears to be important for A9 proinflammatory 
function. Previous work by our group and others suggests that stability and charge 
distribution within helix III may be important for A9 TLR4 activation.109,131 Future 
evolutionary and biochemical studies are required to fully understand the 
mechanism by which A9 activates TLR4, but this work suggests that we are 
focusing our efforts in the right direction. 
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Our pilot screen of MD2 mutations that alter A9 proinflammatory activity 
also highlights promising avenues for determining where A9 interacts with TLR4, 
MD2, and CD14. Previous work showed that A9s and LPS have overlapping, but 
subtly different, requirements for TLR4 activation.130 The preliminary results 
presented here hint that A9 interacts with the exterior of MD2, as opposed to LPS, 
which inserts into the MD2 hydrophobic pocket. This makes sense if A9 maintains 
its native size and shape upon binding to TLR4; A9 is simply too big to mimic LPS 
binding within the MD2 hydrophobic pocket. However, the pilot screen also shows 
overlap between candidate residues that selectively alter A9 and LPS activity. This 
suggests that the A9 and LPS binding interfaces might overlap to some degree. 
Directly measuring the quantitative effects of the candidate MD2 mutations on A9 
proinflammatory activity will be necessary to test these hypotheses. This approach 
can be readily applied to A9s, TLR4s, MD2s, and CD14s from multiple species, 
enabling future determination of differences in binding interface and ultimately 
activation mechanism by A9s across mammals. This will provide valuable context 
in studies employing, for example, mouse models to inform A9-induced 
inflammation in humans. 
 
 
How did endogenous DAMPs evolve to drive inflammation? 
 
Open questions remain regarding how endogenous damage-associated 
molecular patterns (DAMPs) such as A9 evolved to signal tissue damage to the 
innate immune system. Many DAMPs perform normal functions inside of healthy 
cells – and are thus “invisible” to the immune system – until cell damage occurs, 
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leading to DAMP release and induction of an innate immune response.184–186 It 
remains unclear whether DAMP function in proteins is accidental, under some form 
of selection, dependent on the protein being studied, or some combination of each. 
Previous work on the evolution of A9 multifunctionality suggests that A9 
DAMP function is not accidental. We found that a single substitution increased A9 
proinflammatory activity without affecting other functions of A9, suggesting that 
A9 DAMP function has been specifically maintained in mammals.131 Alternatively, 
it has been proposed that common biochemical features of proteins, such as 
hydrophobicity,199 could themselves serve as DAMPs. Many pattern recognition 
receptors (PRRs) like TLR4 bind a variety of diverse molecules that share no 
obvious consensus motif.207–209 This suggests that DAMPs could function through 
a non-specific mechanism such as exposure of hydrophobic residues by proteins in 
the harsh extracellular space. Further studies examining how DAMPs have evolved 
to activate the innate immune system are required to address these questions. 
 
The orthogonal evolutionary and biochemical approaches described in this 
work show promise for enabling future studies of DAMP evolution. These 
strategies can be used to isolate when and how DAMP functions have evolved, 
dissect mechanisms by which DAMPs activate PRRs, and determine common 
features of DAMP evolution. Determining how DAMPs have evolved and how they 
work will enhance our understanding of the innate immune system and enable more 
targeted intervention in inflammatory disease. 
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MATERIALS AND METHODS 
 
 
Phylogenetics and ancestral sequence reconstruction 
 
We reconstructed ancestral sequences using a previously published a 
phylogenetic tree of S100 proteins containing 172 sequences from 30 amniote 
taxa.130 We used PAML4 to generate maximum likelihood ancestors (marginal 
probability method)36,38 using the previously-identified maximum likelihood (ML) 
substitution model (LG+8)
189 on the ML tree. 
 
Cloning and mutagenesis 
 
All S100 genes in this study were purchased as synthetic constructs in 
pUC57 vectors from Genscript. S100 genes were sub-cloned into a pETDuet-1 (pD) 
vector (Millipore) as described previously. Cysteine-free versions of all S100 genes 
were prepared using site-directed mutagenesis (Agilent). 
 
 
Protein expression and purification 
 
Recombinant protein overexpression was conducted in E. coli BL21 (DE3) 
pLysS Rosetta cells. Cultures were innoculated in luria broth overnight at 37°C, 
shaking at 250 rpm, in the presence of ampicillin and chloramphenicol. The 
following day, 10 ml of saturated culture was diluted into 1.5 L of media with 
antibiotics, grown to OD600 = 0.6 – 1, and then induced overnight at 16°C using 1 
mM IPTG. Cells were pelleted at 3,000 rpm for 20 min and stored at -20°C for no 
more than three months. 
105  
Lysates were prepared by vortexing pellets (3-5 g) in tris buffer (25 mM 
tris, 100 mM NaCl, pH 7.4) and incubating for 20 min at RT with DNAse I and 
lysozyme (ThermoFisher Scientific). Lysates were sonicated and cell debris was 
pelleted by centrifugation at 15,000 rpm at 4°C for > 20 min. All proteins were 
purified on an Äkta PrimePlus FPLC using various 5 ml HiTrap columns (HisTrap 
FF (Ni-affinity), Q HP (anion exchange)). All S100s were purified in three steps 
using Ni-affinity chromatography in the presence of calcium followed by two 
rounds of anion exchange chromatography at different pHs. For Ni-affinity 
chromatography, proteins were eluted over a 50 ml gradient from 25-1000 mM 
imidazole in tris buffer. Peak elution fractions were pooled and placed in dialysis 
overnight at 4°C in 4 L of tris buffer (calcium-free) adjusted to pH 8. Anion 
exchange chromatography was then performed the following day over a 50 ml 
gradient from 100-1000 mM NaCl in pH 8 tris buffer. Fractions containing majority 
S100 were pooled and analyzed for purity on an SDS-PAGE gel. If trace 
contaminants remained, an additional anion exchange step was performed at pH 6 
using the same elution strategy as for the previous anion exchange step. All purified 
proteins were dialyzed overnight at 4°C in tris buffer + 2 g/L Chelex-100 resin 
(Biorad), flash-frozen the following day in liquid nitrogen, and stored at -80°C. 
 
 
Biophysical and biochemical characterization 
 
For all experiments, protein aliquots were thawed fresh from freezer stocks 
and were either dialyzed in the appropriate experimental buffer overnight at 4°C or 
exchanged 3X into experimental buffer using 3K microsep spin concentrator 
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columns (Pall Corporation). All samples were filter-sterilized using 0.1 um spin 
filters (EMD Millipore) prior to measuring concentration and using in experiments. 
Thawed aliquots were used for no more than one week before discarding. All 
concentrations were measured by absorbance of protein in > 6M urea at 280 nm 
and correspond to micromolar dimeric protein. Circular dichroism (CD) 
experiments were performed using a Jasco J-815 CD spectrometer. 
 
 
TLR4 activity assay and cell culture conditions 
 
We purchased commercially distributed HEK293T cells from ATCC (CRL- 
11268). Because we are using this cell line as a host for heterologous transient 
transfections, the appropriate control for consistency between assays is the 
measurement of reporter output for a set of control plasmids and a panel of known 
treatments. Upon thawing each batch of cells, we run a positive control for ligand- 
induced response. We transfect the cells with plasmids encoding human CD14, 
human MD-2, human TLR4, renilla luciferase behind a constitutive promoter, and 
firefly luciferase behind an NF-KB promoter. We then characterize the raw 
luciferase output for five treatments: 1) mock, 2) LPS, 3) LPS + polymyxin B, 4) 
S100A9 + polymyxin B, and 5) S100A9 + 1.25x polymyxin B. This has a 
stereotypical pattern of responses in renilla luciferase (high for all) and firefly 
luciferase (low, high, low, high, high). To validate that this response is dependent 
on the transfected TLR4 complex as opposed to the cells themselves, we repeat the 
experiment but exclude the TLR4 plasmid. This should give identical renilla 
luciferase values but no firefly luciferase output in response to any treatment. To 
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ensure that the cells maintain their properties between passages, we repeat the 
mock, LPS, and LPS + polymyxin B control on every single experimental plate. 
This assay has a built-in control for mycoplasma contamination: high firefly 
luciferase signal in the absence of added agonist. This indicates that there is another 
source of TLR4-induced NF-kappa B output in the cells—most plausibly, 
contamination. This mycoplasma sensing approach is used in the commercially 
available HEK-BLUE mycoplasma detection kit (Invivogen). We discard any cells 
that exhibit high background values or reach 30 passages. 
All plasmids, cell culture conditions, and transfections for measuring the activity 
of S100s against TLR4s were identical to those previously described.38,39130,172 
Briefly, human embryonic kidney cells (HEK293T/17, ATCC CRL-11268) were 
maintained up to 30 passages in Dulbecco’s Modified Eagle Media (DMEM) 
supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO2. 
Lipopolysaccharide E. coli K-12 LPS (LPS - tlrl-eklps, Invivogen) aliquots were 
prepared at 5 mg/ml in endotoxin-free water and stored at -20oC. Working solutions 
were prepared at 10 ug/ml and stored at 4oC to avoid freeze-thaw cycles. S100 
proteins were prepared by exchanging into endotoxin-free PBS and incubating with 
an endotoxin removal column (Thermo Fisher Scientific) for 2 hours. S100 LPS 
contamination was assessed by measuring activity with and without Polymyxin B, 
an LPS chelating agent (Figure AA6). LPS (200 ng per 100 ul well) or S100 (0.8, 
0.4, 2, 4, or 5 uM dimer) treatments were prepared by diluting in 25:75 endotoxin- 
free PBS:serum-free Dulbecco’s Modified Eagle Media (DMEM – Thermo Fisher 
Scientific). Polymyxin B (PB, 200 ug per 100 ul well) was added to all S100 
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experimental samples to limit background endotoxin contamination activity from 
recombinant protein preps. Cells were incubated with treatments for 3 hours prior 
to assaying activity. The Dual-Glo Luciferase Assay System (Promega) was used 
to assay Firefly and Renilla luciferase activity of individual wells. Each NF-κB 
induction value shown represents the Firefly luciferase activity divided by the 
Renilla luciferase activity, background-subtracted using the LPS + PB activity for 
each TLR4 species and normalized to the activity of LPS alone for each TLR4 
species to normalize between plates. All measurements were performed using three 
technical replicates per plate, a minimum of three biological replicates total, and a 
minimum of two separate protein preps. 
 
 
FACS and high-throughput MD2 mutant screen 
 
A mutant human MD2 library in a pDuo plasmid backbone was prepared 
using the Genemorph II EZ clone kit (Agilent). 10 ng of MD2 plasmid were used 
to obtain approximately 1 mutation per plasmid. Cells were transfected as described 
above, substituting the firefly luciferase plasmid with a dual firefly luciferase/GFP 
plasmid under an NF-kB promoter and wildtype MD2 with the mutant MD2 library. 
Cells were transfected for 24 hours, and transfections were scaled up to 100 mm 
dishes to increase cell yield for sorting. Transfection mix was removed and cells 
were treated with PBS buffer, 1.5 ug/ul LPS, or 5 uM purified human S100A9 
protein for another 6 hours. Treated cells were sorted on a Sony SH800 cell sorter 
into GFP- (intensity < 10^4) or GFP+ (intensity > 10^4) bins. Plasmid DNA was 
extracted from sorted cells and barcoded Illumina libraries were prepared by PCR. 
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High-throughput sequencing was performed on an Illumina MiSeq instrument set 











We acknowledge Sarah Werning and David Liao as authors of the opossum 
and mouse cartoons respectively, which were made publicly available through the 




BRIDGE TO CHAPTER V 
 
In chapter IV, we highlight ongoing work examining how A9s have evolved 
potent proinflammatory activity in mammals and determining the mechanism by 
which A9 activates TLR4 to drive inflammation. We show preliminary results that 
suggest eutherian A9s, such as those from humans, mice, and elephants, have 
evolved increased proinflammatory activity from the therian mammalian ancestor. 
This increase, however, is not fully accounted for in the reconstructed eutherian A9 
ancestor; further work is needed to determine why supraprimate A9s, such as those 
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from humans and mice, are highly potent and promiscuous activators of amniote 
TLR4s. We also show the results of a pilot screen that focuses on determining the 
TLR4/MD2/CD14 interaction interface with A9. We identify candidate mutations 
in human MD2 that appear to decrease A9 activation of TLR4 without affecting 
LPS activity and prescribe follow-up studies to determine the role of these residues 
in A9 activation of TLR4. We outline future studies to determine how A9s have 
evolved potent proinflammatory activity and the mechanism by which A9 activates 
TLR4 to drive inflammation. We conclude chapter IV by prescribing future studies 
to examine how DAMPs have evolved. Chapter V concludes this dissertation by 
summarizing the work presented in chapters II-IV, discussing the contributions of 
this work to the fields of evolutionary biochemistry and immunology, and outlining 






SUMMARY AND CONCLUDING REMARKS 
 
 
Evolutionary biochemistry is powerful for determining how proteins evolve 
new functions 
The work presented here highlights the value of studying biological 
functions in an evolutionary context.29 Two of the most commonly asked questions 
in biology are “how does it work?” and “why does it work this way?” This 
dissertation demonstrates how one can address both questions simultaneously by 
focusing mechanistic, functional studies through the lens of evolution. This 
approach is broadly applicable to proteins across biology, enabling a richer 
understanding of how biological systems evolve and how they work. 
We provide new insight into how multifunctional proteins evolve using the 
innate immune protein S100A9 (A9) as a case study.131 We showed that 
mammalian A9 proteins underwent radical functional change – gain of potent 
proinflammatory and antimicrobial activities and loss of proteolytic resistance – 
from a less functional amniote ancestor. By isolating this interval of evolutionary 
change in A9s between the ancestors of amniotes and mammals, we identified 
several amino acid changes that impacted each of these functions. A single 
substitution, in particular, played a key role in A9s gaining proinflammatory 
activity and losing proteolytic resistance without affecting its antimicrobial activity. 
Mammals thus evolved a potent proinflammatory molecule that can be quickly 
turned off by endogenous proteases, all while retaining antimicrobial function to 
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combat pathogens. This demonstrates how pleiotropy can be advantageous in 
protein evolution; rather than serving as a constraint,57,145,146,187 pleiotropy 
facilitated the evolution of a multifunctional innate immune protein. 
This work lays the foundation for future evolutionary studies of A9 
proinflammatory activity. We find that A9 proinflammatory potency and 
promiscuity vary across mammalian A9 proteins, with potentially significant 
changes occurring later in eutherian A9s. This suggests a complex pattern of co- 
evolution between A9s and TLR4s in different species; A9s from some species 
activate many different TLR4s potently, while others exhibit more specific activity 
against their species-matched TLR4s or are generally poor activators. This could 
mean that A9s in different species activate TLR4s through overlapping but slightly 
different mechanisms, or that TLR4 complexes themselves have evolved different 
properties in different species, perhaps in response to species-specific pathogens or 
other damage-associated molecular patterns (DAMPs) besides A9. Future studies 
of how A9s have evolved these complex patterns of activity, as outlined in chapter 
IV of this dissertation, are necessary to answer these questions. 
 
 
Mechanistic insight into A9 proinflammatory activity 
 
Using an evolutionary biochemical approach, we identified, to our 
knowledge, the only known point mutation (M63F) of A9 that decreases its 
proinflammatory activity. It is doubtful that this mutation would have been 
identified outside of an evolutionary context, as it is on the inside of the protein and 
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does not stand out in any obvious way. This finding enabled a mechanistic 
dissection of A9 activation of TLR4 that would not have otherwise been possible. 
Determining how the M63F mutation decreases A9 proinflammatory 
activity led us to propose a new mechanism by which A9 activates TLR4 to drive 
inflammation. Through a detailed biophysical analysis, we found that the M63F 
mutation decreases A9 proinflammatory activity by locally stabilizing the protein 
through a direct interaction with a nearby residue. The residues that are stabilized 
by this interaction overlap with residues that have been previously proposed to be 
important for A9 binding to TLR4.109 Breaking this interaction restores wildtype 
A9 stability and proinflammatory activity, indicating that this region of A9 is 
important for its function and might require a rearrangement or conformational 
change to activate TLR4. Recent studies in drug design and protein engineering 
focus on specifically targeting transiently exposed protein surfaces and 
conformations to inhibit pathological proteins that have been previously deemed 
“undruggable.”211,212 These findings will direct future studies toward determining 
the nature of the hypothesized proinflammatory non-native conformation of A9, 




Future mechanistic and evolutionary studies to understand DAMP functions 
 
We prescribe the use of complementary approaches to evolutionary 
biochemistry for determining mechanisms by which proteins evolve and perform 
functions. We highlight the challenges associated with determining where A9 
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interacts with TLR4, MD2, and CD14 and mechanistically understanding how A9 
proinflammatory function works. The findings presented here provide new insight 
into how A9 activates TLR4 and will help focus future studies toward important 
aspects of A9 proinflammatory function. Orthogonal approaches, however – such 
as the high-throughput mutant screening strategy of TLR4 components described 
in chapter IV – will be necessary to fully determine where and how A9 interacts 
with TLR4 to drive inflammation. Creatively combining evolutionary and 
biochemical approaches, particularly in a high-throughput fashion, will be a 
cornerstone of future mechanistic and evolutionary studies of protein functions. 
This work raises important questions regarding the mechanisms by which 
DAMPs have evolved to activate the immune system. We found that the DAMP 
S100A9 lost stability en route to evolving proinflammatory activity. Intriguingly, 
the easily degraded A9 forms a proteolytically resistant A8/A9 complex that has 
different functions, thus allowing A9 to sample two different states of function and 
stability. The relative abundance of A9 in each of these states is likely mediated by 
multiple factors, including relative levels of A8 and A9 expression under different 
conditions and whether the protein is within neutrophils or released into the 
extracellular space. Many DAMPs perform other functions inside cells until they 
are released due to tissue damage.184–186 Perhaps other DAMPs, similar to A9, also 
have binding partners that protect them from degradation until DAMP function is 
required in the harsh environment of the extracellular space. 
Loss of stability could also be a common feature of DAMPs. As 
demonstrated for A9, loss of stability could serve to simultaneously enable DAMP 
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function and create a simple mechanism for regulating it. Studies examining 
evolutionary trends in protein stability indicate that many proteins are marginally 
stable because selection only requires a protein to be “stable enough,” suggesting 
that protein stability is not necessarily under selection.213–215 Different rules may 
apply, however, to DAMPs, as lower stability may be important for both DAMP 
function and for maintaining a mechanism to rapidly remove pathological 
inflammation from the body. Future studies examining the role of stability in 
DAMP evolution and function will aid in addressing these questions. 
This dissertation contributes to the field of evolutionary biochemistry by 
providing mechanistic insight into how the innate immune protein S100A9 evolved 
multiple functions. We highlight evolutionary and biochemical approaches for 
studying mechanisms of protein evolution that can be broadly applied to many 
biological systems. This work lays a foundation for determining how A9 and other 
DAMPs have evolved critical innate immune functions and will help inform 
strategies to alleviate pathological DAMP function. 
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APPENDIX A 










Figure AA1. Hexahistidine site conservation of modern and ancestrally 
reconstructed A8s and A9s. Human (h), mouse (m), opossum (op), maximum 
likelihood therian mammalian ancestors (anc), and AltAll ancestors (altanc) shown. 
Alignment truncated to show conservation of key hexahistidine site metal binding 
residues (boxed + arrows). A8s conserve two (positions 17 and 27 in human A8), 
while A9s conserve four (positions 91, 95, 103, and 105 of human A9). Consensus 






Figure AA2. Oligomeric state analysis of S100 proteins by SECMALS. 
Differential refractive index (left y-axis, lines) and calculated molecular weights 
from light scattering detectors (right y-axis, points) for modern S100 proteins used 
in this study. h = human, op = opossum, ch = chicken species. Opossum A8 + A9 
sample is an equimolar mixture of opossum A8 and A9 homodimers. Table below 




Figure AA3. S. epidermidis growth curves in the presence of S100 proteins. 
Representative S. epidermidis growth curves in the presence of a) human A9, b) 
human A9 M63F, c) human A8/A9, d) human A8/A9 M63F, e) opossum A8/A9 
(cysteine-free), f) opossum A8/A9 (containing cysteines), g) ancA8/A9, and h) 
altancA8/A9. Error bars are the standard deviation for 3 technical replicates, points 
show one representative biological replicate for each protein at four different 
concentrations. 
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# of sites that differ 
Average # sites that 
differ from ML sequence 
reconstructed posterior from the ML for reconstructions on 
protein probability sequence alternate topologies 
ancA9 0.83 -- 5 
altancA9 0.81 10 -- 
ancA8 0.88 -- 1 
altancA8 0.86 17 -- 
ancCG 0.86 -- 8 




Figure AA5. Circular dichroism spectroscopy measurements of ancestral 
proteins. Data shown are the average of 3 scans. Solid lines are maximum 
likelihood ancestral proteins, dotted lines are alt-all ancestors (colored the same as 




Figure AA6. Validation of polymyxin B treatment for endotoxin 
contamination. Top panel: Activity of LPS (0.2 ng/ul) against human (left) and 
opossum TLR4 (right) is inhibited by the addition of Polymyxin B (PB, 0.2 ug/ul). 
Middle and bottom panels: S100 activation of human (middle) and opossum 
(bottom) TLR4 with no PB, 0.2 ug/ul PB (+) and 0.25 ug/ul PB (++). No-PB data 
were not collected for hA9, opA9, and opA9 M60F against opossum TLR4 (bottom 
panel). Data were background-subtracted using the LPS + PB control and 





Figure AA7. Human TLR4 dose curves. Points are the average of >3 biological 
replicates each consisting of 3 technical triplicates, error bars are standard error of 
the mean. An asterisk (*) indicates a concentration at which a single biological 
replicate was measured. Data were background-subtracted using the LPS + PB 







Figure AA8. Opossum TLR4 dose curves. Points are the average of >3 biological 
replicates each consisting of 3 technical triplicates, error bars are standard error of 
the mean. An asterisk (*) indicates a concentration at which a single biological 
replicate was measured. Data were background-subtracted using the LPS + PB 






Figure AA9. Extant S100 protein proteolysis fits. Blue dots are biological 
replicates, orange line is a single exponential decay fit (see methods). Protein is 






Figure AA10. Mammalian A8, A9, and A8/A9 complex proteolysis fits. Blue 
dots are biological replicates, orange line is a single exponential decay fit (see 
methods). Protein is listed at the top. Pixel intensity was quantified by densitometry 
from SDS-PAGE gels. Longer time points were collected for proteins with slower 





Figure AA11. Ancestral S100 proteolysis fits. Blue dots are biological replicates, 
orange line is a single exponential decay fit (see methods). Protein is listed at the 
top. Pixel intensity was quantified by densitometry from SDS-PAGE gels. Longer 







Figure AA12. Mutant S100 proteolysis fits. Blue dots are biological replicates, 
orange line is a single exponential decay fit (see methods). Protein is listed at the 
top. Pixel intensity was quantified by densitometry from SDS-PAGE gels. Longer 





Figure AA13. Sequence alignment highlighting identification of position 63. 
S100 protein sequences are grouped into proteolytically susceptible (top) or 
resistant and potently proinflammatory (red text) or not (black text). Only the first 
90 residues out of 114 total were examined as the disordered A9 tail (residues ~93- 
114) are highly variable and the tail is dispensable for A9 proinflammatory activity. 





Figure AA14. Human A9 and A9 M63F proteolytic degradation using 
neutrophil proteases. Blue dots are biological replicates, orange line is a single 
exponential decay fit (see methods). Protein is listed at the top of each graph. Pixel 
intensity was quantified by densitometry from SDS-PAGE gels. Longer time points 
were collected for proteins with slower degradation rates (see x-axis). 

















Human A9 Urea 1.91  0.14 0.65  0.01 2.96  0.22 
Human A9 M63F Urea 6.57  0.18 1.31  0.01 5.03  0.14 
Human A9 Gdn-HCl 1.62  1.30 1.25  0.22 1.3  1.07 
Human A9 M63F Gdn-HCl 9.36  1.70 3.59  0.26 2.61  0.51 
 
 
Figure AA15. A9 equilibrium chemical denaturation experiments. Chemical 
denaturation experiments using urea (left) and guanidinium hydrochloride (right). 
Graphs represent > 3 replicates. Human A9 is shown in purple, A9 M63F in red. 
An apparent two-state unfolding model was fit to the data to estimate 








Figure AA16. A9 kinetic chemical denaturation experiments. Time course 
measurement of hA9 (top) and hA9 M63F (bottom) unfolding upon addition of 6M 
gdn-HCl. Each curve is a single replicate at one concentration, monitoring CD 
signal at 222 nm (y-axis). 
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APPENDIX B 

















 - Ca + Ca - Ca + Ca - Ca + Ca 
hA9 25.1 ± 0.9 31.0 ± 2.6 1.01 ± 0.05 1.08 ± 0.10 96.1 96.6 
hA9 M63F 25.0 ± 0.2 29.8 ± 3.4 1.00 ± 0.01 1.12 ± 0.16 100 97.2 





25.3 ± 0.9 
 
*46.6 ± 28.2 
 








Figure AB1. Oligomeric state analysis of A9 and A9 variants by SECMALS. 
Differential refractive index (left y-axis, lines) and calculated molecular weights 
from light scattering detectors (right y-axis, points) for A9 proteins used in this 
study. * indicates preliminary low-quality measurement that could not be 
completed due to the coronavirus pandemic. Ca = calcium, Mw = molecular weight. 











Figure AB2. Exponential fits for A9 and A9 M63F NMR HDX experiments. 
Points are HSQC peak intensity at a given timepoint, lines are single exponential 
fits to data (purple = A9, red = A9 M63F). Fitting details are described in methods. 
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Table AB3. Exponential fit data table for A9 and A9 M63F NMR HDX 
experiments. Data corresponding to Chapter III, Figure 3.4b (residues that 
exchanged too quickly to measure for both A9 and A9 M63F – and therefore do not 
differ in rate – are not included). 
 
 
residue a9_ln_rate a9_ln_err m63f_ln_rate m63f_ln_err diff diff_err 
9 -4.4441 1.0429 -6.941 1.974 2.497 0.894 
10 0.6931 0.0000 -7.000 3.190 7.693 0.415 
11 -4.3779 1.1189 -7.122 2.180 2.744 0.893 
13 -5.2635 0.9038 -7.020 1.712 1.757 1.102 
15 -7.5706 0.8437 -9.855 2.579 2.285 1.188 
17 -3.8715 1.2480 -6.755 2.955 2.884 1.112 
20 -4.8776 0.9266 -6.987 1.509 2.109 0.840 
21 -4.8879 0.8743 -9.288 3.629 4.400 0.848 
23 0.6931 0.0000 -8.136 1.581 8.830 0.179 
24 0.6931 0.0000 -8.386 2.392 9.079 0.263 
31 0.6931 0.0000 -8.009 1.778 8.702 0.204 
32 0.6931 0.0000 -9.135 2.821 9.828 0.287 
33 0.6931 0.0000 -8.191 2.214 8.884 0.249 
37 0.6931 0.0000 -9.226 2.730 9.919 0.275 
39 -4.5836 1.0537 -9.962 4.296 5.378 0.822 
42 -4.8710 0.8302 -11.089 3.810 6.218 0.627 
43 0.6931 0.0000 -7.448 3.751 8.142 0.461 
44 0.6931 0.0000 -7.335 4.216 8.028 0.525 
45 -4.8508 0.8912 0.693 0.000 -5.544 -0.161 
64 0.6931 0.0000 -8.032 1.973 8.725 0.226 
65 0.6931 0.0000 -7.346 1.779 8.039 0.221 
67 0.6931 0.0000 -8.614 2.382 9.307 0.256 
68 0.6931 0.0000 -6.937 1.698 7.630 0.223 
71 0.6931 0.0000 -8.116 1.631 8.809 0.185 
73 0.6931 0.0000 -8.833 2.316 9.526 0.243 
81 -7.1834 0.8264 -9.329 4.713 2.145 2.230 
84 -4.1741 1.0207 0.693 0.000 -4.867 -0.210 
85 0.6931 0.0000 -7.446 4.239 8.140 0.521 
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Table AB4. A9 mutant cycle chemical denaturation data. Parameters for a two- 
state unfolding model fit to data in Figure 3.4a-c (see methods). F-F interaction 
energies at different calcium concentrations shown below, calculated from dG 
values listed in upper table (see Figure 3.4d). Err = error from fit (diagonalized 
covariance matrix). Errors in bottom F-F interaction table are propagated from 


















hA9 0 2.9 0.6 1.0 0.0 2.8 0.6 
hA9 500 1.9 0.1 0.6 0.0 3.0 0.2 
hA9 5000 4.8 1.3 1.1 0.1 4.4 1.2 
f37l 0 2.8 0.1 0.9 0.0 3.1 0.1 
f37l 500 1.9 0.8 0.7 0.0 2.9 1.3 
f37l 5000 2.2 0.3 0.7 0.0 3.3 0.5 
m63f 0 3.7 0.1 1.3 0.0 2.9 0.1 
m63f 500 6.6 0.2 1.3 0.0 5.0 0.1 
m63f 5000 11.2 2.8 1.6 0.1 7.0 1.8 
double 0 3.2 0.1 1.0 0.0 3.2 0.1 
double 500 1.4 0.6 0.4 0.0 3.2 1.3 

















 0 0.4 0.7 0.1 0.0 0.0 0.6 
 0.5 5.2 1.0 0.9 0.0 1.7 1.8 
 5 6.1 3.1 0.6 0.1 1.5 2.2 
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Table AB5. A9 mutant cycle HDXMS data. Summary exchange data after 3600 
seconds for peptides from HDXMS experiments (corresponding to Figure 3.5e). 









State Start End Sequence (sec) D #D %D CI (#D) Stddev 
WT 2 8 TSKMSQL 3600 5 3.005 60.109 2.149 0.239 
WT 6 13 SQLERNIE 3600 6 2.925 48.749  0 
WT 8 13 LERNIE 3600 4 1.665 41.628 0.166 0.067 
WT 8 14 LERNIET 3600 5 2.327 46.537 0.157 0.063 


















































































WT 10 17 RNIETIIN 3600 6 2.268 37.796 1.291 0.144 
WT 11 17 NIETIIN 3600 5 1.789 35.789 0.687 0.277 
WT 11 22 NIETIINTFHQY 3600 10 4.007 40.067 6.114 0.68 
WT 11 25 NIETIINTFHQYSVK 3600 13 6.048 46.52 2.399 0.966 
WT 12 17 IETIIN 3600 4 1.299 32.483 0.52 0.209 







































WT 14 17 TIIN 3600 2 0.78 38.98 0.046 0.019 
WT 14 22 TIINTFHQY 3600 7 3.161 45.161 0.144 0.058 















































































































































WT 18 22 TFHQY 3600 3 1.024 34.131 0.172 0.069 
WT 18 25 TFHQYSVK 3600 6 2.895 48.245 0.101 0.096 





















WT 23 29 SVKLGHP 3600 4 2.512 62.795 0.126 0.12 
WT 23 30 SVKLGHPD 3600 5 2.468 49.368 0.146 0.139 
WT 23 32 SVKLGHPDTL 3600 7 3.608 51.536 0.337 0.321 
WT 23 33 SVKLGHPDTLN 3600 8 4.364 54.547 0.203 0.193 


















































































WT 26 32 LGHPDTL 3600 4 1.475 36.87 0.127 0.051 
WT 26 33 LGHPDTLN 3600 5 2.209 44.18 0.378 0.152 
WT 26 37 LGHPDTLNQGEF 3600 9 4.511 50.121 0.312 0.126 
WT 26 38 LGHPDTLNQGEFK 3600 10 4.683 46.83 3.105 0.346 









































WT 30 37 DTLNQGEF 3600 6 3.533 58.875 0.635 0.256 
WT 30 39 DTLNQGEFKE 3600 8 3.84 47.994 0.408 0.164 
WT 30 40 DTLNQGEFKEL 3600 9 5.449 60.546 0.061 0.024 
WT 31 37 TLNQGEF 3600 5 2.916 58.321 0.508 0.205 
WT 31 38 TLNQGEFK 3600 6 3.553 59.222 0.137 0.055 
WT 31 39 TLNQGEFKE 3600 7 4.044 57.775 0.37 0.149 
WT 31 40 TLNQGEFKEL 3600 8 4.404 55.046 0.307 0.124 
WT 33 38 NQGEFK 3600 4 2.376 59.391 0.242 0.097 
WT 33 39 NQGEFKE 3600 5 2.709 54.176 0.137 0.055 
WT 33 40 NQGEFKEL 3600 6 3.301 55.022 0.515 0.207 
WT 34 39 QGEFKE 3600 4 1.921 48.024 0.033 0.013 
WT 34 40 QGEFKEL 3600 5 2.439 48.778 0.371 0.149 
WT 35 40 GEFKEL 3600 4 2.087 52.175 0.291 0.117 





















WT 37 40 FKEL 3600 2 0.967 48.356 0.248 0.1 
WT 38 47 KELVRKDLQN 3600 8 3.883 48.533 0.215 0.258 
WT 38 48 KELVRKDLQNF 3600 9 4.462 49.574 0.142 0.185 
WT 40 47 LVRKDLQN 3600 6 3.15 52.499 0.848 0.342 









































WT 41 49 VRKDLQNFL 3600 7 4.057 57.953 0.094 0.038 
WT 41 50 VRKDLQNFLK 3600 8 4.763 59.538 0.122 0.146 
WT 41 52 VRKDLQNFLKKE 3600 10 5.622 56.219 0.126 0.198 





























































WT 44 48 DLQNF 3600 3 1.877 62.573 0.19 0.181 
WT 44 49 DLQNFL 3600 4 2.686 67.142 0.163 0.155 
WT 44 50 DLQNFLK 3600 5 3.666 73.317 0.157 0.063 





















WT 45 50 LQNFLK 3600 4 2.688 67.203 0.196 0.079 
WT 45 52 LQNFLKKE 3600 6 3.078 51.303 0.272 0.171 
WT 45 54 LQNFLKKENK 3600 8 4.06 50.751 0.267 0.254 





















WT 47 50 NFLK 3600 2 1.54 77.013 0.102 0.041 
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WT 47 51 NFLKK 3600 3 2.325 77.503 0.181 0.073 
WT 47 52 NFLKKE 3600 4 2.701 67.523 0.085 0.081 
WT 47 54 NFLKKENK 3600 6 3.089 51.481 0.742 0.299 









































WT 48 57 FLKKENKNEK 3600 8 3.436 42.948 0.839 0.338 
WT 48 60 FLKKENKNEKVIE 3600 11 4.823 43.843 0.296 0.282 

















































































WT 49 60 LKKENKNEKVIE 3600 10 4.236 42.356 0.267 0.32 










































WT 58 63 VIEHIM 3600 4 1.837 45.937 0.27 0.03 







































WT 65 74 DLDTNADKQL 3600 8 4.301 53.76 0.223 0.09 
WT 65 75 DLDTNADKQLS 3600 9 5.105 56.726 0.405 0.163 
WT 65 76 DLDTNADKQLSF 3600 10 5.115 51.148 0.287 0.274 
WT 65 79 DLDTNADKQLSFEEF 3600 13 5.651 43.473 0.377 0.359 
WT 66 75 LDTNADKQLS 3600 8 4.235 52.943 1.306 0.526 
WT 66 78 LDTNADKQLSFEE 3600 11 5.542 50.377 0.363 0.228 
WT 67 78 DTNADKQLSFEE 3600 10 5.362 53.616 0.689 0.278 
WT 67 79 DTNADKQLSFEEF 3600 11 4.896 44.506 0.49 0.197 
WT 70 76 ADKQLSF 3600 5 2.975 59.506  0 
WT 70 79 ADKQLSFEEF 3600 8 3.38 42.244 0.524 0.211 
WT 71 76 DKQLSF 3600 4 2.401 60.03 0.567 0.228 
WT 73 79 QLSFEEF 3600 5 2.117 42.348 0.109 0.103 
WT 74 79 LSFEEF 3600 4 1.346 33.643 0.268 0.108 
































































WT 86 91 LTWASH 3600 4 2.225 55.617 0.274 0.11 
















































































































































































F37L 2 8 TSKMSQL 3600 5 2.981 59.612 0.681 0.076 
F37L 6 13 SQLERNIE 3600 6 4.351 72.512  0 
F37L 8 13 LERNIE 3600 4 2.587 64.687 0.284 0.114 
F37L 8 14 LERNIET 3600 5 3.466 69.312 0.392 0.158 


















































































F37L 10 17 RNIETIIN 3600 6 4.369 72.809 0.917 0.369 
F37L 11 17 NIETIIN 3600 5 3.212 64.233 0.706 0.284 
F37L 11 22 NIETIINTFHQY 3600 10 8.056 80.559 8.172 0.91 
F37L 11 25 NIETIINTFHQYSVK 3600 13 9.316 71.664 1.02 0.411 
F37L 12 17 IETIIN 3600 4 2.412 60.304 0.57 0.229 









































F37L 14 17 TIIN 3600 2 1.477 73.827 0.196 0.079 
F37L 14 22 TIINTFHQY 3600 7 4.587 65.522 0.413 0.166 













































































































































F37L 18 22 TFHQY 3600 3 1.125 37.513 0.261 0.105 
F37L 18 25 TFHQYSVK 3600 6 2.994 49.904 0.131 0.124 





















F37L 23 29 SVKLGHP 3600 4 2.543 63.569 0.086 0.082 
F37L 23 30 SVKLGHPD 3600 5 2.487 49.731 0.11 0.105 
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F37L 23 32 SVKLGHPDTL 3600 7 3.592 51.314 0.35 0.333 
F37L 23 33 SVKLGHPDTLN 3600 8 4.367 54.587 0.215 0.204 

















































































F37L 26 32 LGHPDTL 3600 4 1.486 37.148 0.145 0.058 
F37L 26 33 LGHPDTLN 3600 5 2.2 44.008 0.299 0.12 
F37L 26 37 LGHPDTLNQGEL 3600 9 4.64 51.559 0.287 0.115 
F37L 26 38 LGHPDTLNQGELK 3600 10 5.363 53.625 0.668 0.269 









































F37L 30 37 DTLNQGEL 3600 6 3.867 64.449 0.713 0.287 
F37L 30 39 DTLNQGELKE 3600 8 5.563 69.532 0.688 0.277 
F37L 30 40 DTLNQGELKEL 3600 9 6.142 68.244 0.445 0.179 
F37L 31 37 TLNQGEL 3600 5 3.085 61.709 0.543 0.219 
F37L 31 38 TLNQGELK 3600 6 3.902 65.03 0.342 0.137 
F37L 31 39 TLNQGELKE 3600 7 4.336 61.946 0.382 0.154 
F37L 31 40 TLNQGELKEL 3600 8 5.143 64.287 0.316 0.127 
F37L 33 38 NQGELK 3600 4     
F37L 33 39 NQGELKE 3600 5     
F37L 33 40 NQGELKEL 3600 6 3.963 66.048 0.361 0.145 
F37L 34 39 QGELKE 3600 4     
F37L 34 40 QGELKEL 3600 5 3.293 65.867 0.287 0.116 



















2.093 69.765 0.241 0.097 
F37L 37 40 LKEL 3600 2 1.445 72.228 0.167 0.067 
F37L 38 47 KELVRKDLQN 3600 8 4.937 61.714 1.789 1.124 
F37L 38 48 KELVRKDLQNF 3600 9 5.262 58.472 0.507 0.483 
F37L 40 47 LVRKDLQN 3600 6 3.852 64.2 0.643 0.259 









































F37L 41 49 VRKDLQNFL 3600 7 4.129 58.988 1.348 0.15 
F37L 41 50 VRKDLQNFLK 3600 8 4.902 61.28 0.234 0.28 
F37L 41 52 VRKDLQNFLKKE 3600 10 5.802 58.021 0.141 0.222 





























































F37L 44 48 DLQNF 3600 3 1.88 62.652 0.188 0.179 
F37L 44 49 DLQNFL 3600 4 2.728 68.211 0.164 0.157 
F37L 44 50 DLQNFLK 3600 5 3.742 74.839 0.318 0.128 





















F37L 45 50 LQNFLK 3600 4 2.704 67.607 0.183 0.074 
F37L 45 52 LQNFLKKE 3600 6 3.37 56.174 0.42 0.169 
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F37L 45 54 LQNFLKKENK 3600 8 4.118 51.472 0.158 0.151 





















F37L 47 50 NFLK 3600 2 1.544 77.217 0.106 0.043 
F37L 47 51 NFLKK 3600 3 2.475 82.492 0.116 0.047 
F37L 47 52 NFLKKE 3600 4 2.716 67.901 0.066 0.063 
F37L 47 54 NFLKKENK 3600 6 3.118 51.966 0.318 0.128 









































F37L 48 57 FLKKENKNEK 3600 8 3.452 43.154 0.887 0.357 
F37L 48 60 FLKKENKNEKVIE 3600 11 4.886 44.418 0.285 0.271 

















































































F37L 49 60 LKKENKNEKVIE 3600 10 4.247 42.475 0.15 0.195 










































F37L 58 63 VIEHIM 3600 4 1.714 42.854 1.713 0.191 









































F37L 65 74 DLDTNADKQL 3600 8 4.549 56.856 0.409 0.165 
F37L 65 75 DLDTNADKQLS 3600 9 5.562 61.799 0.359 0.144 
F37L 65 76 DLDTNADKQLSF 3600 10 5.752 57.519 0.329 0.313 
F37L 65 79 DLDTNADKQLSFEEF 3600 13 7.432 57.171 0.202 0.193 
F37L 66 75 LDTNADKQLS 3600 8 4.834 60.426 1.113 0.448 
F37L 66 78 LDTNADKQLSFEE 3600 11 6.388 58.074 0.511 0.321 
F37L 67 78 DTNADKQLSFEE 3600 10 5.999 59.991 0.673 0.271 
F37L 67 79 DTNADKQLSFEEF 3600 11 6.058 55.075 2.904 1.169 
F37L 70 76 ADKQLSF 3600 5 3.288 65.751 0.242 0.097 
F37L 70 79 ADKQLSFEEF 3600 8 4.853 60.666 0.697 0.281 
F37L 71 76 DKQLSF 3600 4 2.743 68.585 0.154 0.062 
F37L 73 79 QLSFEEF 3600 5 3.093 61.862 0.377 0.359 
F37L 74 79 LSFEEF 3600 4 2.093 52.337 0.779 0.314 
































































F37L 86 91 LTWASH 3600 4 2.152 53.789 0.277 0.112 
F37L 86 97 LTWASHEKMHEG 3600 10 2.189 21.888  0 
F37L 87 91 TWASH 3600 3 1.35 45.016 0.329 0.133 
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   TWASHEKMHEGDE 
GPGHHHKPGLGEGT 
      
















































































































































M63F 2 8 TSKMSQL 3600 5 2.864 57.273 1.675 0.186 
M63F 6 13 SQLERNIE 3600 6 1.469 24.483  0 
M63F 8 13 LERNIE 3600 4 1.077 26.925 0.215 0.087 
M63F 8 14 LERNIET 3600 5 1.736 34.721 3.752 0.418 








































































    
M63F 10 17 RNIETIIN 3600 6 1.415 23.588 0.162 0.065 
M63F 11 17 NIETIIN 3600 5 1.142 22.842 1.422 0.158 
M63F 11 22 NIETIINTFHQY 3600 10 2.039 20.388 1.279 0.515 
M63F 11 25 NIETIINTFHQYSVK 3600 13 3.575 27.498 1.152 0.464 
M63F 12 17 IETIIN 3600 4 0.87 21.762 0.497 0.2 

































    
M63F 14 17 TIIN 3600 2 0.391 19.563 0.038 0.015 
M63F 14 22 TIINTFHQY 3600 7 1.439 20.561 0.025 0.01 















































































































































M63F 18 22 TFHQY 3600 3 0.18 6.008 0.077 0.031 
M63F 18 25 TFHQYSVK 3600 6 1.593 26.549 0.04 0.038 






















M63F 23 29 SVKLGHP 3600 4 2.454 61.348 0.127 0.121 
M63F 23 30 SVKLGHPD 3600 5 2.41 48.198 0.161 0.153 
M63F 23 32 SVKLGHPDTL 3600 7 2.595 37.076 0.298 0.24 
M63F 23 33 SVKLGHPDTLN 3600 8 2.823 35.282 0.157 0.15 

















































































M63F 26 32 LGHPDTL 3600 4 0.464 11.596 0.128 0.051 
M63F 26 33 LGHPDTLN 3600 5 0.727 14.534 0.266 0.107 
M63F 26 37 LGHPDTLNQGEF 3600 9 2.639 29.32 0.241 0.097 
M63F 26 38 LGHPDTLNQGEFK 3600 10 2.503 25.031 0.429 0.173 









































M63F 30 37 DTLNQGEF 3600 6 2.173 36.221 0.963 0.387 
M63F 30 39 DTLNQGEFKE 3600 8 2.511 31.391 0.09 0.01 
M63F 30 40 DTLNQGEFKEL 3600 9 2.515 27.946 0.133 0.054 
M63F 31 37 TLNQGEF 3600 5 2.194 43.885 0.381 0.154 
M63F 31 38 TLNQGEFK 3600 6 2.128 35.461 0.294 0.118 
M63F 31 39 TLNQGEFKE 3600 7 2.094 29.915 0.233 0.094 
M63F 31 40 TLNQGEFKEL 3600 8 2.15 26.871 0.164 0.066 
M63F 33 38 NQGEFK 3600 4 1.115 27.88 0.402 0.162 
M63F 33 39 NQGEFKE 3600 5 1.104 22.072 0.349 0.141 
M63F 33 40 NQGEFKEL 3600 6 1.213 20.213 0.198 0.08 
M63F 34 39 QGEFKE 3600 4 0.477 11.92 0.305 0.123 
M63F 34 40 QGEFKEL 3600 5 0.619 12.372 0.073 0.029 
M63F 35 40 GEFKEL 3600 4 0.331 8.278 0.083 0.033 





















M63F 37 40 FKEL 3600 2 0.093 4.668 0.028 0.011 
M63F 38 47 KELVRKDLQN 3600 8 2.307 28.843 0.176 0.21 
M63F 38 48 KELVRKDLQNF 3600 9 2.882 32.017 0.089 0.116 
















































M63F 41 49 VRKDLQNFL 3600 7     
M63F 41 50 VRKDLQNFLK 3600 8 4.382 54.769 0.169 0.22 
M63F 41 52 VRKDLQNFLKKE 3600 10 5.165 51.649 0.179 0.281 





























































M63F 44 48 DLQNF 3600 3 1.843 61.434 0.24 0.229 
M63F 44 49 DLQNFL 3600 4 2.762 69.042 0.271 0.258 
M63F 44 50 DLQNFLK 3600 5 3.572 71.443 0.52 0.209 






















M63F 45 50 LQNFLK 3600 4 2.652 66.312 0.261 0.105 
M63F 45 52 LQNFLKKE 3600 6 2.654 44.24 0.158 0.099 
M63F 45 54 LQNFLKKENK 3600 8 4.032 50.399 0.323 0.308 





















M63F 47 50 NFLK 3600 2 1.516 75.806 0.105 0.042 
M63F 47 51 NFLKK 3600 3 2.33 77.652 0.238 0.096 
M63F 47 52 NFLKKE 3600 4 2.667 66.663 0.096 0.091 
M63F 47 54 NFLKKENK 3600 6 3.19 53.161 0.534 0.215 

































    
M63F 48 57 FLKKENKNEK 3600 8 3.441 43.007 0.968 0.39 
M63F 48 60 FLKKENKNEKVIE 3600 11 4.656 42.324 0.454 0.433 

















































































M63F 49 60 LKKENKNEKVIE 3600 10 4.18 41.802 2.045 0.228 





























































































M63F 65 74 DLDTNADKQL 3600 8 2.447 30.586 0.225 0.091 
M63F 65 75 DLDTNADKQLS 3600 9 2.278 25.314 4.91 0.546 
M63F 65 76 DLDTNADKQLSF 3600 10 2.702 27.018 0.3 0.241 
M63F 65 79 DLDTNADKQLSFEEF 3600 13 3.059 23.534 0.438 0.353 
M63F 66 75 LDTNADKQLS 3600 8 2.251 28.141 0.291 0.117 
M63F 66 78 LDTNADKQLSFEE 3600 11 3.355 30.499 3.05 0.339 
M63F 67 78 DTNADKQLSFEE 3600 10 3.142 31.417 0.665 0.268 
M63F 67 79 DTNADKQLSFEEF 3600 11 2.831 25.736 0.559 0.225 
M63F 70 76 ADKQLSF 3600 5 1.461 29.228 0.072 0.008 
M63F 70 79 ADKQLSFEEF 3600 8 1.77 22.124 0.309 0.124 
M63F 71 76 DKQLSF 3600 4 1.017 25.426 0.282 0.113 
M63F 73 79 QLSFEEF 3600 5 1.444 28.877 0.075 0.071 
M63F 74 79 LSFEEF 3600 4 1.265 31.626 0.535 0.215 
































M63F 85 88 RLTW 3600 2 1.423 71.134 0.484 0.195 
M63F 85 91 RLTWASH 3600 5 2.359 47.187 0.291 0.277 
149  
   RLTWASHEKMHEG 
DEGPGHHHKPGLGE 
      
M63F 85 114 GTP 3600 25 21.69 86.761 1.363 0.549 
M63F 86 91 LTWASH 3600 4 2.222 55.538 0.347 0.14 













































































































































































































































































































































  ERNIETIINTFHQYSV 
KLGHPDTLNQGELK 
      


















































































































































































































































F37L/M   TIINTFHQYSVKLGH       
63F 14 39 PDTLNQGELKE 3600 23 13.39 58.218 0.608 0.79 
F37L/M   TIINTFHQYSVKLGH       
63F 14 40 PDTLNQGELKEL 3600 24 14.109 58.786 14.807 1.648 
F37L/M          
63F 15 25 IINTFHQYSVK 3600 9 4.313 47.921 0.777 0.489 
F37L/M   IINTFHQYSVKLGHP       
63F 15 36 DTLNQGE 3600 19 9.571 50.374 1.622 0.653 
F37L/M   IINTFHQYSVKLGHP       
63F 15 37 DTLNQGEL 3600 20 10.154 50.771 1.153 0.128 
F37L/M   IINTFHQYSVKLGHP       
63F 15 39 DTLNQGELKE 3600 22 11.102 50.463 0.256 0.334 
   IINTFHQYSVKLGHP       
F37L/M   DTLNQGELKELVRK       
63F 15 48 DLQNF 3600 31 16.449 53.063  0 
F37L/M          
63F 18 22 TFHQY 3600 3 1.104 36.796 0.035 0.014 
F37L/M          
63F 18 25 TFHQYSVK 3600 6 2.888 48.131 0.058 0.055 
F37L/M          
63F 19 25 FHQYSVK 3600 5 2.008 40.167 0.607 0.244 
F37L/M   FHQYSVKLGHPDTL       
63F 19 39 NQGELKE 3600 18 9.137 50.759 0.467 0.445 
F37L/M          
63F 23 29 SVKLGHP 3600 4 2.481 62.025 0.056 0.053 
F37L/M          
63F 23 30 SVKLGHPD 3600 5 2.455 49.108 0.072 0.069 
F37L/M          
63F 23 32 SVKLGHPDTL 3600 7 3.555 50.782 0.094 0.09 
F37L/M          
63F 23 33 SVKLGHPDTLN 3600 8 4.258 53.22 0.134 0.128 
F37L/M          
63F 23 34 SVKLGHPDTLNQ 3600 9 4.942 54.912 0.133 0.126 
F37L/M   SVKLGHPDTLNQGE       
63F 23 37 L 3600 12 6.638 55.313 0.152 0.122 
F37L/M   SVKLGHPDTLNQGE       
63F 23 38 LK 3600 13 7.191 55.314 0.538 0.217 
F37L/M   SVKLGHPDTLNQGE       
63F 23 39 LKE 3600 14 7.652 54.654 0.267 0.348 
F37L/M   SVKLGHPDTLNQGE       
63F 23 40 LKEL 3600 15 8.287 55.248 0.185 0.24 
F37L/M          
63F 26 32 LGHPDTL 3600 4 1.473 36.823 0.148 0.06 
F37L/M          
63F 26 33 LGHPDTLN 3600 5 2.123 42.464 0.11 0.044 
F37L/M          
63F 26 37 LGHPDTLNQGEL 3600 9 4.39 48.781 0.339 0.136 
F37L/M          
63F 26 38 LGHPDTLNQGELK 3600 10 5.275 52.752 0.583 0.235 
F37L/M          
63F 26 39 LGHPDTLNQGELKE 3600 11 5.675 51.593 0.159 0.151 
F37L/M   LGHPDTLNQGELKE       
63F 26 40 L 3600 12 6.485 54.039 0.151 0.144 
F37L/M   LGHPDTLNQGELKE       
63F 26 48 LVRKDLQNF 3600 20 12.895 64.475 1.208 0.973 
F37L/M          
63F 30 37 DTLNQGEL 3600 6 3.731 62.189 0.774 0.312 
F37L/M          
63F 30 39 DTLNQGELKE 3600 8 5.241 65.512 0.608 0.245 
F37L/M          
63F 30 40 DTLNQGELKEL 3600 9 5.877 65.302 0.369 0.149 
F37L/M          
63F 31 37 TLNQGEL 3600 5 3.065 61.307 0.333 0.134 
F37L/M          
63F 31 38 TLNQGELK 3600 6 3.771 62.842 0.23 0.093 
F37L/M          
63F 31 39 TLNQGELKE 3600 7 4.156 59.378 0.323 0.13 
F37L/M          
63F 31 40 TLNQGELKEL 3600 8 4.929 61.616 0.206 0.083 
151  
F37L/M          
63F 33 38 NQGELK 3600 4     
F37L/M          
63F 33 39 NQGELKE 3600 5     
F37L/M          
63F 33 40 NQGELKEL 3600 6 3.812 63.54 0.031 0.013 
F37L/M          
63F 34 39 QGELKE 3600 4     
F37L/M          
63F 34 40 QGELKEL 3600 5 3.122 62.432  0 
F37L/M          
63F 35 40 GELKEL 3600 4 2.765 69.127 0.181 0.073 
F37L/M          
63F 36 40 ELKEL 3600 3 1.994 66.464 0.169 0.068 
F37L/M   ELKELVRKDLQNFL       
63F 36 62 KKENKNEKVIEHI 3600 25     
F37L/M          
63F 37 40 LKEL 3600 2 1.372 68.58 0.129 0.052 
F37L/M          
63F 38 47 KELVRKDLQN 3600 8 4.5 56.25 1.934 0.215 
F37L/M          
63F 38 48 KELVRKDLQNF 3600 9 5.021 55.786 0.577 0.55 
F37L/M          
63F 40 47 LVRKDLQN 3600 6 3.968 66.134 0.325 0.31 
F37L/M          
63F 40 49 LVRKDLQNFL 3600 8 5.198 64.974 0.278 0.112 
F37L/M   LVRKDLQNFLKKEN       
63F 40 60 KNEKVIE 3600 19 10.313 54.281 1.244 0.782 
F37L/M   LVRKDLQNFLKKEN       
63F 40 64 KNEKVIEHIFE 3600 23 12.311 53.525 0.283 0.338 
F37L/M          
63F 41 49 VRKDLQNFL 3600 7     
F37L/M          
63F 41 50 VRKDLQNFLK 3600 8 4.771 59.636 0.214 0.231 
F37L/M          
63F 41 52 VRKDLQNFLKKE 3600 10 5.852 58.521 0.167 0.249 
F37L/M          
63F 41 54 VRKDLQNFLKKENK 3600 12 6.15 51.249 0.133 0.144 
F37L/M   VRKDLQNFLKKENK       
63F 41 57 NEK 3600 15 6.801 45.341 0.191 0.285 
F37L/M   VRKDLQNFLKKENK       
63F 41 60 NEKVIE 3600 18 9.015 50.086 0.449 0.361 
F37L/M   VRKDLQNFLKKENK       
63F 41 61 NEKVIEH 3600 19 8.738 45.989 0.574 0.547 
F37L/M          
63F 44 48 DLQNF 3600 3 1.82 60.671 0.165 0.157 
F37L/M          
63F 44 49 DLQNFL 3600 4 2.722 68.051 0.128 0.122 
F37L/M          
63F 44 50 DLQNFLK 3600 5 3.6 72.001 0.235 0.095 
F37L/M          
63F 44 54 DLQNFLKKENK 3600 9 5.561 61.79 1.189 0.132 
F37L/M   DLQNFLKKENKNEK       
63F 44 61 VIEH 3600 16 8.572 53.574 0.363 0.346 
F37L/M          
63F 45 50 LQNFLK 3600 4 2.618 65.452 0.136 0.055 
F37L/M          
63F 45 52 LQNFLKKE 3600 6 3.428 57.131 0.59 0.238 
F37L/M          
63F 45 54 LQNFLKKENK 3600 8 4.06 50.749 0.108 0.103 
F37L/M          
63F 45 57 LQNFLKKENKNEK 3600 11 4.704 42.766 0.099 0.119 
F37L/M   LQNFLKKENKNEKV       
63F 45 61 IEH 3600 15 6.742 44.945 0.454 0.543 
F37L/M          
63F 47 50 NFLK 3600 2 1.492 74.602 0.029 0.012 
F37L/M          
63F 47 51 NFLKK 3600 3 2.316 77.212 0.442 0.178 
F37L/M          
63F 47 52 NFLKKE 3600 4 2.634 65.838 0.037 0.035 
152  
F37L/M          
63F 47 54 NFLKKENK 3600 6 3.153 52.542 0.667 0.268 
F37L/M          
63F 47 57 NFLKKENKNEK 3600 9 3.962 44.027 0.39 0.157 
F37L/M   NFLKKENKNEKVIE       
63F 47 61 H 3600 13 5.768 44.366 0.253 0.241 
F37L/M   NFLKKENKNEKVIE       
63F 47 63 HIF 3600 15 6.622 44.148 0.214 0.204 
F37L/M          
63F 48 57 FLKKENKNEK 3600 8 3.492 43.656 0.8 0.322 
F37L/M          
63F 48 60 FLKKENKNEKVIE 3600 11 4.65 42.273 0.226 0.182 
F37L/M          
63F 48 61 FLKKENKNEKVIEH 3600 12 4.82 40.169 0.082 0.107 
F37L/M   FLKKENKNEKVIEHI       
63F 48 63 F 3600 14 5.401 38.58 0.107 0.14 
F37L/M   FLKKENKNEKVIEHI       
63F 48 64 FE 3600 15 5.951 39.677 0.408 0.389 
F37L/M   FLKKENKNEKVIEHI       
63F 48 65 FED 3600 16 6.721 42.005 0.68 0.548 
F37L/M   FLKKENKNEKVIEHI       
63F 48 66 FEDL 3600 17 7.199 42.346 0.426 0.51 
F37L/M          
63F 49 60 LKKENKNEKVIE 3600 10 4.13 41.297 0.485 0.391 
F37L/M          
63F 49 61 LKKENKNEKVIEH 3600 11 4.366 39.69 0.115 0.15 
F37L/M   LKKENKNEKVIEHIF       
63F 49 66 EDL 3600 16 6.616 41.353 0.518 0.771 
F37L/M          
63F 50 62 KKENKNEKVIEHI 3600 11 4.247 38.613 0.331 0.133 
F37L/M   KKENKNEKVIEHIFE       
63F 50 66 DL 3600 15 6.842 45.614 0.628 0.679 
F37L/M          
63F 58 63 VIEHIF 3600 4     
F37L/M          
63F 59 63 IEHIF 3600 3     
F37L/M   EDLDTNADKQLSFE       
63F 64 78 E 3600 13 6.874 52.876 0.474 0.191 
F37L/M   EDLDTNADKQLSFE       
63F 64 79 EF 3600 14 7.096 50.684 1.108 0.446 
F37L/M          
63F 65 74 DLDTNADKQL 3600 8 4.346 54.326 0.141 0.057 
F37L/M          
63F 65 75 DLDTNADKQLS 3600 9 5.232 58.132  0 
F37L/M          
63F 65 76 DLDTNADKQLSF 3600 10 5.367 53.668 0.534 0.43 
F37L/M          
63F 65 79 DLDTNADKQLSFEEF 3600 13 6.082 46.781 0.386 0.311 
F37L/M          
63F 66 75 LDTNADKQLS 3600 8 4.672 58.403 0.344 0.138 
F37L/M          
63F 66 78 LDTNADKQLSFEE 3600 11 5.892 53.565  0 
F37L/M          
63F 67 78 DTNADKQLSFEE 3600 10 5.503 55.034 0.387 0.156 
F37L/M          
63F 67 79 DTNADKQLSFEEF 3600 11 5.394 49.037 0.072 0.029 
F37L/M          
63F 70 76 ADKQLSF 3600 5 3.338 66.759 0.16 0.065 
F37L/M          
63F 70 79 ADKQLSFEEF 3600 8 4.081 51.016 0.481 0.194 
F37L/M          
63F 71 76 DKQLSF 3600 4 2.622 65.541 0.685 0.276 
F37L/M          
63F 73 79 QLSFEEF 3600 5 2.495 49.905 0.254 0.242 
F37L/M          
63F 74 79 LSFEEF 3600 4 1.657 41.426 0.764 0.308 
F37L/M          
63F 75 79 SFEEF 3600 3 1.176 39.202 0.115 0.11 
F37L/M          




  ARLTWASHEKMHE 
GDEGPGHHHKPGLG 
      
63F 84 114 EGTP 3600 26 22.494 86.515 0.195 0.186 
F37L/M          
63F 85 88 RLTW 3600 2 1.352 67.579 0.167 0.067 
F37L/M          
63F 85 91 RLTWASH 3600 5 2.428 48.568 0.159 0.151 
   RLTWASHEKMHEG       
F37L/M   DEGPGHHHKPGLGE       
63F 85 114 GTP 3600 25 21.974 87.898 0.22 0.21 
F37L/M          
63F 86 91 LTWASH 3600 4 2.222 55.558 0.184 0.074 
F37L/M          
63F 86 97 LTWASHEKMHEG 3600 10 2.861 28.606 1.752 0.705 
F37L/M          
63F 87 91 TWASH 3600 3 1.409 46.963 0.108 0.044 
   TWASHEKMHEGDE       
F37L/M   GPGHHHKPGLGEGT       
63F 87 114 P 3600 23 21.395 93.02 0.227 0.245 
F37L/M   MHEGDEGPGHHHKP       
63F 94 114 GLGEGTP 3600 16 1.673 10.456 0.584 0.76 
F37L/M   HEGDEGPGHHHKPG       
63F 95 114 LGEGTP 3600 15 2.608 17.385 0.786 0.494 
F37L/M   EGDEGPGHHHKPGL       
63F 96 110 G 3600 11 1.9 17.275 0.16 0.153 
F37L/M   EGDEGPGHHHKPGL       
63F 96 114 GEGTP 3600 14 3.119 22.277 0.069 0.109 
F37L/M          
63F 97 110 GDEGPGHHHKPGLG 3600 10 1.684 16.842 0.114 0.108 
F37L/M   GDEGPGHHHKPGLG       
63F 97 114 EGTP 3600 13 3.082 23.708 0.078 0.101 
F37L/M          
63F 98 110 DEGPGHHHKPGLG 3600 9 1.552 17.239 0.112 0.07 
F37L/M   DEGPGHHHKPGLGE       
63F 98 114 GTP 3600 12 3.078 25.654 0.107 0.14 
F37L/M          
63F 99 110 EGPGHHHKPGLG 3600 8 1.749 21.858 0.097 0.092 
F37L/M   EGPGHHHKPGLGEG       






Figure AB6. Calcium binding by A9 and A9 variants by ITC. A global single- 
site model was fit to each dataset using the software package pytc. Filled points are 
experimental data, lines and unfilled points are model fit to data. Model parameters 












A9 31.0 ± 0.5 0.98 1 
A9 M63F 26.8 ± 1.2 0.21 1 
A9 M63F/F37L 79.8 ± 1.8 0.42 1 
A9 F37L 35.9 ± 0.7 0.58 1 
A9 M63F 





31.6 ± 0.5 
0.98 
2 
-121.1 ± 177.3 2 
A9 M63F 




31.4 ± 12.4 2 
A9 M63F/F37L 




138.7 ± 96.8 2 
A9 F37L 




119.7 ± 145.2 2 
Figure AB7. Models fit to calcium binding data for A9 and A9 variants by ITC. 
A global 1-site model was fit to each dataset using the software package pytc. Filled 
points are experimental data, lines and unfilled points are model fit to data. Inset in 
top right shows 1-site model fit to A9 M63F transition 2. 
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Table AB8. Fit parameters for A9 and A9 variant calcium binding in Figure 
AB5. Fit values are shown for both 1-site and 2-site fits. See methods for 



















global_beta1 32228707.4 516464.707 31306594.3 33305691.6 a9 1 
global_dH1 -11897.044 9.21924946 -11915.066 -11878.719 a9 1 
fx_competent 0.97668994 0.00022442 0.97625225 0.97713034 a9 1 
global_heat -2856.4478 335.673135 -3515.5008 -2197.0496 a9 1 
global_intercept -0.0201415 0.01712789 -0.0537238 0.01338561 a9 1 
Kd1 (nM) 31.0282379 0.4972272   a9 1 
global_beta1 37368358.9 1700405.99 34160692 40844014.5 m63f 1 
global_dH1 -11302.535 34.0337762 -11369.215 -11235.807 m63f 1 
fx_competent 0.21321373 0.00031129 0.2126012 0.21382461 m63f 1 
global_heat 66587.2227 482.976545 65636.8108 67540.0848 m63f 1 
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global_beta1 12531395.6 280374.66 12000820.4 13099428 double 1 
global_dH1 -12669.36 27.0161299 -12722.165 -12616.776 double 1 
fx_competent 0.41663275 0.00035293 0.41594566 0.41733575 double 1 
global_heat -15149.272 701.067449 -16532.036 -13777.601 double 1 
global_intercept 0.26408788 0.02211314 0.2207673 0.30765762 double 1 
Kd1 (nM) 79.7995714 1.78541787   double 1 
global_beta1 27874569.1 533262.676 26868598.1 29003287.3 f37l 1 
global_dH1 -12974.424 19.5578747 -13012.294 -12935.951 f37l 1 
fx_competent 0.5813502 0.00023856 0.58088217 0.58181775 f37l 1 
global_heat 10114.5387 643.693665 8860.82272 11393.0581 f37l 1 
global_intercept -0.5177881 0.02108731 -0.5597927 -0.4765572 f37l 1 
Kd1 (nM) 35.874994 0.68631717   f37l 1 
global_beta1 31602549.7 523013.761 30562551 32693725.7 a9 2 
global_dH1 -11895.491 9.47241505 -11913.764 -11877.096 a9 2 
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global_beta2 -8254604.9 12082635.6 -42090471 -101419.82 a9 2 
global_dH2 -19412348 30659573.4 -113781321 -229820.55 a9 2 
fx_competent 0.97680545 0.00023428 0.97634434 0.97726643 a9 2 
global_heat -3793.4025 486.23839 -4749.7951 -2850.7882 a9 2 
global_intercept -0.0067445 0.01759122 -0.0409632 0.02802263 a9 2 
Kd1 (nM) 31.6430165 0.52368348   a9 2 
Kd2 (nM) -121.1445 177.324645   a9 2 
global_beta1 65520718 3620225.94 58846801.9 72978388.1 m63f 2 
global_dH1 -11370.8 31.2793439 -11433.701 -11310.969 m63f 2 
global_beta2 31869685 12604834.1 13899746.2 59008843.7 m63f 2 
global_dH2 -286504293 118091251 -558099533 -130652747 m63f 2 
fx_competent 0.2111714 0.00032247 0.21054289 0.21180318 m63f 2 
global_heat 79653.0862 531.156243 78629.5717 80722.5173 m63f 2 
global_intercept -2.7800567 0.01200469 -2.804679 -2.7566439 m63f 2 
Kd1 (nM) 15.262348 0.84329278   m63f 2 
Kd2 (nM) 31.3777811 12.4102804   m63f 2 
global_beta1 13645115.8 335003.031 13006693.9 14326242.1 double 2 
global_dH1 -12661.685 26.7346176 -12713.987 -12608.944 double 2 
global_beta2 7209599.17 5031803.73 1338493.06 19518143.7 double 2 
global_dH2 -40111078 32288816.9 -126691382 -8613791.3 double 2 
fx_competent 0.41563233 0.00035602 0.41491589 0.41632745 double 2 
global_heat -11873.374 800.026603 -13405.073 -10322.201 double 2 
global_intercept 0.25660546 0.02245748 0.21223876 0.2994366 double 2 
Kd1 (nM) 73.2862961 1.79926148   double 2 
Kd2 (nM) 138.703966 96.8058164   double 2 
global_beta1 28786224.4 640662.075 27538058.1 30041288.3 f37l 2 
global_dH1 -12973.954 20.4551602 -13013.688 -12934.026 f37l 2 
global_beta2 8351379.7 10128121.7 335357.312 36483552.4 f37l 2 
global_dH2 -37938328 48225191.8 -171767783 -1730218.3 f37l 2 
competent 0.58122387 0.00024219 0.58074397 0.5816949 f37l 2 
global_heat 11443.4824 800.852515 9886.11337 13025.9061 f37l 2 
global_intercept -0.529113 0.02211435 -0.5733811 -0.4860587 f37l 2 
Kd1 (nM) 34.7388385 0.7731426   f37l 2 






Figure AB9. A9 mutant cycle TLR4 activation dose curves. Dose curves 
corresponding to data in Figure 3.5f. 
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APPENDIX C 






This section includes supplemental figures referenced in Chapter IV. 
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Table AC1. Activation of amniote TLR4s by modern and ancestrally 
reconstructed S100 proteins. Compiled data from multiple studies. Protein 
species indicated; Anc indicates maximum likelihood reconstructed ancestral 
protein (see referenced studies and/or methods section for details). All 
TLR4/MD2/CD14 components are from same species. NF-kB values are mean ± 
standard error for > 3 biological replicates. Note that differences in values between 
studies are partially due to changes in protein preparation and treatment. See 
methods for details of cell culture assay. Values in scaled average activity column 
put each set of TLR4 species measurements on a scale of 0-1 and correspond to 
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Figure AC3. CD spectroscopy of therian ancA9 and 5X mutant therian ancA9. 
Dark purple - therian ancA9, light purple - eutherian ancA9, red – “5X therian 
ancA9”; therian A9 with mutations N51K, D55N, P56E, A57K, Q64E (human A9 







Figure AC4. Mutation rates for MD2 mutant library treatment conditions. 
Average number of mutations and distribution of number of mutations from high- 
throughput sequencing data for library (top), LPS GFP- (top left), LPS GFP+ (top 
right), A9 GFP- (top left), A9 GFP+ (top right). 
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Table AC5. Top single MD2 mutants that alter LPS or A9 activation of TLR4. 
Enrichment cutoff for LPS and A9 defined as log2enrichment > 0, log2de- 
enrichment < -0.7 (for example. de-enrichment in A9 when calculating enrichment 
for LPS), and a log2(de-enriched/enriched) score < -1. See Chapter III results and 




enrichment) enrichment)  
0.637 -1.282 I117L LPS over A9 
1.137 -0.743 Y79N LPS over A9 
0.485 -1.121 K58E LPS over A9 
0.359 -1.198 V134I LPS over A9 
0.227 -1.060 G97R LPS over A9 
0.359 -0.913 D99V LPS over A9 
0.096 -1.093 N86K LPS over A9 
0.374 -0.751 K132E LPS over A9 
0.167 -0.880 I66L LPS over A9 
0.158 -0.847 A30T LPS over A9 
-0.756 0.335 Y42F A9 over LPS 
-0.854 0.278 I66N A9 over LPS 
-0.811 0.364 F64I A9 over LPS 
-0.740 0.525 N26K A9 over LPS 
-0.963 0.327 K132I A9 over LPS 
-1.033 0.302 V134D A9 over LPS 
-0.785 0.690 D100G A9 over LPS 
-0.811 0.731 K72M A9 over LPS 
-1.313 0.272 L61F A9 over LPS 
-0.778 0.954 I63T A9 over LPS 
-0.749 1.217 K91E A9 over LPS 
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